id	sid	tid	token	lemma	pos
dpc-1515	1	1	dermatology	dermatology	NOUN
dpc-1515	1	2	:	:	PUNCT
dpc-1515	1	3	practical	practical	ADJ
dpc-1515	1	4	and	and	CCONJ
dpc-1515	1	5	conceptual	conceptual	ADJ
dpc-1515	1	6	dermatology	dermatology	NOUN
dpc-1515	1	7	practical	practical	ADJ
dpc-1515	1	8	&	&	CCONJ
dpc-1515	1	9	conceptual	conceptual	ADJ
dpc-1515	1	10	research	research	NOUN
dpc-1515	1	11	|	|	ADV
dpc-1515	1	12	dermatol	dermatol	ADJ
dpc-1515	1	13	pract	pract	NOUN
dpc-1515	1	14	concept	concept	NOUN
dpc-1515	1	15	.	.	PUNCT
dpc-1515	2	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	2	2	1	1	NUM
dpc-1515	2	3	drug	drug	NOUN
dpc-1515	2	4	intake	intake	NOUN
dpc-1515	2	5	and	and	CCONJ
dpc-1515	2	6	actinic	actinic	ADJ
dpc-1515	2	7	keratosis	keratosis	NOUN
dpc-1515	2	8	:	:	PUNCT
dpc-1515	2	9	a	a	DET
dpc-1515	2	10	case	case	NOUN
dpc-1515	2	11	-	-	PUNCT
dpc-1515	2	12	control	control	NOUN
dpc-1515	2	13	study	study	NOUN
dpc-1515	2	14	andrea	andrea	PROPN
dpc-1515	2	15	sechi1	sechi1	PROPN
dpc-1515	2	16	,	,	PUNCT
dpc-1515	2	17	ambra	ambra	NOUN
dpc-1515	2	18	di	di	X
dpc-1515	2	19	altobrando1	altobrando1	PROPN
dpc-1515	2	20	,	,	PUNCT
dpc-1515	2	21	eugenio	eugenio	PROPN
dpc-1515	2	22	cerciello1	cerciello1	PROPN
dpc-1515	2	23	,	,	PUNCT
dpc-1515	2	24	elisa	elisa	PROPN
dpc-1515	2	25	maietti2	maietti2	PROPN
dpc-1515	2	26	,	,	PUNCT
dpc-1515	2	27	annalisa	annalisa	PROPN
dpc-1515	2	28	patrizi1	patrizi1	PROPN
dpc-1515	2	29	,	,	PUNCT
dpc-1515	2	30	francesco	francesco	PROPN
dpc-1515	2	31	savoia1	savoia1	PROPN
dpc-1515	2	32	1	1	NUM
dpc-1515	2	33	dermatology	dermatology	NOUN
dpc-1515	2	34	,	,	PUNCT
dpc-1515	2	35	irccs	ircc	VERB
dpc-1515	2	36	policlinico	policlinico	PROPN
dpc-1515	2	37	di	di	PROPN
dpc-1515	2	38	sant’orsola	sant’orsola	PROPN
dpc-1515	2	39	.	.	PUNCT
dpc-1515	3	1	department	department	PROPN
dpc-1515	3	2	of	of	ADP
dpc-1515	3	3	experimental	experimental	ADJ
dpc-1515	3	4	,	,	PUNCT
dpc-1515	3	5	diagnostic	diagnostic	ADJ
dpc-1515	3	6	and	and	CCONJ
dpc-1515	3	7	specialty	specialty	NOUN
dpc-1515	3	8	medicine	medicine	NOUN
dpc-1515	3	9	,	,	PUNCT
dpc-1515	3	10	alma	alma	NOUN
dpc-1515	3	11	mater	mater	PROPN
dpc-1515	3	12	studiorum	studiorum	PROPN
dpc-1515	3	13	university	university	PROPN
dpc-1515	3	14	of	of	ADP
dpc-1515	3	15	bologna	bologna	PROPN
dpc-1515	3	16	,	,	PUNCT
dpc-1515	3	17	italy	italy	PROPN
dpc-1515	3	18	2	2	NUM
dpc-1515	3	19	department	department	NOUN
dpc-1515	3	20	of	of	ADP
dpc-1515	3	21	biomedical	biomedical	ADJ
dpc-1515	3	22	and	and	CCONJ
dpc-1515	3	23	neuromotor	neuromotor	NOUN
dpc-1515	3	24	sciences	sciences	PROPN
dpc-1515	3	25	,	,	PUNCT
dpc-1515	3	26	university	university	NOUN
dpc-1515	3	27	of	of	ADP
dpc-1515	3	28	bologna	bologna	PROPN
dpc-1515	3	29	,	,	PUNCT
dpc-1515	3	30	italy	italy	PROPN
dpc-1515	3	31	key	key	ADJ
dpc-1515	3	32	words	word	NOUN
dpc-1515	3	33	:	:	PUNCT
dpc-1515	3	34	drug	drug	NOUN
dpc-1515	3	35	reaction	reaction	NOUN
dpc-1515	3	36	,	,	PUNCT
dpc-1515	3	37	photosensitivity	photosensitivity	NOUN
dpc-1515	3	38	,	,	PUNCT
dpc-1515	3	39	actinic	actinic	ADJ
dpc-1515	3	40	keratosis	keratosis	NOUN
dpc-1515	3	41	,	,	PUNCT
dpc-1515	3	42	angiotensin	angiotensin	NOUN
dpc-1515	3	43	receptor	receptor	NOUN
dpc-1515	3	44	blockers	blocker	NOUN
dpc-1515	3	45	,	,	PUNCT
dpc-1515	3	46	antiplatelet	antiplatelet	VERB
dpc-1515	3	47	drug	drug	NOUN
dpc-1515	3	48	citation	citation	NOUN
dpc-1515	3	49	:	:	PUNCT
dpc-1515	3	50	sechi	sechi	PROPN
dpc-1515	3	51	a	a	PROPN
dpc-1515	3	52	,	,	PUNCT
dpc-1515	3	53	di	di	NOUN
dpc-1515	3	54	altobrando	altobrando	NOUN
dpc-1515	3	55	a	a	PRON
dpc-1515	3	56	,	,	PUNCT
dpc-1515	3	57	cerciello	cerciello	ADJ
dpc-1515	3	58	e	e	NOUN
dpc-1515	3	59	,	,	PUNCT
dpc-1515	3	60	maietti	maietti	NOUN
dpc-1515	3	61	e	e	NOUN
dpc-1515	3	62	,	,	PUNCT
dpc-1515	3	63	patrizi	patrizi	NOUN
dpc-1515	3	64	a	a	PRON
dpc-1515	3	65	,	,	PUNCT
dpc-1515	3	66	savoia	savoia	PROPN
dpc-1515	3	67	f.	f.	PROPN
dpc-1515	3	68	drug	drug	PROPN
dpc-1515	3	69	intake	intake	PROPN
dpc-1515	3	70	and	and	CCONJ
dpc-1515	3	71	actinic	actinic	ADJ
dpc-1515	3	72	keratosis	keratosis	NOUN
dpc-1515	3	73	:	:	PUNCT
dpc-1515	3	74	a	a	DET
dpc-1515	3	75	case	case	NOUN
dpc-1515	3	76	-	-	PUNCT
dpc-1515	3	77	control	control	NOUN
dpc-1515	3	78	study	study	NOUN
dpc-1515	3	79	.	.	PUNCT
dpc-1515	4	1	dermatol	dermatol	NOUN
dpc-1515	4	2	pract	pract	PROPN
dpc-1515	4	3	concept	concept	NOUN
dpc-1515	4	4	.	.	PUNCT
dpc-1515	5	1	2021;11(2):e2021031	2021;11(2):e2021031	X
dpc-1515	5	2	.	.	PUNCT
dpc-1515	6	1	doi	doi	NOUN
dpc-1515	6	2	:	:	PUNCT
dpc-1515	6	3	https://doi.org/10.5826/dpc.1102a31	https://doi.org/10.5826/dpc.1102a31	NOUN
dpc-1515	6	4	accepted	accept	VERB
dpc-1515	6	5	:	:	PUNCT
dpc-1515	6	6	february	february	NOUN
dpc-1515	6	7	3	3	NUM
dpc-1515	6	8	,	,	PUNCT
dpc-1515	6	9	2021	2021	NUM
dpc-1515	6	10	;	;	PUNCT
dpc-1515	6	11	published	publish	VERB
dpc-1515	6	12	:	:	PUNCT
dpc-1515	6	13	april	april	PROPN
dpc-1515	6	14	12	12	NUM
dpc-1515	6	15	,	,	PUNCT
dpc-1515	6	16	2021	2021	NUM
dpc-1515	6	17	copyright	copyright	NOUN
dpc-1515	6	18	:	:	PUNCT
dpc-1515	7	1	©	©	PROPN
dpc-1515	7	2	2021	2021	NUM
dpc-1515	7	3	sechi	sechi	PROPN
dpc-1515	7	4	et	et	PROPN
dpc-1515	7	5	al	al	PROPN
dpc-1515	7	6	.	.	PUNCT
dpc-1515	8	1	this	this	PRON
dpc-1515	8	2	is	be	AUX
dpc-1515	8	3	an	an	DET
dpc-1515	8	4	open	open	ADJ
dpc-1515	8	5	-	-	PUNCT
dpc-1515	8	6	access	access	NOUN
dpc-1515	8	7	article	article	NOUN
dpc-1515	8	8	distributed	distribute	VERB
dpc-1515	8	9	under	under	ADP
dpc-1515	8	10	the	the	DET
dpc-1515	8	11	terms	term	NOUN
dpc-1515	8	12	of	of	ADP
dpc-1515	8	13	the	the	DET
dpc-1515	8	14	creative	creative	ADJ
dpc-1515	8	15	commons	common	NOUN
dpc-1515	8	16	attribution	attribution	NOUN
dpc-1515	8	17	license	license	NOUN
dpc-1515	8	18	bync-4.0	bync-4.0	NOUN
dpc-1515	8	19	,	,	PUNCT
dpc-1515	8	20	which	which	PRON
dpc-1515	8	21	permits	permit	VERB
dpc-1515	8	22	unrestricted	unrestricted	ADJ
dpc-1515	8	23	noncommercial	noncommercial	ADJ
dpc-1515	8	24	use	use	NOUN
dpc-1515	8	25	,	,	PUNCT
dpc-1515	8	26	distribution	distribution	NOUN
dpc-1515	8	27	,	,	PUNCT
dpc-1515	8	28	and	and	CCONJ
dpc-1515	8	29	reproduction	reproduction	NOUN
dpc-1515	8	30	in	in	ADP
dpc-1515	8	31	any	any	DET
dpc-1515	8	32	medium	medium	NOUN
dpc-1515	8	33	,	,	PUNCT
dpc-1515	8	34	provided	provide	VERB
dpc-1515	8	35	the	the	DET
dpc-1515	8	36	original	original	ADJ
dpc-1515	8	37	authors	author	NOUN
dpc-1515	8	38	and	and	CCONJ
dpc-1515	8	39	source	source	NOUN
dpc-1515	8	40	are	be	AUX
dpc-1515	8	41	credited	credit	VERB
dpc-1515	8	42	.	.	PUNCT
dpc-1515	9	1	funding	funding	NOUN
dpc-1515	9	2	:	:	PUNCT
dpc-1515	9	3	none	none	NOUN
dpc-1515	9	4	.	.	PUNCT
dpc-1515	10	1	competing	compete	VERB
dpc-1515	10	2	interests	interest	NOUN
dpc-1515	10	3	:	:	PUNCT
dpc-1515	10	4	the	the	DET
dpc-1515	10	5	authors	author	NOUN
dpc-1515	10	6	have	have	VERB
dpc-1515	10	7	no	no	DET
dpc-1515	10	8	conflicts	conflict	NOUN
dpc-1515	10	9	of	of	ADP
dpc-1515	10	10	interest	interest	NOUN
dpc-1515	10	11	to	to	PART
dpc-1515	10	12	disclose	disclose	VERB
dpc-1515	10	13	.	.	PUNCT
dpc-1515	11	1	authorship	authorship	NOUN
dpc-1515	11	2	:	:	PUNCT
dpc-1515	11	3	a.s	a.s	PROPN
dpc-1515	11	4	and	and	CCONJ
dpc-1515	11	5	a.d	a.d	PROPN
dpc-1515	11	6	.	.	PROPN
dpc-1515	11	7	contributed	contribute	VERB
dpc-1515	11	8	equally	equally	ADV
dpc-1515	11	9	to	to	ADP
dpc-1515	11	10	this	this	DET
dpc-1515	11	11	work	work	NOUN
dpc-1515	11	12	.	.	PUNCT
dpc-1515	12	1	all	all	DET
dpc-1515	12	2	authors	author	NOUN
dpc-1515	12	3	have	have	AUX
dpc-1515	12	4	contributed	contribute	VERB
dpc-1515	12	5	significantly	significantly	ADV
dpc-1515	12	6	to	to	ADP
dpc-1515	12	7	this	this	DET
dpc-1515	12	8	publication	publication	NOUN
dpc-1515	12	9	.	.	PUNCT
dpc-1515	13	1	corresponding	correspond	VERB
dpc-1515	13	2	author	author	NOUN
dpc-1515	13	3	:	:	PUNCT
dpc-1515	13	4	andrea	andrea	PROPN
dpc-1515	13	5	sechi	sechi	PROPN
dpc-1515	13	6	,	,	PUNCT
dpc-1515	13	7	md	md	PROPN
dpc-1515	13	8	,	,	PUNCT
dpc-1515	13	9	dermatology	dermatology	NOUN
dpc-1515	13	10	-irccs	-irccs	PROPN
dpc-1515	13	11	policlinico	policlinico	PROPN
dpc-1515	13	12	di	di	PROPN
dpc-1515	13	13	sant’orsola	sant’orsola	PROPN
dpc-1515	13	14	.	.	PUNCT
dpc-1515	14	1	department	department	PROPN
dpc-1515	14	2	of	of	ADP
dpc-1515	14	3	experimental	experimental	ADJ
dpc-1515	14	4	,	,	PUNCT
dpc-1515	14	5	diagnostic	diagnostic	ADJ
dpc-1515	14	6	and	and	CCONJ
dpc-1515	14	7	specialty	specialty	NOUN
dpc-1515	14	8	medicine	medicine	NOUN
dpc-1515	14	9	,	,	PUNCT
dpc-1515	14	10	alma	alma	NOUN
dpc-1515	14	11	mater	mater	PROPN
dpc-1515	14	12	studiorum	studiorum	PROPN
dpc-1515	14	13	university	university	PROPN
dpc-1515	14	14	of	of	ADP
dpc-1515	14	15	bologna	bologna	PROPN
dpc-1515	14	16	,	,	PUNCT
dpc-1515	14	17	italy	italy	PROPN
dpc-1515	14	18	,	,	PUNCT
dpc-1515	14	19	via	via	ADP
dpc-1515	14	20	massarenti	massarenti	NOUN
dpc-1515	14	21	9	9	NUM
dpc-1515	14	22	,	,	PUNCT
dpc-1515	14	23	40138	40138	NUM
dpc-1515	14	24	bologna	bologna	PROPN
dpc-1515	14	25	,	,	PUNCT
dpc-1515	14	26	italy	italy	PROPN
dpc-1515	14	27	.	.	PUNCT
dpc-1515	15	1	email	email	NOUN
dpc-1515	15	2	:	:	PUNCT
dpc-1515	15	3	andrea.sechi@	andrea.sechi@	PROPN
dpc-1515	15	4	hotmail.com	hotmail.com	X
dpc-1515	15	5	background	background	NOUN
dpc-1515	15	6	:	:	PUNCT
dpc-1515	15	7	actinic	actinic	ADJ
dpc-1515	15	8	keratosis	keratosis	NOUN
dpc-1515	15	9	(	(	PUNCT
dpc-1515	15	10	ak	ak	PROPN
dpc-1515	15	11	)	)	PUNCT
dpc-1515	15	12	is	be	AUX
dpc-1515	15	13	a	a	DET
dpc-1515	15	14	form	form	NOUN
dpc-1515	15	15	of	of	ADP
dpc-1515	15	16	premalignant	premalignant	ADJ
dpc-1515	15	17	keratinocyte	keratinocyte	NOUN
dpc-1515	15	18	dysplasia	dysplasia	NOUN
dpc-1515	15	19	.	.	PUNCT
dpc-1515	16	1	recently	recently	ADV
dpc-1515	16	2	,	,	PUNCT
dpc-1515	16	3	the	the	DET
dpc-1515	16	4	role	role	NOUN
dpc-1515	16	5	of	of	ADP
dpc-1515	16	6	photosensitizing	photosensitize	VERB
dpc-1515	16	7	drugs	drug	NOUN
dpc-1515	16	8	in	in	ADP
dpc-1515	16	9	the	the	DET
dpc-1515	16	10	development	development	NOUN
dpc-1515	16	11	of	of	ADP
dpc-1515	16	12	ak	ak	PROPN
dpc-1515	16	13	has	have	AUX
dpc-1515	16	14	been	be	AUX
dpc-1515	16	15	postulated	postulate	VERB
dpc-1515	16	16	.	.	PUNCT
dpc-1515	17	1	objective	objective	NOUN
dpc-1515	17	2	:	:	PUNCT
dpc-1515	17	3	this	this	DET
dpc-1515	17	4	study	study	NOUN
dpc-1515	17	5	evaluated	evaluate	VERB
dpc-1515	17	6	a	a	DET
dpc-1515	17	7	possible	possible	ADJ
dpc-1515	17	8	association	association	NOUN
dpc-1515	17	9	between	between	ADP
dpc-1515	17	10	the	the	DET
dpc-1515	17	11	use	use	NOUN
dpc-1515	17	12	of	of	ADP
dpc-1515	17	13	photosensitizing	photosensitize	VERB
dpc-1515	17	14	drugs	drug	NOUN
dpc-1515	17	15	and	and	CCONJ
dpc-1515	17	16	the	the	DET
dpc-1515	17	17	development	development	NOUN
dpc-1515	17	18	of	of	ADP
dpc-1515	17	19	ak	ak	PROPN
dpc-1515	17	20	.	.	PROPN
dpc-1515	18	1	a	a	DET
dpc-1515	18	2	secondary	secondary	ADJ
dpc-1515	18	3	aim	aim	NOUN
dpc-1515	18	4	was	be	AUX
dpc-1515	18	5	to	to	PART
dpc-1515	18	6	identify	identify	VERB
dpc-1515	18	7	a	a	DET
dpc-1515	18	8	possible	possible	ADJ
dpc-1515	18	9	association	association	NOUN
dpc-1515	18	10	between	between	ADP
dpc-1515	18	11	any	any	DET
dpc-1515	18	12	medication	medication	NOUN
dpc-1515	18	13	other	other	ADJ
dpc-1515	18	14	than	than	ADP
dpc-1515	18	15	those	those	DET
dpc-1515	18	16	primarily	primarily	ADV
dpc-1515	18	17	examined	examine	VERB
dpc-1515	18	18	and	and	CCONJ
dpc-1515	18	19	ak	ak	PROPN
dpc-1515	18	20	.	.	PROPN
dpc-1515	18	21	methods	method	NOUN
dpc-1515	18	22	:	:	PUNCT
dpc-1515	18	23	a	a	DET
dpc-1515	18	24	single	single	ADJ
dpc-1515	18	25	-	-	PUNCT
dpc-1515	18	26	center	center	NOUN
dpc-1515	18	27	,	,	PUNCT
dpc-1515	18	28	case	case	NOUN
dpc-1515	18	29	-	-	PUNCT
dpc-1515	18	30	control	control	NOUN
dpc-1515	18	31	study	study	NOUN
dpc-1515	18	32	assessed	assess	VERB
dpc-1515	18	33	the	the	DET
dpc-1515	18	34	cumulative	cumulative	ADJ
dpc-1515	18	35	drug	drug	NOUN
dpc-1515	18	36	exposure	exposure	NOUN
dpc-1515	18	37	of	of	ADP
dpc-1515	18	38	90	90	NUM
dpc-1515	18	39	patients	patient	NOUN
dpc-1515	18	40	with	with	ADP
dpc-1515	18	41	ak	ak	PROPN
dpc-1515	18	42	and	and	CCONJ
dpc-1515	18	43	90	90	NUM
dpc-1515	18	44	controls	control	NOUN
dpc-1515	18	45	visiting	visit	VERB
dpc-1515	18	46	a	a	DET
dpc-1515	18	47	dermatology	dermatology	NOUN
dpc-1515	18	48	service	service	NOUN
dpc-1515	18	49	for	for	ADP
dpc-1515	18	50	other	other	ADJ
dpc-1515	18	51	skin	skin	NOUN
dpc-1515	18	52	ailments	ailment	NOUN
dpc-1515	18	53	.	.	PUNCT
dpc-1515	19	1	before	before	ADP
dpc-1515	19	2	the	the	DET
dpc-1515	19	3	visit	visit	NOUN
dpc-1515	19	4	,	,	PUNCT
dpc-1515	19	5	patients	patient	NOUN
dpc-1515	19	6	were	be	AUX
dpc-1515	19	7	interviewed	interview	VERB
dpc-1515	19	8	to	to	PART
dpc-1515	19	9	collect	collect	VERB
dpc-1515	19	10	data	datum	NOUN
dpc-1515	19	11	on	on	ADP
dpc-1515	19	12	daily	daily	ADJ
dpc-1515	19	13	therapy	therapy	NOUN
dpc-1515	19	14	and	and	CCONJ
dpc-1515	19	15	the	the	DET
dpc-1515	19	16	lag	lag	NOUN
dpc-1515	19	17	-	-	PUNCT
dpc-1515	19	18	time	time	NOUN
dpc-1515	19	19	of	of	ADP
dpc-1515	19	20	discontinued	discontinue	VERB
dpc-1515	19	21	drugs	drug	NOUN
dpc-1515	19	22	within	within	ADP
dpc-1515	19	23	the	the	DET
dpc-1515	19	24	last	last	ADJ
dpc-1515	19	25	2	2	NUM
dpc-1515	19	26	years	year	NOUN
dpc-1515	19	27	,	,	PUNCT
dpc-1515	19	28	and	and	CCONJ
dpc-1515	19	29	to	to	PART
dpc-1515	19	30	record	record	VERB
dpc-1515	19	31	the	the	DET
dpc-1515	19	32	drug	drug	NOUN
dpc-1515	19	33	’s	’s	PART
dpc-1515	19	34	active	active	ADJ
dpc-1515	19	35	ingredient	ingredient	NOUN
dpc-1515	19	36	,	,	PUNCT
dpc-1515	19	37	dosage	dosage	NOUN
dpc-1515	19	38	,	,	PUNCT
dpc-1515	19	39	and	and	CCONJ
dpc-1515	19	40	duration	duration	NOUN
dpc-1515	19	41	of	of	ADP
dpc-1515	19	42	therapy	therapy	NOUN
dpc-1515	19	43	.	.	PUNCT
dpc-1515	20	1	in	in	ADP
dpc-1515	20	2	addition	addition	NOUN
dpc-1515	20	3	,	,	PUNCT
dpc-1515	20	4	sociodemographic	sociodemographic	ADJ
dpc-1515	20	5	characteristics	characteristic	NOUN
dpc-1515	20	6	including	include	VERB
dpc-1515	20	7	age	age	NOUN
dpc-1515	20	8	,	,	PUNCT
dpc-1515	20	9	sex	sex	NOUN
dpc-1515	20	10	,	,	PUNCT
dpc-1515	20	11	educational	educational	ADJ
dpc-1515	20	12	level	level	NOUN
dpc-1515	20	13	,	,	PUNCT
dpc-1515	20	14	skin	skin	NOUN
dpc-1515	20	15	phototype	phototype	NOUN
dpc-1515	20	16	,	,	PUNCT
dpc-1515	20	17	and	and	CCONJ
dpc-1515	20	18	cumulative	cumulative	ADJ
dpc-1515	20	19	sun	sun	NOUN
dpc-1515	20	20	exposure	exposure	NOUN
dpc-1515	20	21	habits	habit	NOUN
dpc-1515	20	22	were	be	AUX
dpc-1515	20	23	gathered	gather	VERB
dpc-1515	20	24	.	.	PUNCT
dpc-1515	21	1	results	result	NOUN
dpc-1515	21	2	:	:	PUNCT
dpc-1515	21	3	by	by	ADP
dpc-1515	21	4	logistic	logistic	ADJ
dpc-1515	21	5	regression	regression	NOUN
dpc-1515	21	6	,	,	PUNCT
dpc-1515	21	7	exposures	exposure	NOUN
dpc-1515	21	8	to	to	ADP
dpc-1515	21	9	angiotensin	angiotensin	PROPN
dpc-1515	21	10	ii	ii	PROPN
dpc-1515	21	11	receptor	receptor	NOUN
dpc-1515	21	12	blockers	blocker	NOUN
dpc-1515	21	13	(	(	PUNCT
dpc-1515	21	14	arbs	arb	NOUN
dpc-1515	21	15	)	)	PUNCT
dpc-1515	21	16	and	and	CCONJ
dpc-1515	21	17	antiplatelet	antiplatelet	NOUN
dpc-1515	21	18	agents	agent	NOUN
dpc-1515	21	19	were	be	AUX
dpc-1515	21	20	identified	identify	VERB
dpc-1515	21	21	as	as	ADP
dpc-1515	21	22	independent	independent	ADJ
dpc-1515	21	23	risk	risk	NOUN
dpc-1515	21	24	factors	factor	NOUN
dpc-1515	21	25	for	for	ADP
dpc-1515	21	26	the	the	DET
dpc-1515	21	27	development	development	NOUN
dpc-1515	21	28	of	of	ADP
dpc-1515	21	29	ak	ak	PROPN
dpc-1515	21	30	.	.	PROPN
dpc-1515	21	31	arb	arb	PROPN
dpc-1515	21	32	intake	intake	PROPN
dpc-1515	21	33	was	be	AUX
dpc-1515	21	34	associated	associate	VERB
dpc-1515	21	35	with	with	ADP
dpc-1515	21	36	ak	ak	PROPN
dpc-1515	21	37	only	only	ADV
dpc-1515	21	38	at	at	ADP
dpc-1515	21	39	high	high	ADJ
dpc-1515	21	40	exposure	exposure	NOUN
dpc-1515	21	41	(	(	PUNCT
dpc-1515	21	42	or	or	CCONJ
dpc-1515	21	43	=	=	SYM
dpc-1515	21	44	13.6	13.6	NUM
dpc-1515	21	45	;	;	PUNCT
dpc-1515	21	46	95	95	NUM
dpc-1515	21	47	%	%	NOUN
dpc-1515	21	48	ci	ci	NOUN
dpc-1515	21	49	,	,	PUNCT
dpc-1515	21	50	2.0	2.0	NUM
dpc-1515	21	51	-	-	SYM
dpc-1515	21	52	93.8	93.8	NUM
dpc-1515	21	53	)	)	PUNCT
dpc-1515	21	54	.	.	PUNCT
dpc-1515	22	1	the	the	DET
dpc-1515	22	2	use	use	NOUN
dpc-1515	22	3	of	of	ADP
dpc-1515	22	4	antiplatelet	antiplatelet	NOUN
dpc-1515	22	5	drugs	drug	NOUN
dpc-1515	22	6	was	be	AUX
dpc-1515	22	7	borderline	borderline	NOUN
dpc-1515	22	8	,	,	PUNCT
dpc-1515	22	9	yet	yet	ADV
dpc-1515	22	10	not	not	PART
dpc-1515	22	11	significant	significant	ADJ
dpc-1515	22	12	,	,	PUNCT
dpc-1515	22	13	at	at	ADP
dpc-1515	22	14	low	low	ADJ
dpc-1515	22	15	exposure	exposure	NOUN
dpc-1515	22	16	(	(	PUNCT
dpc-1515	22	17	or	or	CCONJ
dpc-1515	22	18	=	=	SYM
dpc-1515	22	19	3.31	3.31	NUM
dpc-1515	22	20	;	;	PUNCT
dpc-1515	22	21	95	95	NUM
dpc-1515	22	22	%	%	NOUN
dpc-1515	22	23	ci	ci	NOUN
dpc-1515	22	24	,	,	PUNCT
dpc-1515	22	25	0.86	0.86	NUM
dpc-1515	22	26	-	-	PUNCT
dpc-1515	22	27	12.7	12.7	NUM
dpc-1515	22	28	)	)	PUNCT
dpc-1515	22	29	,	,	PUNCT
dpc-1515	22	30	but	but	CCONJ
dpc-1515	22	31	increased	increase	VERB
dpc-1515	22	32	in	in	ADP
dpc-1515	22	33	a	a	DET
dpc-1515	22	34	dose	dose	NOUN
dpc-1515	22	35	-	-	PUNCT
dpc-1515	22	36	dependent	dependent	ADJ
dpc-1515	22	37	manner	manner	NOUN
dpc-1515	22	38	.	.	PUNCT
dpc-1515	23	1	the	the	DET
dpc-1515	23	2	strongest	strong	ADJ
dpc-1515	23	3	correlation	correlation	NOUN
dpc-1515	23	4	was	be	AUX
dpc-1515	23	5	found	find	VERB
dpc-1515	23	6	at	at	ADP
dpc-1515	23	7	the	the	DET
dpc-1515	23	8	highest	high	ADJ
dpc-1515	23	9	cumulative	cumulative	ADJ
dpc-1515	23	10	dose	dose	NOUN
dpc-1515	23	11	(	(	PUNCT
dpc-1515	23	12	>	>	SYM
dpc-1515	23	13	1100	1100	NUM
dpc-1515	23	14	dose	dose	PROPN
dpc-1515	23	15	unit	unit	NOUN
dpc-1515	23	16	-	-	PUNCT
dpc-1515	23	17	years	year	NOUN
dpc-1515	23	18	(	(	PUNCT
dpc-1515	23	19	or	or	CCONJ
dpc-1515	23	20	=	=	SYM
dpc-1515	23	21	4.38	4.38	NUM
dpc-1515	23	22	;	;	PUNCT
dpc-1515	23	23	95	95	NUM
dpc-1515	23	24	%	%	NOUN
dpc-1515	23	25	ci	ci	NOUN
dpc-1515	23	26	,	,	PUNCT
dpc-1515	23	27	1.16	1.16	NUM
dpc-1515	23	28	-	-	SYM
dpc-1515	23	29	16.6	16.6	NUM
dpc-1515	23	30	)	)	PUNCT
dpc-1515	23	31	.	.	PUNCT
dpc-1515	24	1	conclusions	conclusion	NOUN
dpc-1515	24	2	:	:	PUNCT
dpc-1515	24	3	high	high	ADJ
dpc-1515	24	4	exposure	exposure	NOUN
dpc-1515	24	5	to	to	ADP
dpc-1515	24	6	arbs	arbs	VERB
dpc-1515	24	7	and	and	CCONJ
dpc-1515	24	8	antiplatelet	antiplatelet	ADJ
dpc-1515	24	9	agents	agent	NOUN
dpc-1515	24	10	may	may	AUX
dpc-1515	24	11	promote	promote	VERB
dpc-1515	24	12	ak	ak	PROPN
dpc-1515	24	13	carcinogenesis	carcinogenesis	NOUN
dpc-1515	24	14	in	in	ADP
dpc-1515	24	15	atrisk	atrisk	PROPN
dpc-1515	24	16	patients	patient	NOUN
dpc-1515	24	17	.	.	PUNCT
dpc-1515	25	1	abstract	abstract	ADJ
dpc-1515	25	2	2	2	NUM
dpc-1515	25	3	research	research	NOUN
dpc-1515	25	4	|	|	ADV
dpc-1515	25	5	dermatol	dermatol	ADJ
dpc-1515	25	6	pract	pract	NOUN
dpc-1515	25	7	concept	concept	NOUN
dpc-1515	25	8	.	.	PUNCT
dpc-1515	26	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	26	2	introduction	introduction	NOUN
dpc-1515	26	3	actinic	actinic	ADJ
dpc-1515	26	4	keratosis	keratosis	NOUN
dpc-1515	26	5	(	(	PUNCT
dpc-1515	26	6	ak	ak	PROPN
dpc-1515	26	7	)	)	PUNCT
dpc-1515	26	8	is	be	AUX
dpc-1515	26	9	a	a	DET
dpc-1515	26	10	common	common	ADJ
dpc-1515	26	11	skin	skin	NOUN
dpc-1515	26	12	lesion	lesion	NOUN
dpc-1515	26	13	caused	cause	VERB
dpc-1515	26	14	by	by	ADP
dpc-1515	26	15	the	the	DET
dpc-1515	26	16	proliferation	proliferation	NOUN
dpc-1515	26	17	of	of	ADP
dpc-1515	26	18	atypical	atypical	ADJ
dpc-1515	26	19	keratinocytes	keratinocyte	NOUN
dpc-1515	26	20	.	.	PUNCT
dpc-1515	27	1	in	in	ADP
dpc-1515	27	2	the	the	DET
dpc-1515	27	3	literature	literature	NOUN
dpc-1515	27	4	,	,	PUNCT
dpc-1515	27	5	ak	ak	PROPN
dpc-1515	27	6	is	be	AUX
dpc-1515	27	7	considered	consider	VERB
dpc-1515	27	8	as	as	ADP
dpc-1515	27	9	a	a	DET
dpc-1515	27	10	form	form	NOUN
dpc-1515	27	11	of	of	ADP
dpc-1515	27	12	either	either	CCONJ
dpc-1515	27	13	premalignant	premalignant	ADJ
dpc-1515	27	14	dysplasia	dysplasia	NOUN
dpc-1515	27	15	or	or	CCONJ
dpc-1515	27	16	in	in	ADP
dpc-1515	27	17	situ	situ	ADJ
dpc-1515	27	18	squamous	squamous	ADJ
dpc-1515	27	19	cell	cell	NOUN
dpc-1515	27	20	carcinoma	carcinoma	NOUN
dpc-1515	27	21	(	(	PUNCT
dpc-1515	27	22	scc	scc	NOUN
dpc-1515	27	23	)	)	PUNCT
dpc-1515	27	24	.	.	PUNCT
dpc-1515	28	1	the	the	DET
dpc-1515	28	2	finding	finding	NOUN
dpc-1515	28	3	that	that	SCONJ
dpc-1515	28	4	60	60	NUM
dpc-1515	28	5	%	%	NOUN
dpc-1515	28	6	of	of	ADP
dpc-1515	28	7	sccs	sccs	NOUN
dpc-1515	28	8	arise	arise	VERB
dpc-1515	28	9	at	at	ADP
dpc-1515	28	10	the	the	DET
dpc-1515	28	11	site	site	NOUN
dpc-1515	28	12	of	of	ADP
dpc-1515	28	13	a	a	DET
dpc-1515	28	14	previous	previous	ADJ
dpc-1515	28	15	ak	ak	PROPN
dpc-1515	28	16	supports	support	VERB
dpc-1515	28	17	the	the	DET
dpc-1515	28	18	pathogenetic	pathogenetic	ADJ
dpc-1515	28	19	model	model	NOUN
dpc-1515	28	20	of	of	ADP
dpc-1515	28	21	a	a	DET
dpc-1515	28	22	continuous	continuous	ADJ
dpc-1515	28	23	progression	progression	NOUN
dpc-1515	28	24	between	between	ADP
dpc-1515	28	25	ak	ak	PROPN
dpc-1515	28	26	and	and	CCONJ
dpc-1515	28	27	scc	scc	NOUN
dpc-1515	29	1	[	[	X
dpc-1515	29	2	1	1	NUM
dpc-1515	29	3	]	]	PUNCT
dpc-1515	29	4	.	.	PUNCT
dpc-1515	30	1	aks	ak	NOUN
dpc-1515	30	2	may	may	AUX
dpc-1515	30	3	evolve	evolve	VERB
dpc-1515	30	4	following	follow	VERB
dpc-1515	30	5	1	1	NUM
dpc-1515	30	6	of	of	ADP
dpc-1515	30	7	3	3	NUM
dpc-1515	30	8	paths	path	NOUN
dpc-1515	30	9	:	:	PUNCT
dpc-1515	30	10	spontaneous	spontaneous	ADJ
dpc-1515	30	11	regression	regression	NOUN
dpc-1515	30	12	,	,	PUNCT
dpc-1515	30	13	stable	stable	ADJ
dpc-1515	30	14	existence	existence	NOUN
dpc-1515	30	15	,	,	PUNCT
dpc-1515	30	16	or	or	CCONJ
dpc-1515	30	17	malignant	malignant	ADJ
dpc-1515	30	18	progression	progression	NOUN
dpc-1515	30	19	.	.	PUNCT
dpc-1515	31	1	natural	natural	ADJ
dpc-1515	31	2	remission	remission	NOUN
dpc-1515	31	3	positively	positively	ADV
dpc-1515	31	4	correlates	correlate	VERB
dpc-1515	31	5	with	with	ADP
dpc-1515	31	6	working	work	VERB
dpc-1515	31	7	outdoors	outdoor	NOUN
dpc-1515	31	8	due	due	ADP
dpc-1515	31	9	to	to	ADP
dpc-1515	31	10	decreased	decrease	VERB
dpc-1515	31	11	sun	sun	NOUN
dpc-1515	31	12	sensitivity	sensitivity	NOUN
dpc-1515	31	13	,	,	PUNCT
dpc-1515	31	14	and	and	CCONJ
dpc-1515	31	15	has	have	AUX
dpc-1515	31	16	been	be	AUX
dpc-1515	31	17	observed	observe	VERB
dpc-1515	31	18	in	in	ADP
dpc-1515	31	19	more	more	ADJ
dpc-1515	31	20	than	than	ADP
dpc-1515	31	21	50	50	NUM
dpc-1515	31	22	%	%	NOUN
dpc-1515	31	23	of	of	ADP
dpc-1515	31	24	aks	ak	NOUN
dpc-1515	31	25	.	.	PUNCT
dpc-1515	32	1	however	however	ADV
dpc-1515	32	2	,	,	PUNCT
dpc-1515	32	3	regressed	regress	VERB
dpc-1515	32	4	lesions	lesion	NOUN
dpc-1515	32	5	easily	easily	ADV
dpc-1515	32	6	reappear	reappear	VERB
dpc-1515	32	7	over	over	ADP
dpc-1515	32	8	time	time	NOUN
dpc-1515	32	9	[	[	X
dpc-1515	32	10	2	2	NUM
dpc-1515	32	11	]	]	PUNCT
dpc-1515	32	12	.	.	PUNCT
dpc-1515	33	1	the	the	DET
dpc-1515	33	2	risk	risk	NOUN
dpc-1515	33	3	of	of	ADP
dpc-1515	33	4	malignant	malignant	ADJ
dpc-1515	33	5	transformation	transformation	NOUN
dpc-1515	33	6	of	of	ADP
dpc-1515	33	7	ak	ak	PROPN
dpc-1515	33	8	into	into	ADP
dpc-1515	33	9	an	an	DET
dpc-1515	33	10	invasive	invasive	ADJ
dpc-1515	33	11	scc	scc	NOUN
dpc-1515	33	12	has	have	AUX
dpc-1515	33	13	been	be	AUX
dpc-1515	33	14	investigated	investigate	VERB
dpc-1515	33	15	in	in	ADP
dpc-1515	33	16	many	many	ADJ
dpc-1515	33	17	studies	study	NOUN
dpc-1515	33	18	.	.	PUNCT
dpc-1515	34	1	a	a	DET
dpc-1515	34	2	0.6	0.6	NUM
dpc-1515	34	3	%	%	NOUN
dpc-1515	34	4	progression	progression	NOUN
dpc-1515	34	5	rate	rate	NOUN
dpc-1515	34	6	for	for	ADP
dpc-1515	34	7	a	a	DET
dpc-1515	34	8	single	single	ADJ
dpc-1515	34	9	ak	ak	PROPN
dpc-1515	34	10	was	be	AUX
dpc-1515	34	11	reported	report	VERB
dpc-1515	34	12	over	over	ADP
dpc-1515	34	13	1	1	NUM
dpc-1515	34	14	year	year	NOUN
dpc-1515	34	15	,	,	PUNCT
dpc-1515	34	16	and	and	CCONJ
dpc-1515	34	17	2.6	2.6	NUM
dpc-1515	34	18	%	%	NOUN
dpc-1515	34	19	in	in	ADP
dpc-1515	34	20	4	4	NUM
dpc-1515	34	21	years	year	NOUN
dpc-1515	34	22	[	[	X
dpc-1515	34	23	1	1	NUM
dpc-1515	34	24	]	]	PUNCT
dpc-1515	34	25	;	;	PUNCT
dpc-1515	34	26	in	in	ADP
dpc-1515	34	27	a	a	DET
dpc-1515	34	28	20	20	NUM
dpc-1515	34	29	-	-	PUNCT
dpc-1515	34	30	year	year	NOUN
dpc-1515	34	31	period	period	NOUN
dpc-1515	34	32	,	,	PUNCT
dpc-1515	34	33	this	this	DET
dpc-1515	34	34	rate	rate	NOUN
dpc-1515	34	35	ranges	range	VERB
dpc-1515	34	36	from	from	ADP
dpc-1515	34	37	0.025	0.025	NUM
dpc-1515	34	38	%	%	NOUN
dpc-1515	34	39	to	to	PART
dpc-1515	34	40	20	20	NUM
dpc-1515	34	41	%	%	NOUN
dpc-1515	34	42	[	[	X
dpc-1515	34	43	2	2	NUM
dpc-1515	34	44	]	]	PUNCT
dpc-1515	34	45	.	.	PUNCT
dpc-1515	35	1	the	the	DET
dpc-1515	35	2	reason	reason	NOUN
dpc-1515	35	3	for	for	ADP
dpc-1515	35	4	such	such	DET
dpc-1515	35	5	a	a	DET
dpc-1515	35	6	wide	wide	ADJ
dpc-1515	35	7	difference	difference	NOUN
dpc-1515	35	8	is	be	AUX
dpc-1515	35	9	mainly	mainly	ADV
dpc-1515	35	10	the	the	DET
dpc-1515	35	11	lack	lack	NOUN
dpc-1515	35	12	of	of	ADP
dpc-1515	35	13	a	a	DET
dpc-1515	35	14	consensus	consensus	NOUN
dpc-1515	35	15	definition	definition	NOUN
dpc-1515	35	16	of	of	ADP
dpc-1515	35	17	ak	ak	PROPN
dpc-1515	35	18	,	,	PUNCT
dpc-1515	35	19	with	with	ADP
dpc-1515	35	20	no	no	DET
dpc-1515	35	21	risk	risk	NOUN
dpc-1515	35	22	stratification	stratification	NOUN
dpc-1515	35	23	according	accord	VERB
dpc-1515	35	24	to	to	ADP
dpc-1515	35	25	ak	ak	PROPN
dpc-1515	35	26	features	feature	NOUN
dpc-1515	35	27	.	.	PUNCT
dpc-1515	36	1	ak	ak	PROPN
dpc-1515	36	2	clinical	clinical	ADJ
dpc-1515	36	3	presentation	presentation	NOUN
dpc-1515	36	4	is	be	AUX
dpc-1515	36	5	highly	highly	ADV
dpc-1515	36	6	polymorphic	polymorphic	ADJ
dpc-1515	36	7	,	,	PUNCT
dpc-1515	36	8	with	with	ADP
dpc-1515	36	9	a	a	DET
dpc-1515	36	10	variable	variable	ADJ
dpc-1515	36	11	combination	combination	NOUN
dpc-1515	36	12	of	of	ADP
dpc-1515	36	13	erythema	erythema	ADJ
dpc-1515	36	14	,	,	PUNCT
dpc-1515	36	15	hyperkeratosis	hyperkeratosis	NOUN
dpc-1515	36	16	,	,	PUNCT
dpc-1515	36	17	and	and	CCONJ
dpc-1515	36	18	telangiectasia	telangiectasia	NOUN
dpc-1515	36	19	.	.	PUNCT
dpc-1515	37	1	in	in	ADP
dpc-1515	37	2	this	this	DET
dpc-1515	37	3	scenario	scenario	NOUN
dpc-1515	37	4	,	,	PUNCT
dpc-1515	37	5	aks	ak	NOUN
dpc-1515	37	6	with	with	ADP
dpc-1515	37	7	rapid	rapid	ADJ
dpc-1515	37	8	growth	growth	NOUN
dpc-1515	37	9	,	,	PUNCT
dpc-1515	37	10	bleeding	bleeding	NOUN
dpc-1515	37	11	,	,	PUNCT
dpc-1515	37	12	ulceration	ulceration	NOUN
dpc-1515	37	13	,	,	PUNCT
dpc-1515	37	14	induration	induration	NOUN
dpc-1515	37	15	and	and	CCONJ
dpc-1515	37	16	inflammation	inflammation	NOUN
dpc-1515	37	17	,	,	PUNCT
dpc-1515	37	18	and	and	CCONJ
dpc-1515	37	19	those	those	PRON
dpc-1515	37	20	>	>	SYM
dpc-1515	37	21	1	1	NUM
dpc-1515	37	22	cm	cm	NOUN
dpc-1515	37	23	in	in	ADP
dpc-1515	37	24	size	size	NOUN
dpc-1515	37	25	are	be	AUX
dpc-1515	37	26	at	at	ADP
dpc-1515	37	27	increased	increase	VERB
dpc-1515	37	28	risk	risk	NOUN
dpc-1515	37	29	of	of	ADP
dpc-1515	37	30	progression	progression	NOUN
dpc-1515	37	31	to	to	ADP
dpc-1515	37	32	invasive	invasive	ADJ
dpc-1515	37	33	scc	scc	NOUN
dpc-1515	37	34	[	[	X
dpc-1515	37	35	3	3	NUM
dpc-1515	37	36	]	]	PUNCT
dpc-1515	37	37	.	.	PUNCT
dpc-1515	38	1	there	there	PRON
dpc-1515	38	2	is	be	VERB
dpc-1515	38	3	extensive	extensive	ADJ
dpc-1515	38	4	evidence	evidence	NOUN
dpc-1515	38	5	regarding	regard	VERB
dpc-1515	38	6	ak	ak	PROPN
dpc-1515	38	7	risk	risk	NOUN
dpc-1515	38	8	factors	factor	NOUN
dpc-1515	38	9	.	.	PUNCT
dpc-1515	39	1	for	for	ADP
dpc-1515	39	2	instance	instance	NOUN
dpc-1515	39	3	,	,	PUNCT
dpc-1515	39	4	uv	uv	NOUN
dpc-1515	39	5	irradiation	irradiation	NOUN
dpc-1515	39	6	promotes	promote	VERB
dpc-1515	39	7	carcinogenesis	carcinogenesis	NOUN
dpc-1515	39	8	through	through	ADP
dpc-1515	39	9	the	the	DET
dpc-1515	39	10	induction	induction	NOUN
dpc-1515	39	11	of	of	ADP
dpc-1515	39	12	p53	p53	NOUN
dpc-1515	39	13	mutations	mutation	NOUN
dpc-1515	39	14	,	,	PUNCT
dpc-1515	39	15	which	which	PRON
dpc-1515	39	16	elude	elude	VERB
dpc-1515	39	17	cell	cell	NOUN
dpc-1515	39	18	-	-	PUNCT
dpc-1515	39	19	cycle	cycle	NOUN
dpc-1515	39	20	checkpoints	checkpoint	NOUN
dpc-1515	39	21	and	and	CCONJ
dpc-1515	39	22	promote	promote	VERB
dpc-1515	39	23	the	the	DET
dpc-1515	39	24	uncontrolled	uncontrolled	ADJ
dpc-1515	39	25	proliferation	proliferation	NOUN
dpc-1515	39	26	of	of	ADP
dpc-1515	39	27	dysplastic	dysplastic	ADJ
dpc-1515	39	28	keratinocytes	keratinocyte	NOUN
dpc-1515	39	29	[	[	X
dpc-1515	39	30	2	2	NUM
dpc-1515	39	31	]	]	PUNCT
dpc-1515	39	32	.	.	PUNCT
dpc-1515	40	1	recent	recent	ADJ
dpc-1515	40	2	advances	advance	NOUN
dpc-1515	40	3	confirm	confirm	VERB
dpc-1515	40	4	the	the	DET
dpc-1515	40	5	influential	influential	ADJ
dpc-1515	40	6	role	role	NOUN
dpc-1515	40	7	of	of	ADP
dpc-1515	40	8	uvb	uvb	ADJ
dpc-1515	40	9	rays	ray	NOUN
dpc-1515	40	10	in	in	ADP
dpc-1515	40	11	the	the	DET
dpc-1515	40	12	formation	formation	NOUN
dpc-1515	40	13	of	of	ADP
dpc-1515	40	14	thymidine	thymidine	ADJ
dpc-1515	40	15	dimers	dimer	NOUN
dpc-1515	40	16	in	in	ADP
dpc-1515	40	17	the	the	DET
dpc-1515	40	18	dna	dna	PROPN
dpc-1515	40	19	and	and	CCONJ
dpc-1515	40	20	rna	rna	PROPN
dpc-1515	40	21	of	of	ADP
dpc-1515	40	22	keratinocytes	keratinocyte	NOUN
dpc-1515	40	23	[	[	X
dpc-1515	40	24	2	2	NUM
dpc-1515	40	25	]	]	PUNCT
dpc-1515	40	26	.	.	PUNCT
dpc-1515	41	1	as	as	ADP
dpc-1515	41	2	a	a	DET
dpc-1515	41	3	consequence	consequence	NOUN
dpc-1515	41	4	,	,	PUNCT
dpc-1515	41	5	cumulative	cumulative	ADJ
dpc-1515	41	6	sun	sun	NOUN
dpc-1515	41	7	exposure	exposure	NOUN
dpc-1515	41	8	is	be	AUX
dpc-1515	41	9	closely	closely	ADV
dpc-1515	41	10	related	relate	VERB
dpc-1515	41	11	to	to	ADP
dpc-1515	41	12	the	the	DET
dpc-1515	41	13	onset	onset	NOUN
dpc-1515	41	14	of	of	ADP
dpc-1515	41	15	ak	ak	PROPN
dpc-1515	41	16	and	and	CCONJ
dpc-1515	41	17	scc	scc	PROPN
dpc-1515	41	18	in	in	ADP
dpc-1515	41	19	the	the	DET
dpc-1515	41	20	photo	photo	NOUN
dpc-1515	41	21	-	-	PUNCT
dpc-1515	41	22	exposed	expose	VERB
dpc-1515	41	23	areas	area	NOUN
dpc-1515	41	24	[	[	X
dpc-1515	41	25	4	4	NUM
dpc-1515	41	26	]	]	PUNCT
dpc-1515	41	27	.	.	PUNCT
dpc-1515	42	1	both	both	DET
dpc-1515	42	2	a	a	DET
dpc-1515	42	3	history	history	NOUN
dpc-1515	42	4	of	of	ADP
dpc-1515	42	5	sunburns	sunburn	NOUN
dpc-1515	42	6	,	,	PUNCT
dpc-1515	42	7	mainly	mainly	ADV
dpc-1515	42	8	those	those	PRON
dpc-1515	42	9	occurring	occur	VERB
dpc-1515	42	10	in	in	ADP
dpc-1515	42	11	childhood	childhood	NOUN
dpc-1515	42	12	[	[	X
dpc-1515	42	13	5	5	NUM
dpc-1515	42	14	]	]	PUNCT
dpc-1515	42	15	,	,	PUNCT
dpc-1515	42	16	and	and	CCONJ
dpc-1515	42	17	chronic	chronic	ADJ
dpc-1515	42	18	sun	sun	NOUN
dpc-1515	42	19	exposure	exposure	NOUN
dpc-1515	42	20	(	(	PUNCT
dpc-1515	42	21	due	due	ADP
dpc-1515	42	22	to	to	ADP
dpc-1515	42	23	outdoor	outdoor	ADJ
dpc-1515	42	24	occupations	occupation	NOUN
dpc-1515	42	25	or	or	CCONJ
dpc-1515	42	26	hobbies	hobby	NOUN
dpc-1515	42	27	)	)	PUNCT
dpc-1515	42	28	increase	increase	VERB
dpc-1515	42	29	the	the	DET
dpc-1515	42	30	risk	risk	NOUN
dpc-1515	42	31	of	of	ADP
dpc-1515	42	32	developing	develop	VERB
dpc-1515	42	33	ak	ak	PROPN
dpc-1515	42	34	,	,	PUNCT
dpc-1515	42	35	with	with	ADP
dpc-1515	42	36	an	an	DET
dpc-1515	42	37	increasing	increase	VERB
dpc-1515	42	38	trend	trend	NOUN
dpc-1515	42	39	towards	towards	ADP
dpc-1515	42	40	older	old	ADJ
dpc-1515	42	41	ages	age	NOUN
dpc-1515	42	42	[	[	X
dpc-1515	42	43	4	4	NUM
dpc-1515	42	44	]	]	PUNCT
dpc-1515	42	45	.	.	PUNCT
dpc-1515	43	1	moreover	moreover	ADV
dpc-1515	43	2	,	,	PUNCT
dpc-1515	43	3	the	the	DET
dpc-1515	43	4	most	most	ADV
dpc-1515	43	5	susceptible	susceptible	ADJ
dpc-1515	43	6	subjects	subject	NOUN
dpc-1515	43	7	have	have	VERB
dpc-1515	43	8	fair	fair	ADJ
dpc-1515	43	9	skin	skin	NOUN
dpc-1515	43	10	phototypes	phototype	NOUN
dpc-1515	43	11	[	[	X
dpc-1515	43	12	4	4	NUM
dpc-1515	43	13	]	]	PUNCT
dpc-1515	43	14	or	or	CCONJ
dpc-1515	43	15	are	be	AUX
dpc-1515	43	16	immunosuppressed	immunosuppresse	VERB
dpc-1515	43	17	(	(	PUNCT
dpc-1515	43	18	eg	eg	NOUN
dpc-1515	43	19	,	,	PUNCT
dpc-1515	43	20	transplant	transplant	NOUN
dpc-1515	43	21	recipients	recipient	NOUN
dpc-1515	43	22	and	and	CCONJ
dpc-1515	43	23	people	people	NOUN
dpc-1515	43	24	with	with	ADP
dpc-1515	43	25	genetic	genetic	ADJ
dpc-1515	43	26	disorders	disorder	NOUN
dpc-1515	43	27	affecting	affect	VERB
dpc-1515	43	28	dna	dna	NOUN
dpc-1515	43	29	-	-	PUNCT
dpc-1515	43	30	repair	repair	NOUN
dpc-1515	43	31	mechanisms	mechanism	NOUN
dpc-1515	43	32	)	)	PUNCT
dpc-1515	44	1	[	[	X
dpc-1515	44	2	2	2	NUM
dpc-1515	44	3	]	]	PUNCT
dpc-1515	44	4	.	.	PUNCT
dpc-1515	45	1	additional	additional	ADJ
dpc-1515	45	2	risk	risk	NOUN
dpc-1515	45	3	factors	factor	NOUN
dpc-1515	45	4	are	be	AUX
dpc-1515	45	5	male	male	ADJ
dpc-1515	45	6	sex	sex	NOUN
dpc-1515	45	7	,	,	PUNCT
dpc-1515	45	8	a	a	DET
dpc-1515	45	9	smoking	smoking	NOUN
dpc-1515	45	10	habit	habit	NOUN
dpc-1515	45	11	,	,	PUNCT
dpc-1515	45	12	and	and	CCONJ
dpc-1515	45	13	the	the	DET
dpc-1515	45	14	assumption	assumption	NOUN
dpc-1515	45	15	of	of	ADP
dpc-1515	45	16	photosensitizing	photosensitize	VERB
dpc-1515	45	17	drugs	drug	NOUN
dpc-1515	45	18	[	[	X
dpc-1515	45	19	6,7	6,7	NUM
dpc-1515	45	20	]	]	PUNCT
dpc-1515	45	21	.	.	PUNCT
dpc-1515	46	1	the	the	DET
dpc-1515	46	2	assumption	assumption	NOUN
dpc-1515	46	3	of	of	ADP
dpc-1515	46	4	drugs	drug	NOUN
dpc-1515	46	5	that	that	PRON
dpc-1515	46	6	target	target	VERB
dpc-1515	46	7	the	the	DET
dpc-1515	46	8	skin	skin	NOUN
dpc-1515	46	9	by	by	ADP
dpc-1515	46	10	any	any	DET
dpc-1515	46	11	mechanism	mechanism	NOUN
dpc-1515	46	12	(	(	PUNCT
dpc-1515	46	13	eg	eg	NOUN
dpc-1515	46	14	,	,	PUNCT
dpc-1515	46	15	dermal	dermal	ADJ
dpc-1515	46	16	deposit	deposit	NOUN
dpc-1515	46	17	,	,	PUNCT
dpc-1515	46	18	skin	skin	NOUN
dpc-1515	46	19	thinning	thinning	NOUN
dpc-1515	46	20	)	)	PUNCT
dpc-1515	46	21	,	,	PUNCT
dpc-1515	46	22	such	such	ADJ
dpc-1515	46	23	as	as	ADP
dpc-1515	46	24	oral	oral	ADJ
dpc-1515	46	25	retinoids	retinoid	NOUN
dpc-1515	46	26	,	,	PUNCT
dpc-1515	46	27	topical	topical	ADJ
dpc-1515	46	28	retinoids	retinoid	NOUN
dpc-1515	46	29	,	,	PUNCT
dpc-1515	46	30	tetracycline	tetracycline	NOUN
dpc-1515	46	31	,	,	PUNCT
dpc-1515	46	32	macrolides	macrolide	NOUN
dpc-1515	46	33	,	,	PUNCT
dpc-1515	46	34	aminoquinolines	aminoquinoline	NOUN
dpc-1515	46	35	,	,	PUNCT
dpc-1515	46	36	amiodarone	amiodarone	NOUN
dpc-1515	46	37	,	,	PUNCT
dpc-1515	46	38	and	and	CCONJ
dpc-1515	46	39	methoxypsoralen	methoxypsoralen	ADJ
dpc-1515	46	40	,	,	PUNCT
dpc-1515	46	41	make	make	VERB
dpc-1515	46	42	the	the	DET
dpc-1515	46	43	skin	skin	NOUN
dpc-1515	46	44	more	more	ADV
dpc-1515	46	45	vulnerable	vulnerable	ADJ
dpc-1515	46	46	to	to	ADP
dpc-1515	46	47	sun	sun	NOUN
dpc-1515	46	48	damage	damage	NOUN
dpc-1515	46	49	[	[	X
dpc-1515	46	50	7	7	NUM
dpc-1515	46	51	]	]	PUNCT
dpc-1515	46	52	.	.	PUNCT
dpc-1515	47	1	in	in	ADP
dpc-1515	47	2	2018	2018	NUM
dpc-1515	47	3	,	,	PUNCT
dpc-1515	47	4	the	the	DET
dpc-1515	47	5	european	european	PROPN
dpc-1515	47	6	medicines	medicines	PROPN
dpc-1515	47	7	agency	agency	NOUN
dpc-1515	47	8	(	(	PUNCT
dpc-1515	47	9	ema	ema	PROPN
dpc-1515	47	10	)	)	PUNCT
dpc-1515	47	11	released	release	VERB
dpc-1515	47	12	a	a	DET
dpc-1515	47	13	warning	warning	NOUN
dpc-1515	47	14	concerning	concern	VERB
dpc-1515	47	15	the	the	DET
dpc-1515	47	16	risk	risk	NOUN
dpc-1515	47	17	of	of	ADP
dpc-1515	47	18	developing	develop	VERB
dpc-1515	47	19	non	non	ADJ
dpc-1515	47	20	-	-	ADJ
dpc-1515	47	21	melanoma	melanoma	ADJ
dpc-1515	47	22	skin	skin	NOUN
dpc-1515	47	23	cancer	cancer	NOUN
dpc-1515	47	24	(	(	PUNCT
dpc-1515	47	25	nmsc	nmsc	NOUN
dpc-1515	47	26	)	)	PUNCT
dpc-1515	47	27	from	from	ADP
dpc-1515	47	28	the	the	DET
dpc-1515	47	29	use	use	NOUN
dpc-1515	47	30	of	of	ADP
dpc-1515	47	31	thiazide	thiazide	ADJ
dpc-1515	47	32	diuretics	diuretic	NOUN
dpc-1515	47	33	[	[	X
dpc-1515	47	34	8	8	NUM
dpc-1515	47	35	]	]	PUNCT
dpc-1515	47	36	.	.	PUNCT
dpc-1515	48	1	the	the	DET
dpc-1515	48	2	ema	ema	PROPN
dpc-1515	48	3	pharmacovigilance	pharmacovigilance	NOUN
dpc-1515	48	4	risk	risk	NOUN
dpc-1515	48	5	assessment	assessment	NOUN
dpc-1515	48	6	committee	committee	NOUN
dpc-1515	48	7	based	base	VERB
dpc-1515	48	8	this	this	DET
dpc-1515	48	9	warning	warning	NOUN
dpc-1515	48	10	on	on	ADP
dpc-1515	48	11	the	the	DET
dpc-1515	48	12	results	result	NOUN
dpc-1515	48	13	of	of	ADP
dpc-1515	48	14	a	a	DET
dpc-1515	48	15	danish	danish	ADJ
dpc-1515	48	16	case	case	NOUN
dpc-1515	48	17	-	-	PUNCT
dpc-1515	48	18	control	control	NOUN
dpc-1515	48	19	study	study	NOUN
dpc-1515	48	20	that	that	PRON
dpc-1515	48	21	found	find	VERB
dpc-1515	48	22	dose	dose	NOUN
dpc-1515	48	23	-	-	PUNCT
dpc-1515	48	24	response	response	NOUN
dpc-1515	48	25	relationships	relationship	NOUN
dpc-1515	48	26	between	between	ADP
dpc-1515	48	27	the	the	DET
dpc-1515	48	28	long	long	ADJ
dpc-1515	48	29	-	-	PUNCT
dpc-1515	48	30	term	term	NOUN
dpc-1515	48	31	intake	intake	NOUN
dpc-1515	48	32	of	of	ADP
dpc-1515	48	33	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	48	34	and	and	CCONJ
dpc-1515	48	35	the	the	DET
dpc-1515	48	36	risk	risk	NOUN
dpc-1515	48	37	of	of	ADP
dpc-1515	48	38	developing	develop	VERB
dpc-1515	48	39	basal	basal	NOUN
dpc-1515	48	40	cell	cell	NOUN
dpc-1515	48	41	carcinoma	carcinoma	NOUN
dpc-1515	48	42	and	and	CCONJ
dpc-1515	48	43	scc	scc	NOUN
dpc-1515	49	1	[	[	X
dpc-1515	49	2	9	9	NUM
dpc-1515	49	3	]	]	PUNCT
dpc-1515	49	4	.	.	PUNCT
dpc-1515	50	1	therefore	therefore	ADV
dpc-1515	50	2	,	,	PUNCT
dpc-1515	50	3	patients	patient	NOUN
dpc-1515	50	4	assuming	assume	VERB
dpc-1515	50	5	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	50	6	alone	alone	ADV
dpc-1515	50	7	or	or	CCONJ
dpc-1515	50	8	in	in	ADP
dpc-1515	50	9	combination	combination	NOUN
dpc-1515	50	10	with	with	ADP
dpc-1515	50	11	other	other	ADJ
dpc-1515	50	12	diuretics	diuretic	NOUN
dpc-1515	50	13	,	,	PUNCT
dpc-1515	50	14	or	or	CCONJ
dpc-1515	50	15	nondiuretic	nondiuretic	ADJ
dpc-1515	50	16	antihypertensives	antihypertensive	NOUN
dpc-1515	50	17	,	,	PUNCT
dpc-1515	50	18	especially	especially	ADV
dpc-1515	50	19	those	those	PRON
dpc-1515	50	20	with	with	ADP
dpc-1515	50	21	prior	prior	ADJ
dpc-1515	50	22	nmsc	nmsc	NOUN
dpc-1515	50	23	,	,	PUNCT
dpc-1515	50	24	are	be	AUX
dpc-1515	50	25	recommended	recommend	VERB
dpc-1515	50	26	to	to	PART
dpc-1515	50	27	apply	apply	VERB
dpc-1515	50	28	sunscreen	sunscreen	NOUN
dpc-1515	50	29	daily	daily	ADV
dpc-1515	50	30	and	and	CCONJ
dpc-1515	50	31	to	to	PART
dpc-1515	50	32	attend	attend	VERB
dpc-1515	50	33	regular	regular	ADJ
dpc-1515	50	34	dermatological	dermatological	ADJ
dpc-1515	50	35	check	check	NOUN
dpc-1515	50	36	-	-	PUNCT
dpc-1515	50	37	ups	up	NOUN
dpc-1515	50	38	.	.	PUNCT
dpc-1515	51	1	prompted	prompt	VERB
dpc-1515	51	2	by	by	ADP
dpc-1515	51	3	this	this	DET
dpc-1515	51	4	warning	warning	NOUN
dpc-1515	51	5	,	,	PUNCT
dpc-1515	51	6	we	we	PRON
dpc-1515	51	7	performed	perform	VERB
dpc-1515	51	8	a	a	DET
dpc-1515	51	9	prospective	prospective	ADJ
dpc-1515	51	10	,	,	PUNCT
dpc-1515	51	11	single	single	ADJ
dpc-1515	51	12	-	-	PUNCT
dpc-1515	51	13	center	center	NOUN
dpc-1515	51	14	case	case	NOUN
dpc-1515	51	15	-	-	PUNCT
dpc-1515	51	16	control	control	NOUN
dpc-1515	51	17	study	study	NOUN
dpc-1515	51	18	to	to	PART
dpc-1515	51	19	evaluate	evaluate	VERB
dpc-1515	51	20	a	a	DET
dpc-1515	51	21	possible	possible	ADJ
dpc-1515	51	22	association	association	NOUN
dpc-1515	51	23	between	between	ADP
dpc-1515	51	24	the	the	DET
dpc-1515	51	25	use	use	NOUN
dpc-1515	51	26	of	of	ADP
dpc-1515	51	27	photosensitizing	photosensitize	VERB
dpc-1515	51	28	drugs	drug	NOUN
dpc-1515	51	29	and	and	CCONJ
dpc-1515	51	30	the	the	DET
dpc-1515	51	31	development	development	NOUN
dpc-1515	51	32	of	of	ADP
dpc-1515	51	33	ak	ak	PROPN
dpc-1515	51	34	.	.	PROPN
dpc-1515	52	1	a	a	DET
dpc-1515	52	2	secondary	secondary	ADJ
dpc-1515	52	3	aim	aim	NOUN
dpc-1515	52	4	of	of	ADP
dpc-1515	52	5	the	the	DET
dpc-1515	52	6	study	study	NOUN
dpc-1515	52	7	was	be	AUX
dpc-1515	52	8	to	to	PART
dpc-1515	52	9	identify	identify	VERB
dpc-1515	52	10	a	a	DET
dpc-1515	52	11	possible	possible	ADJ
dpc-1515	52	12	association	association	NOUN
dpc-1515	52	13	between	between	ADP
dpc-1515	52	14	any	any	DET
dpc-1515	52	15	medication	medication	NOUN
dpc-1515	52	16	other	other	ADJ
dpc-1515	52	17	than	than	ADP
dpc-1515	52	18	those	those	DET
dpc-1515	52	19	primarily	primarily	ADV
dpc-1515	52	20	examined	examine	VERB
dpc-1515	52	21	and	and	CCONJ
dpc-1515	52	22	ak	ak	PROPN
dpc-1515	52	23	.	.	PROPN
dpc-1515	52	24	materials	material	NOUN
dpc-1515	52	25	and	and	CCONJ
dpc-1515	52	26	methods	method	NOUN
dpc-1515	52	27	over	over	ADP
dpc-1515	52	28	a	a	DET
dpc-1515	52	29	6	6	NUM
dpc-1515	52	30	-	-	PUNCT
dpc-1515	52	31	month	month	NOUN
dpc-1515	52	32	period	period	NOUN
dpc-1515	52	33	,	,	PUNCT
dpc-1515	52	34	90	90	NUM
dpc-1515	52	35	ak	ak	PROPN
dpc-1515	52	36	cases	case	NOUN
dpc-1515	52	37	were	be	AUX
dpc-1515	52	38	recruited	recruit	VERB
dpc-1515	52	39	consecutively	consecutively	ADV
dpc-1515	52	40	from	from	ADP
dpc-1515	52	41	the	the	DET
dpc-1515	52	42	dedicated	dedicated	ADJ
dpc-1515	52	43	nmsc	nmsc	NOUN
dpc-1515	52	44	outpatient	outpatient	NOUN
dpc-1515	52	45	service	service	NOUN
dpc-1515	52	46	and	and	CCONJ
dpc-1515	52	47	90	90	NUM
dpc-1515	52	48	controls	control	NOUN
dpc-1515	52	49	were	be	AUX
dpc-1515	52	50	recruited	recruit	VERB
dpc-1515	52	51	from	from	ADP
dpc-1515	52	52	several	several	ADJ
dpc-1515	52	53	services	service	NOUN
dpc-1515	52	54	of	of	ADP
dpc-1515	52	55	general	general	ADJ
dpc-1515	52	56	dermatology	dermatology	NOUN
dpc-1515	52	57	at	at	ADP
dpc-1515	52	58	the	the	DET
dpc-1515	52	59	sant’orsola	sant’orsola	PROPN
dpc-1515	52	60	-	-	PUNCT
dpc-1515	52	61	malpighi	malpighi	PROPN
dpc-1515	52	62	hospital	hospital	NOUN
dpc-1515	52	63	.	.	PUNCT
dpc-1515	53	1	the	the	DET
dpc-1515	53	2	study	study	NOUN
dpc-1515	53	3	was	be	AUX
dpc-1515	53	4	approved	approve	VERB
dpc-1515	53	5	by	by	ADP
dpc-1515	53	6	central	central	ADJ
dpc-1515	53	7	emilia	emilia	PROPN
dpc-1515	53	8	wide	wide	ADJ
dpc-1515	53	9	area	area	PROPN
dpc-1515	53	10	ethical	ethical	PROPN
dpc-1515	53	11	committee	committee	NOUN
dpc-1515	53	12	;	;	PUNCT
dpc-1515	53	13	it	it	PRON
dpc-1515	53	14	started	start	VERB
dpc-1515	53	15	on	on	ADP
dpc-1515	53	16	january	january	PROPN
dpc-1515	53	17	1	1	NUM
dpc-1515	53	18	,	,	PUNCT
dpc-1515	53	19	2020	2020	NUM
dpc-1515	53	20	,	,	PUNCT
dpc-1515	53	21	and	and	CCONJ
dpc-1515	53	22	ended	end	VERB
dpc-1515	53	23	on	on	ADP
dpc-1515	53	24	may	may	PROPN
dpc-1515	53	25	31	31	NUM
dpc-1515	53	26	,	,	PUNCT
dpc-1515	53	27	2020	2020	NUM
dpc-1515	53	28	.	.	PUNCT
dpc-1515	54	1	a	a	DET
dpc-1515	54	2	cut	cut	VERB
dpc-1515	54	3	-	-	PUNCT
dpc-1515	54	4	off	off	ADP
dpc-1515	54	5	age	age	NOUN
dpc-1515	54	6	higher	high	ADJ
dpc-1515	54	7	than	than	ADP
dpc-1515	54	8	60	60	NUM
dpc-1515	54	9	years	year	NOUN
dpc-1515	54	10	was	be	AUX
dpc-1515	54	11	set	set	VERB
dpc-1515	54	12	as	as	ADP
dpc-1515	54	13	an	an	DET
dpc-1515	54	14	inclusion	inclusion	NOUN
dpc-1515	54	15	criterion	criterion	NOUN
dpc-1515	54	16	for	for	ADP
dpc-1515	54	17	both	both	DET
dpc-1515	54	18	groups	group	NOUN
dpc-1515	54	19	.	.	PUNCT
dpc-1515	55	1	a	a	DET
dpc-1515	55	2	medical	medical	ADJ
dpc-1515	55	3	history	history	NOUN
dpc-1515	55	4	of	of	ADP
dpc-1515	55	5	ak	ak	PROPN
dpc-1515	55	6	or	or	CCONJ
dpc-1515	55	7	nmsc	nmsc	NOUN
dpc-1515	55	8	was	be	AUX
dpc-1515	55	9	an	an	DET
dpc-1515	55	10	exclusion	exclusion	NOUN
dpc-1515	55	11	criterion	criterion	NOUN
dpc-1515	55	12	for	for	ADP
dpc-1515	55	13	controls	control	NOUN
dpc-1515	55	14	.	.	PUNCT
dpc-1515	56	1	all	all	DET
dpc-1515	56	2	patients	patient	NOUN
dpc-1515	56	3	provided	provide	VERB
dpc-1515	56	4	written	write	VERB
dpc-1515	56	5	informed	inform	VERB
dpc-1515	56	6	consent	consent	NOUN
dpc-1515	56	7	for	for	ADP
dpc-1515	56	8	enrollment	enrollment	NOUN
dpc-1515	56	9	in	in	ADP
dpc-1515	56	10	the	the	DET
dpc-1515	56	11	study	study	NOUN
dpc-1515	56	12	.	.	PUNCT
dpc-1515	57	1	to	to	PART
dpc-1515	57	2	collect	collect	VERB
dpc-1515	57	3	information	information	NOUN
dpc-1515	57	4	on	on	ADP
dpc-1515	57	5	sociodemographic	sociodemographic	ADJ
dpc-1515	57	6	characteristics	characteristic	NOUN
dpc-1515	57	7	,	,	PUNCT
dpc-1515	57	8	skin	skin	NOUN
dpc-1515	57	9	phototype	phototype	NOUN
dpc-1515	57	10	,	,	PUNCT
dpc-1515	57	11	cumulative	cumulative	ADJ
dpc-1515	57	12	sun	sun	NOUN
dpc-1515	57	13	exposure	exposure	NOUN
dpc-1515	57	14	,	,	PUNCT
dpc-1515	57	15	and	and	CCONJ
dpc-1515	57	16	drug	drug	NOUN
dpc-1515	57	17	intake	intake	NOUN
dpc-1515	57	18	,	,	PUNCT
dpc-1515	57	19	patients	patient	NOUN
dpc-1515	57	20	were	be	AUX
dpc-1515	57	21	interviewed	interview	VERB
dpc-1515	57	22	on	on	ADP
dpc-1515	57	23	a	a	DET
dpc-1515	57	24	standardized	standardized	ADJ
dpc-1515	57	25	questionnaire	questionnaire	NOUN
dpc-1515	57	26	and	and	CCONJ
dpc-1515	57	27	then	then	ADV
dpc-1515	57	28	examined	examine	VERB
dpc-1515	57	29	by	by	ADP
dpc-1515	57	30	an	an	DET
dpc-1515	57	31	experienced	experienced	ADJ
dpc-1515	57	32	dermatologist	dermatologist	NOUN
dpc-1515	57	33	.	.	PUNCT
dpc-1515	58	1	sun	sun	NOUN
dpc-1515	58	2	exposure	exposure	NOUN
dpc-1515	58	3	was	be	AUX
dpc-1515	58	4	considered	consider	VERB
dpc-1515	58	5	high	high	ADJ
dpc-1515	58	6	in	in	ADP
dpc-1515	58	7	the	the	DET
dpc-1515	58	8	case	case	NOUN
dpc-1515	58	9	of	of	ADP
dpc-1515	58	10	more	more	ADJ
dpc-1515	58	11	than	than	ADP
dpc-1515	58	12	a	a	DET
dpc-1515	58	13	5	5	NUM
dpc-1515	58	14	-	-	PUNCT
dpc-1515	58	15	year	year	NOUN
dpc-1515	58	16	outdoor	outdoor	ADJ
dpc-1515	58	17	occupation	occupation	NOUN
dpc-1515	58	18	or	or	CCONJ
dpc-1515	58	19	more	more	ADJ
dpc-1515	58	20	than	than	ADP
dpc-1515	58	21	10	10	NUM
dpc-1515	58	22	years	year	NOUN
dpc-1515	58	23	of	of	ADP
dpc-1515	58	24	outdoor	outdoor	ADJ
dpc-1515	58	25	recreational	recreational	ADJ
dpc-1515	58	26	exposure	exposure	NOUN
dpc-1515	58	27	.	.	PUNCT
dpc-1515	59	1	the	the	DET
dpc-1515	59	2	survey	survey	NOUN
dpc-1515	59	3	also	also	ADV
dpc-1515	59	4	inquired	inquire	VERB
dpc-1515	59	5	about	about	ADP
dpc-1515	59	6	the	the	DET
dpc-1515	59	7	long	long	ADJ
dpc-1515	59	8	-	-	PUNCT
dpc-1515	59	9	term	term	NOUN
dpc-1515	59	10	use	use	NOUN
dpc-1515	59	11	of	of	ADP
dpc-1515	59	12	any	any	DET
dpc-1515	59	13	class	class	NOUN
dpc-1515	59	14	of	of	ADP
dpc-1515	59	15	medications	medication	NOUN
dpc-1515	59	16	,	,	PUNCT
dpc-1515	59	17	including	include	VERB
dpc-1515	59	18	drugs	drug	NOUN
dpc-1515	59	19	taken	take	VERB
dpc-1515	59	20	for	for	ADP
dpc-1515	59	21	at	at	ADV
dpc-1515	59	22	least	least	ADV
dpc-1515	59	23	2	2	NUM
dpc-1515	59	24	consecutive	consecutive	ADJ
dpc-1515	59	25	years	year	NOUN
dpc-1515	59	26	and	and	CCONJ
dpc-1515	59	27	withdrawn	withdraw	VERB
dpc-1515	59	28	within	within	ADP
dpc-1515	59	29	3	3	NUM
dpc-1515	59	30	months	month	NOUN
dpc-1515	59	31	of	of	ADP
dpc-1515	59	32	the	the	DET
dpc-1515	59	33	index	index	NOUN
dpc-1515	59	34	date	date	NOUN
dpc-1515	59	35	.	.	PUNCT
dpc-1515	60	1	data	datum	NOUN
dpc-1515	60	2	recorded	record	VERB
dpc-1515	60	3	included	include	VERB
dpc-1515	60	4	the	the	DET
dpc-1515	60	5	drug	drug	NOUN
dpc-1515	60	6	’s	’s	PART
dpc-1515	60	7	active	active	ADJ
dpc-1515	60	8	ingredient	ingredient	NOUN
dpc-1515	60	9	,	,	PUNCT
dpc-1515	60	10	daily	daily	ADJ
dpc-1515	60	11	dosage	dosage	NOUN
dpc-1515	60	12	,	,	PUNCT
dpc-1515	60	13	duration	duration	NOUN
dpc-1515	60	14	of	of	ADP
dpc-1515	60	15	therapy	therapy	NOUN
dpc-1515	60	16	and	and	CCONJ
dpc-1515	60	17	,	,	PUNCT
dpc-1515	60	18	in	in	ADP
dpc-1515	60	19	case	case	NOUN
dpc-1515	60	20	of	of	ADP
dpc-1515	60	21	dosage	dosage	NOUN
dpc-1515	60	22	variation	variation	NOUN
dpc-1515	60	23	,	,	PUNCT
dpc-1515	60	24	the	the	DET
dpc-1515	60	25	new	new	ADJ
dpc-1515	60	26	dosage	dosage	NOUN
dpc-1515	60	27	and	and	CCONJ
dpc-1515	60	28	year	year	NOUN
dpc-1515	60	29	of	of	ADP
dpc-1515	60	30	variation	variation	NOUN
dpc-1515	60	31	.	.	PUNCT
dpc-1515	61	1	for	for	ADP
dpc-1515	61	2	each	each	DET
dpc-1515	61	3	patient	patient	NOUN
dpc-1515	61	4	,	,	PUNCT
dpc-1515	61	5	cumulative	cumulative	ADJ
dpc-1515	61	6	exposure	exposure	NOUN
dpc-1515	61	7	was	be	AUX
dpc-1515	61	8	calculated	calculate	VERB
dpc-1515	61	9	as	as	ADP
dpc-1515	61	10	the	the	DET
dpc-1515	61	11	product	product	NOUN
dpc-1515	61	12	of	of	ADP
dpc-1515	61	13	the	the	DET
dpc-1515	61	14	duration	duration	NOUN
dpc-1515	61	15	of	of	ADP
dpc-1515	61	16	treatment	treatment	NOUN
dpc-1515	61	17	multiplied	multiply	VERB
dpc-1515	61	18	by	by	ADP
dpc-1515	61	19	the	the	DET
dpc-1515	61	20	daily	daily	ADJ
dpc-1515	61	21	dosage	dosage	NOUN
dpc-1515	61	22	(	(	PUNCT
dpc-1515	61	23	dose	dose	NOUN
dpc-1515	61	24	unit	unit	NOUN
dpc-1515	61	25	-	-	PUNCT
dpc-1515	61	26	years	year	NOUN
dpc-1515	61	27	)	)	PUNCT
dpc-1515	61	28	.	.	PUNCT
dpc-1515	62	1	statistical	statistical	ADJ
dpc-1515	62	2	analysis	analysis	NOUN
dpc-1515	62	3	continuous	continuous	ADJ
dpc-1515	62	4	data	datum	NOUN
dpc-1515	62	5	were	be	AUX
dpc-1515	62	6	described	describe	VERB
dpc-1515	62	7	by	by	ADP
dpc-1515	62	8	means	mean	NOUN
dpc-1515	62	9	and	and	CCONJ
dpc-1515	62	10	standard	standard	ADJ
dpc-1515	62	11	deviations	deviation	NOUN
dpc-1515	62	12	(	(	PUNCT
dpc-1515	62	13	sd	sd	NOUN
dpc-1515	62	14	)	)	PUNCT
dpc-1515	62	15	or	or	CCONJ
dpc-1515	62	16	by	by	ADP
dpc-1515	62	17	median	median	NOUN
dpc-1515	62	18	and	and	CCONJ
dpc-1515	62	19	interquartile	interquartile	NOUN
dpc-1515	62	20	ranges	range	NOUN
dpc-1515	62	21	in	in	ADP
dpc-1515	62	22	case	case	NOUN
dpc-1515	62	23	of	of	ADP
dpc-1515	62	24	a	a	DET
dpc-1515	62	25	strongly	strongly	ADV
dpc-1515	62	26	asymmetric	asymmetric	ADJ
dpc-1515	62	27	distribution	distribution	NOUN
dpc-1515	62	28	(	(	PUNCT
dpc-1515	62	29	eg	eg	NOUN
dpc-1515	62	30	,	,	PUNCT
dpc-1515	62	31	exposure	exposure	NOUN
dpc-1515	62	32	to	to	ADP
dpc-1515	62	33	drugs	drug	NOUN
dpc-1515	62	34	)	)	PUNCT
dpc-1515	62	35	.	.	PUNCT
dpc-1515	63	1	for	for	ADP
dpc-1515	63	2	each	each	DET
dpc-1515	63	3	categorical	categorical	ADJ
dpc-1515	63	4	variable	variable	NOUN
dpc-1515	63	5	,	,	PUNCT
dpc-1515	63	6	we	we	PRON
dpc-1515	63	7	reported	report	VERB
dpc-1515	63	8	the	the	DET
dpc-1515	63	9	absolute	absolute	ADJ
dpc-1515	63	10	and	and	CCONJ
dpc-1515	63	11	relative	relative	ADJ
dpc-1515	63	12	frequencies	frequency	NOUN
dpc-1515	63	13	expressed	express	VERB
dpc-1515	63	14	as	as	ADP
dpc-1515	63	15	percentages	percentage	NOUN
dpc-1515	63	16	.	.	PUNCT
dpc-1515	64	1	the	the	DET
dpc-1515	64	2	comparison	comparison	NOUN
dpc-1515	64	3	between	between	ADP
dpc-1515	64	4	cases	case	NOUN
dpc-1515	64	5	and	and	CCONJ
dpc-1515	64	6	controls	control	NOUN
dpc-1515	64	7	was	be	AUX
dpc-1515	64	8	performed	perform	VERB
dpc-1515	64	9	using	use	VERB
dpc-1515	64	10	the	the	DET
dpc-1515	64	11	t	t	NOUN
dpc-1515	64	12	-	-	PUNCT
dpc-1515	64	13	test	test	NOUN
dpc-1515	64	14	for	for	ADP
dpc-1515	64	15	continuous	continuous	ADJ
dpc-1515	64	16	variables	variable	NOUN
dpc-1515	64	17	with	with	ADP
dpc-1515	64	18	a	a	DET
dpc-1515	64	19	normal	normal	ADJ
dpc-1515	64	20	research	research	NOUN
dpc-1515	64	21	|	|	ADV
dpc-1515	64	22	dermatol	dermatol	ADJ
dpc-1515	64	23	pract	pract	NOUN
dpc-1515	64	24	concept	concept	NOUN
dpc-1515	64	25	.	.	PUNCT
dpc-1515	65	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	65	2	3	3	NUM
dpc-1515	65	3	distribution	distribution	NOUN
dpc-1515	65	4	(	(	PUNCT
dpc-1515	65	5	eg	eg	NOUN
dpc-1515	65	6	,	,	PUNCT
dpc-1515	65	7	age	age	NOUN
dpc-1515	65	8	)	)	PUNCT
dpc-1515	65	9	and	and	CCONJ
dpc-1515	65	10	the	the	DET
dpc-1515	65	11	mann	mann	PROPN
dpc-1515	65	12	-	-	PUNCT
dpc-1515	65	13	whitney	whitney	PROPN
dpc-1515	65	14	test	test	NOUN
dpc-1515	65	15	for	for	ADP
dpc-1515	65	16	continuous	continuous	ADJ
dpc-1515	65	17	variables	variable	NOUN
dpc-1515	65	18	with	with	ADP
dpc-1515	65	19	a	a	DET
dpc-1515	65	20	skewed	skewed	ADJ
dpc-1515	65	21	distribution	distribution	NOUN
dpc-1515	65	22	(	(	PUNCT
dpc-1515	65	23	eg	eg	NOUN
dpc-1515	65	24	,	,	PUNCT
dpc-1515	65	25	drug	drug	NOUN
dpc-1515	65	26	exposure	exposure	NOUN
dpc-1515	65	27	)	)	PUNCT
dpc-1515	65	28	.	.	PUNCT
dpc-1515	66	1	pearson	pearson	PROPN
dpc-1515	66	2	’s	’s	PART
dpc-1515	66	3	chi	chi	ADJ
dpc-1515	66	4	-	-	PUNCT
dpc-1515	66	5	square	square	NOUN
dpc-1515	66	6	test	test	NOUN
dpc-1515	66	7	and	and	CCONJ
dpc-1515	66	8	fisher	fisher	PROPN
dpc-1515	66	9	’s	’s	PART
dpc-1515	66	10	exact	exact	ADJ
dpc-1515	66	11	test	test	NOUN
dpc-1515	66	12	were	be	AUX
dpc-1515	66	13	used	use	VERB
dpc-1515	66	14	for	for	ADP
dpc-1515	66	15	comparisons	comparison	NOUN
dpc-1515	66	16	of	of	ADP
dpc-1515	66	17	categorical	categorical	ADJ
dpc-1515	66	18	variables	variable	NOUN
dpc-1515	66	19	.	.	PUNCT
dpc-1515	67	1	to	to	PART
dpc-1515	67	2	assess	assess	VERB
dpc-1515	67	3	an	an	DET
dpc-1515	67	4	association	association	NOUN
dpc-1515	67	5	between	between	ADP
dpc-1515	67	6	drug	drug	NOUN
dpc-1515	67	7	exposure	exposure	NOUN
dpc-1515	67	8	and	and	CCONJ
dpc-1515	67	9	ak	ak	PROPN
dpc-1515	67	10	development	development	NOUN
dpc-1515	67	11	,	,	PUNCT
dpc-1515	67	12	we	we	PRON
dpc-1515	67	13	used	use	VERB
dpc-1515	67	14	a	a	DET
dpc-1515	67	15	multiple	multiple	ADJ
dpc-1515	67	16	logistic	logistic	ADJ
dpc-1515	67	17	regression	regression	NOUN
dpc-1515	67	18	model	model	NOUN
dpc-1515	67	19	adjusted	adjust	VERB
dpc-1515	67	20	for	for	ADP
dpc-1515	67	21	the	the	DET
dpc-1515	67	22	possible	possible	ADJ
dpc-1515	67	23	confounding	confound	VERB
dpc-1515	67	24	effects	effect	NOUN
dpc-1515	67	25	of	of	ADP
dpc-1515	67	26	sociodemographic	sociodemographic	ADJ
dpc-1515	67	27	characteristics	characteristic	NOUN
dpc-1515	67	28	.	.	PUNCT
dpc-1515	68	1	the	the	DET
dpc-1515	68	2	results	result	NOUN
dpc-1515	68	3	of	of	ADP
dpc-1515	68	4	logistic	logistic	ADJ
dpc-1515	68	5	regression	regression	NOUN
dpc-1515	68	6	were	be	AUX
dpc-1515	68	7	expressed	express	VERB
dpc-1515	68	8	as	as	ADP
dpc-1515	68	9	odds	odd	NOUN
dpc-1515	68	10	ratios	ratio	NOUN
dpc-1515	68	11	(	(	PUNCT
dpc-1515	68	12	ors	or	NOUN
dpc-1515	68	13	)	)	PUNCT
dpc-1515	68	14	and	and	CCONJ
dpc-1515	68	15	confidence	confidence	NOUN
dpc-1515	68	16	intervals	interval	NOUN
dpc-1515	68	17	(	(	PUNCT
dpc-1515	68	18	95	95	NUM
dpc-1515	68	19	%	%	NOUN
dpc-1515	68	20	ci	ci	NOUN
dpc-1515	68	21	)	)	PUNCT
dpc-1515	68	22	.	.	PUNCT
dpc-1515	69	1	statistical	statistical	ADJ
dpc-1515	69	2	significance	significance	NOUN
dpc-1515	69	3	was	be	AUX
dpc-1515	69	4	set	set	VERB
dpc-1515	69	5	at	at	ADP
dpc-1515	69	6	p	p	NOUN
dpc-1515	69	7	=	=	SYM
dpc-1515	69	8	.05	.05	NUM
dpc-1515	69	9	.	.	PUNCT
dpc-1515	70	1	the	the	DET
dpc-1515	70	2	analyses	analysis	NOUN
dpc-1515	70	3	were	be	AUX
dpc-1515	70	4	conducted	conduct	VERB
dpc-1515	70	5	using	use	VERB
dpc-1515	70	6	the	the	DET
dpc-1515	70	7	statistical	statistical	ADJ
dpc-1515	70	8	software	software	NOUN
dpc-1515	70	9	stata	stata	VERB
dpc-1515	70	10	version	version	NOUN
dpc-1515	70	11	15	15	NUM
dpc-1515	70	12	(	(	PUNCT
dpc-1515	70	13	statacorp	statacorp	PROPN
dpc-1515	70	14	,	,	PUNCT
dpc-1515	70	15	college	college	NOUN
dpc-1515	70	16	station	station	NOUN
dpc-1515	70	17	,	,	PUNCT
dpc-1515	70	18	tx	tx	PROPN
dpc-1515	70	19	,	,	PUNCT
dpc-1515	70	20	usa	usa	PROPN
dpc-1515	70	21	)	)	PUNCT
dpc-1515	70	22	.	.	PUNCT
dpc-1515	71	1	results	result	VERB
dpc-1515	71	2	overall	overall	ADV
dpc-1515	71	3	,	,	PUNCT
dpc-1515	71	4	180	180	NUM
dpc-1515	71	5	patients	patient	NOUN
dpc-1515	71	6	were	be	AUX
dpc-1515	71	7	assessed	assess	VERB
dpc-1515	71	8	,	,	PUNCT
dpc-1515	71	9	90	90	NUM
dpc-1515	71	10	cases	case	NOUN
dpc-1515	71	11	and	and	CCONJ
dpc-1515	71	12	90	90	NUM
dpc-1515	71	13	controls	control	NOUN
dpc-1515	71	14	(	(	PUNCT
dpc-1515	71	15	table	table	NOUN
dpc-1515	71	16	1	1	NUM
dpc-1515	71	17	)	)	PUNCT
dpc-1515	71	18	.	.	PUNCT
dpc-1515	72	1	the	the	DET
dpc-1515	72	2	2	2	NUM
dpc-1515	72	3	groups	group	NOUN
dpc-1515	72	4	differed	differ	VERB
dpc-1515	72	5	significantly	significantly	ADV
dpc-1515	72	6	in	in	ADP
dpc-1515	72	7	age	age	NOUN
dpc-1515	72	8	,	,	PUNCT
dpc-1515	72	9	sex	sex	NOUN
dpc-1515	72	10	,	,	PUNCT
dpc-1515	72	11	skin	skin	NOUN
dpc-1515	72	12	type	type	NOUN
dpc-1515	72	13	,	,	PUNCT
dpc-1515	72	14	and	and	CCONJ
dpc-1515	72	15	recreational	recreational	ADJ
dpc-1515	72	16	sun	sun	NOUN
dpc-1515	72	17	exposure	exposure	NOUN
dpc-1515	72	18	(	(	PUNCT
dpc-1515	72	19	p	p	X
dpc-1515	72	20	<	<	X
dpc-1515	72	21	.001	.001	NUM
dpc-1515	72	22	)	)	PUNCT
dpc-1515	72	23	.	.	PUNCT
dpc-1515	73	1	compared	compare	VERB
dpc-1515	73	2	with	with	ADP
dpc-1515	73	3	controls	control	NOUN
dpc-1515	73	4	,	,	PUNCT
dpc-1515	73	5	cases	case	NOUN
dpc-1515	73	6	were	be	AUX
dpc-1515	73	7	older	old	ADJ
dpc-1515	73	8	(	(	PUNCT
dpc-1515	73	9	mean	mean	ADJ
dpc-1515	73	10	,	,	PUNCT
dpc-1515	73	11	79.4	79.4	NUM
dpc-1515	73	12	vs.	vs.	ADP
dpc-1515	73	13	73.3	73.3	NUM
dpc-1515	73	14	years	year	NOUN
dpc-1515	73	15	)	)	PUNCT
dpc-1515	73	16	,	,	PUNCT
dpc-1515	73	17	more	more	ADV
dpc-1515	73	18	frequently	frequently	ADV
dpc-1515	73	19	male	male	ADJ
dpc-1515	73	20	(	(	PUNCT
dpc-1515	73	21	73.3	73.3	NUM
dpc-1515	73	22	%	%	NOUN
dpc-1515	73	23	vs.	vs.	ADP
dpc-1515	73	24	38.9	38.9	NUM
dpc-1515	73	25	%	%	NOUN
dpc-1515	73	26	)	)	PUNCT
dpc-1515	73	27	,	,	PUNCT
dpc-1515	73	28	and	and	CCONJ
dpc-1515	73	29	more	more	ADV
dpc-1515	73	30	likely	likely	ADJ
dpc-1515	73	31	to	to	PART
dpc-1515	73	32	have	have	VERB
dpc-1515	73	33	skin	skin	NOUN
dpc-1515	73	34	phototype	phototype	NOUN
dpc-1515	73	35	i	i	PROPN
dpc-1515	73	36	-	-	PUNCT
dpc-1515	73	37	ii	ii	PROPN
dpc-1515	73	38	(	(	PUNCT
dpc-1515	73	39	52.2	52.2	NUM
dpc-1515	73	40	%	%	NOUN
dpc-1515	73	41	vs.	vs.	ADP
dpc-1515	73	42	14.4	14.4	NUM
dpc-1515	73	43	%	%	NOUN
dpc-1515	73	44	)	)	PUNCT
dpc-1515	73	45	.	.	PUNCT
dpc-1515	74	1	combined	combine	VERB
dpc-1515	74	2	sun	sun	PROPN
dpc-1515	74	3	exposure	exposure	NOUN
dpc-1515	74	4	was	be	AUX
dpc-1515	74	5	lacking	lack	VERB
dpc-1515	74	6	in	in	ADP
dpc-1515	74	7	11.1	11.1	NUM
dpc-1515	74	8	%	%	NOUN
dpc-1515	74	9	of	of	ADP
dpc-1515	74	10	cases	case	NOUN
dpc-1515	74	11	and	and	CCONJ
dpc-1515	74	12	46.6	46.6	NUM
dpc-1515	74	13	%	%	NOUN
dpc-1515	74	14	of	of	ADP
dpc-1515	74	15	controls	control	NOUN
dpc-1515	74	16	,	,	PUNCT
dpc-1515	74	17	mild	mild	ADJ
dpc-1515	74	18	-	-	PUNCT
dpc-1515	74	19	moderate	moderate	ADJ
dpc-1515	74	20	in	in	ADP
dpc-1515	74	21	4.4	4.4	NUM
dpc-1515	74	22	%	%	NOUN
dpc-1515	74	23	and	and	CCONJ
dpc-1515	74	24	18.9	18.9	NUM
dpc-1515	74	25	%	%	NOUN
dpc-1515	74	26	,	,	PUNCT
dpc-1515	74	27	and	and	CCONJ
dpc-1515	74	28	high	high	ADJ
dpc-1515	74	29	in	in	ADP
dpc-1515	74	30	84.4	84.4	NUM
dpc-1515	74	31	%	%	NOUN
dpc-1515	74	32	and	and	CCONJ
dpc-1515	74	33	34.4	34.4	NUM
dpc-1515	74	34	%	%	NOUN
dpc-1515	74	35	,	,	PUNCT
dpc-1515	74	36	respectively	respectively	ADV
dpc-1515	74	37	.	.	PUNCT
dpc-1515	75	1	no	no	DET
dpc-1515	75	2	difference	difference	NOUN
dpc-1515	75	3	in	in	ADP
dpc-1515	75	4	terms	term	NOUN
dpc-1515	75	5	of	of	ADP
dpc-1515	75	6	educational	educational	ADJ
dpc-1515	75	7	level	level	NOUN
dpc-1515	75	8	was	be	AUX
dpc-1515	75	9	observed	observe	VERB
dpc-1515	75	10	between	between	ADP
dpc-1515	75	11	the	the	DET
dpc-1515	75	12	groups	group	NOUN
dpc-1515	75	13	.	.	PUNCT
dpc-1515	76	1	drug	drug	NOUN
dpc-1515	76	2	exposure	exposure	NOUN
dpc-1515	76	3	differed	differ	VERB
dpc-1515	76	4	between	between	ADP
dpc-1515	76	5	groups	group	NOUN
dpc-1515	76	6	for	for	ADP
dpc-1515	76	7	2	2	NUM
dpc-1515	76	8	classes	class	NOUN
dpc-1515	76	9	of	of	ADP
dpc-1515	76	10	medications	medication	NOUN
dpc-1515	76	11	:	:	PUNCT
dpc-1515	76	12	angiotensin	angiotensin	NOUN
dpc-1515	76	13	receptor	receptor	NOUN
dpc-1515	76	14	blockers	blocker	NOUN
dpc-1515	76	15	(	(	PUNCT
dpc-1515	76	16	arbs	arb	NOUN
dpc-1515	76	17	)	)	PUNCT
dpc-1515	76	18	and	and	CCONJ
dpc-1515	76	19	antiplatelet	antiplatelet	VERB
dpc-1515	76	20	drugs	drug	NOUN
dpc-1515	76	21	(	(	PUNCT
dpc-1515	76	22	table	table	NOUN
dpc-1515	76	23	2	2	NUM
dpc-1515	76	24	)	)	PUNCT
dpc-1515	76	25	.	.	PUNCT
dpc-1515	77	1	similar	similar	ADJ
dpc-1515	77	2	proportions	proportion	NOUN
dpc-1515	77	3	of	of	ADP
dpc-1515	77	4	patients	patient	NOUN
dpc-1515	77	5	took	take	VERB
dpc-1515	77	6	arbs	arb	NOUN
dpc-1515	77	7	in	in	ADP
dpc-1515	77	8	the	the	DET
dpc-1515	77	9	case	case	NOUN
dpc-1515	77	10	and	and	CCONJ
dpc-1515	77	11	control	control	NOUN
dpc-1515	77	12	groups	group	NOUN
dpc-1515	77	13	(	(	PUNCT
dpc-1515	77	14	22.2	22.2	NUM
dpc-1515	77	15	%	%	NOUN
dpc-1515	77	16	vs.	vs.	ADP
dpc-1515	77	17	18.9	18.9	NUM
dpc-1515	77	18	%	%	NOUN
dpc-1515	77	19	)	)	PUNCT
dpc-1515	77	20	;	;	PUNCT
dpc-1515	77	21	however	however	ADV
dpc-1515	77	22	,	,	PUNCT
dpc-1515	77	23	the	the	DET
dpc-1515	77	24	cumulative	cumulative	ADJ
dpc-1515	77	25	exposure	exposure	NOUN
dpc-1515	77	26	was	be	AUX
dpc-1515	77	27	significantly	significantly	ADV
dpc-1515	77	28	higher	high	ADJ
dpc-1515	77	29	in	in	ADP
dpc-1515	77	30	cases	case	NOUN
dpc-1515	77	31	(	(	PUNCT
dpc-1515	77	32	p	p	X
dpc-1515	77	33	<	<	X
dpc-1515	77	34	.015	.015	NUM
dpc-1515	77	35	)	)	PUNCT
dpc-1515	77	36	.	.	PUNCT
dpc-1515	78	1	on	on	ADP
dpc-1515	78	2	the	the	DET
dpc-1515	78	3	other	other	ADJ
dpc-1515	78	4	hand	hand	NOUN
dpc-1515	78	5	,	,	PUNCT
dpc-1515	78	6	more	more	ADJ
dpc-1515	78	7	than	than	ADP
dpc-1515	78	8	twice	twice	ADV
dpc-1515	78	9	as	as	ADV
dpc-1515	78	10	many	many	ADJ
dpc-1515	78	11	cases	case	NOUN
dpc-1515	78	12	than	than	ADP
dpc-1515	78	13	controls	control	NOUN
dpc-1515	78	14	took	take	VERB
dpc-1515	78	15	antiplatelet	antiplatelet	NOUN
dpc-1515	78	16	drugs	drug	NOUN
dpc-1515	78	17	(	(	PUNCT
dpc-1515	78	18	48.9	48.9	NUM
dpc-1515	78	19	%	%	NOUN
dpc-1515	78	20	vs.	vs.	ADP
dpc-1515	78	21	22.2	22.2	NUM
dpc-1515	78	22	%	%	NOUN
dpc-1515	78	23	)	)	PUNCT
dpc-1515	78	24	.	.	PUNCT
dpc-1515	79	1	no	no	DET
dpc-1515	79	2	association	association	NOUN
dpc-1515	79	3	was	be	AUX
dpc-1515	79	4	found	find	VERB
dpc-1515	79	5	between	between	ADP
dpc-1515	79	6	ak	ak	PROPN
dpc-1515	79	7	and	and	CCONJ
dpc-1515	79	8	other	other	ADJ
dpc-1515	79	9	drugs	drug	NOUN
dpc-1515	79	10	,	,	PUNCT
dpc-1515	79	11	including	include	VERB
dpc-1515	79	12	thiazides	thiazide	NOUN
dpc-1515	79	13	and	and	CCONJ
dpc-1515	79	14	other	other	ADJ
dpc-1515	79	15	diuretics	diuretic	NOUN
dpc-1515	79	16	,	,	PUNCT
dpc-1515	79	17	statins	statin	NOUN
dpc-1515	79	18	,	,	PUNCT
dpc-1515	79	19	ß	ß	NOUN
dpc-1515	79	20	-	-	PUNCT
dpc-1515	79	21	blockers	blocker	NOUN
dpc-1515	79	22	,	,	PUNCT
dpc-1515	79	23	calcium	calcium	NOUN
dpc-1515	79	24	channel	channel	NOUN
dpc-1515	79	25	blockers	blocker	NOUN
dpc-1515	79	26	,	,	PUNCT
dpc-1515	79	27	ace	ace	VERB
dpc-1515	79	28	inhibitors	inhibitor	NOUN
dpc-1515	79	29	,	,	PUNCT
dpc-1515	79	30	anticoagulants	anticoagulant	NOUN
dpc-1515	79	31	(	(	PUNCT
dpc-1515	79	32	warfarin	warfarin	NOUN
dpc-1515	79	33	and	and	CCONJ
dpc-1515	79	34	novel	novel	ADJ
dpc-1515	79	35	oral	oral	ADJ
dpc-1515	79	36	anticoagulants	anticoagulant	NOUN
dpc-1515	79	37	)	)	PUNCT
dpc-1515	79	38	and	and	CCONJ
dpc-1515	79	39	the	the	DET
dpc-1515	79	40	antiarrhythmic	antiarrhythmic	ADJ
dpc-1515	79	41	drug	drug	NOUN
dpc-1515	79	42	amiodarone	amiodarone	PROPN
dpc-1515	79	43	(	(	PUNCT
dpc-1515	79	44	data	datum	NOUN
dpc-1515	79	45	not	not	PART
dpc-1515	79	46	shown	show	VERB
dpc-1515	79	47	)	)	PUNCT
dpc-1515	79	48	.	.	PUNCT
dpc-1515	80	1	the	the	DET
dpc-1515	80	2	exposure	exposure	NOUN
dpc-1515	80	3	to	to	ADP
dpc-1515	80	4	arbs	arbs	VERB
dpc-1515	80	5	and	and	CCONJ
dpc-1515	80	6	antiplatelet	antiplatelet	ADJ
dpc-1515	80	7	agents	agent	NOUN
dpc-1515	80	8	was	be	AUX
dpc-1515	80	9	categorized	categorize	VERB
dpc-1515	80	10	into	into	ADP
dpc-1515	80	11	3	3	NUM
dpc-1515	80	12	classes	class	NOUN
dpc-1515	80	13	:	:	PUNCT
dpc-1515	80	14	high	high	ADJ
dpc-1515	80	15	,	,	PUNCT
dpc-1515	80	16	low	low	ADJ
dpc-1515	80	17	,	,	PUNCT
dpc-1515	80	18	and	and	CCONJ
dpc-1515	80	19	no	no	DET
dpc-1515	80	20	exposure	exposure	NOUN
dpc-1515	80	21	.	.	PUNCT
dpc-1515	81	1	cut	cut	VERB
dpc-1515	81	2	-	-	PUNCT
dpc-1515	81	3	off	off	ADP
dpc-1515	81	4	values	value	NOUN
dpc-1515	81	5	of	of	ADP
dpc-1515	81	6	750	750	NUM
dpc-1515	81	7	and	and	CCONJ
dpc-1515	81	8	1100	1100	NUM
dpc-1515	81	9	unit	unit	NOUN
dpc-1515	81	10	-	-	PUNCT
dpc-1515	81	11	years	year	NOUN
dpc-1515	81	12	,	,	PUNCT
dpc-1515	81	13	respectively	respectively	ADV
dpc-1515	81	14	for	for	ADP
dpc-1515	81	15	arbs	arb	NOUN
dpc-1515	81	16	and	and	CCONJ
dpc-1515	81	17	antiplatelet	antiplatelet	NOUN
dpc-1515	81	18	drugs	drug	NOUN
dpc-1515	81	19	,	,	PUNCT
dpc-1515	81	20	were	be	AUX
dpc-1515	81	21	used	use	VERB
dpc-1515	81	22	to	to	PART
dpc-1515	81	23	distinguish	distinguish	VERB
dpc-1515	81	24	high	high	ADJ
dpc-1515	81	25	vs.	vs.	ADP
dpc-1515	81	26	low	low	ADJ
dpc-1515	81	27	exposure	exposure	NOUN
dpc-1515	81	28	.	.	PUNCT
dpc-1515	82	1	these	these	DET
dpc-1515	82	2	new	new	ADJ
dpc-1515	82	3	variables	variable	NOUN
dpc-1515	82	4	were	be	AUX
dpc-1515	82	5	included	include	VERB
dpc-1515	82	6	in	in	ADP
dpc-1515	82	7	a	a	DET
dpc-1515	82	8	logistic	logistic	ADJ
dpc-1515	82	9	regression	regression	NOUN
dpc-1515	82	10	model	model	NOUN
dpc-1515	82	11	,	,	PUNCT
dpc-1515	82	12	adjusted	adjust	VERB
dpc-1515	82	13	for	for	ADP
dpc-1515	82	14	age	age	NOUN
dpc-1515	82	15	,	,	PUNCT
dpc-1515	82	16	sex	sex	NOUN
dpc-1515	82	17	,	,	PUNCT
dpc-1515	82	18	skin	skin	NOUN
dpc-1515	82	19	type	type	NOUN
dpc-1515	82	20	,	,	PUNCT
dpc-1515	82	21	and	and	CCONJ
dpc-1515	82	22	sun	sun	NOUN
dpc-1515	82	23	exposure	exposure	NOUN
dpc-1515	82	24	(	(	PUNCT
dpc-1515	82	25	table	table	NOUN
dpc-1515	82	26	3	3	NUM
dpc-1515	82	27	)	)	PUNCT
dpc-1515	82	28	.	.	PUNCT
dpc-1515	83	1	even	even	ADV
dpc-1515	83	2	after	after	ADP
dpc-1515	83	3	adjusting	adjust	VERB
dpc-1515	83	4	for	for	ADP
dpc-1515	83	5	sociodemographic	sociodemographic	ADJ
dpc-1515	83	6	features	feature	NOUN
dpc-1515	83	7	,	,	PUNCT
dpc-1515	83	8	the	the	DET
dpc-1515	83	9	exposure	exposure	NOUN
dpc-1515	83	10	to	to	ADP
dpc-1515	83	11	arbs	arbs	VERB
dpc-1515	83	12	and	and	CCONJ
dpc-1515	83	13	antiplatelet	antiplatelet	ADJ
dpc-1515	83	14	agents	agent	NOUN
dpc-1515	83	15	was	be	AUX
dpc-1515	83	16	significantly	significantly	ADV
dpc-1515	83	17	associated	associate	VERB
dpc-1515	83	18	with	with	ADP
dpc-1515	83	19	the	the	DET
dpc-1515	83	20	presence	presence	NOUN
dpc-1515	83	21	of	of	ADP
dpc-1515	83	22	ak	ak	PROPN
dpc-1515	83	23	.	.	PROPN
dpc-1515	83	24	an	an	DET
dpc-1515	83	25	increase	increase	NOUN
dpc-1515	83	26	in	in	ADP
dpc-1515	83	27	the	the	DET
dpc-1515	83	28	probability	probability	NOUN
dpc-1515	83	29	of	of	ADP
dpc-1515	83	30	ak	ak	PROPN
dpc-1515	83	31	was	be	AUX
dpc-1515	83	32	found	find	VERB
dpc-1515	83	33	only	only	ADV
dpc-1515	83	34	with	with	ADP
dpc-1515	83	35	high	high	ADJ
dpc-1515	83	36	exposure	exposure	NOUN
dpc-1515	83	37	to	to	ADP
dpc-1515	83	38	arbs	arbs	X
dpc-1515	83	39	(	(	PUNCT
dpc-1515	83	40	or	or	CCONJ
dpc-1515	83	41	=	=	SYM
dpc-1515	83	42	13.6	13.6	NUM
dpc-1515	83	43	;	;	PUNCT
dpc-1515	83	44	95	95	NUM
dpc-1515	83	45	%	%	NOUN
dpc-1515	83	46	ci	ci	NOUN
dpc-1515	83	47	,	,	PUNCT
dpc-1515	83	48	2.0	2.0	NUM
dpc-1515	83	49	-	-	SYM
dpc-1515	83	50	93.8	93.8	NUM
dpc-1515	83	51	)	)	PUNCT
dpc-1515	83	52	.	.	PUNCT
dpc-1515	84	1	the	the	DET
dpc-1515	84	2	low	low	ADJ
dpc-1515	84	3	exposure	exposure	NOUN
dpc-1515	84	4	to	to	PART
dpc-1515	84	5	antiplatelet	antiplatelet	VERB
dpc-1515	84	6	agents	agent	NOUN
dpc-1515	84	7	was	be	AUX
dpc-1515	84	8	not	not	PART
dpc-1515	84	9	significant	significant	ADJ
dpc-1515	84	10	at	at	ADP
dpc-1515	84	11	the	the	DET
dpc-1515	84	12	statistical	statistical	ADJ
dpc-1515	84	13	analysis	analysis	NOUN
dpc-1515	84	14	(	(	PUNCT
dpc-1515	84	15	or	or	CCONJ
dpc-1515	84	16	=	=	SYM
dpc-1515	84	17	3.31	3.31	NUM
dpc-1515	84	18	;	;	PUNCT
dpc-1515	84	19	95	95	NUM
dpc-1515	84	20	%	%	NOUN
dpc-1515	84	21	ci	ci	NOUN
dpc-1515	84	22	,	,	PUNCT
dpc-1515	84	23	0.86	0.86	NUM
dpc-1515	84	24	-	-	PUNCT
dpc-1515	84	25	12.7	12.7	NUM
dpc-1515	84	26	)	)	PUNCT
dpc-1515	84	27	,	,	PUNCT
dpc-1515	84	28	but	but	CCONJ
dpc-1515	84	29	the	the	DET
dpc-1515	84	30	high	high	ADJ
dpc-1515	84	31	exposure	exposure	NOUN
dpc-1515	84	32	was	be	AUX
dpc-1515	84	33	significant	significant	ADJ
dpc-1515	84	34	(	(	PUNCT
dpc-1515	84	35	or	or	CCONJ
dpc-1515	84	36	=	=	SYM
dpc-1515	84	37	4.38	4.38	NUM
dpc-1515	84	38	;	;	PUNCT
dpc-1515	84	39	95	95	NUM
dpc-1515	84	40	%	%	NOUN
dpc-1515	84	41	ci	ci	NOUN
dpc-1515	84	42	,	,	PUNCT
dpc-1515	84	43	1.16–16.60	1.16–16.60	NUM
dpc-1515	84	44	)	)	PUNCT
dpc-1515	84	45	,	,	PUNCT
dpc-1515	84	46	showing	show	VERB
dpc-1515	84	47	a	a	DET
dpc-1515	84	48	dose	dose	NOUN
dpc-1515	84	49	-	-	PUNCT
dpc-1515	84	50	dependent	dependent	ADJ
dpc-1515	84	51	association	association	NOUN
dpc-1515	84	52	.	.	PUNCT
dpc-1515	85	1	table	table	NOUN
dpc-1515	85	2	1	1	NUM
dpc-1515	85	3	.	.	PUNCT
dpc-1515	86	1	sociodemographic	sociodemographic	ADJ
dpc-1515	86	2	features	feature	NOUN
dpc-1515	86	3	of	of	ADP
dpc-1515	86	4	cases	case	NOUN
dpc-1515	86	5	and	and	CCONJ
dpc-1515	86	6	controls	control	NOUN
dpc-1515	86	7	factor	factor	NOUN
dpc-1515	86	8	cases	case	NOUN
dpc-1515	86	9	(	(	PUNCT
dpc-1515	86	10	n	n	NOUN
dpc-1515	86	11	=	=	SYM
dpc-1515	86	12	90	90	NUM
dpc-1515	86	13	)	)	PUNCT
dpc-1515	86	14	controls	control	NOUN
dpc-1515	86	15	(	(	PUNCT
dpc-1515	86	16	n	n	NOUN
dpc-1515	86	17	=	=	SYM
dpc-1515	86	18	90	90	NUM
dpc-1515	86	19	)	)	PUNCT
dpc-1515	86	20	p	p	NOUN
dpc-1515	86	21	age	age	NOUN
dpc-1515	86	22	,	,	PUNCT
dpc-1515	86	23	mean	mean	VERB
dpc-1515	86	24	±	±	NUM
dpc-1515	86	25	sd	sd	ADP
dpc-1515	86	26	79.4	79.4	NUM
dpc-1515	86	27	±	±	NUM
dpc-1515	86	28	7.2	7.2	NUM
dpc-1515	86	29	73.3	73.3	NUM
dpc-1515	86	30	±	±	NUM
dpc-1515	86	31	8.6	8.6	NUM
dpc-1515	86	32	<	<	X
dpc-1515	86	33	.001	.001	NUM
dpc-1515	86	34	sex	sex	NOUN
dpc-1515	86	35	,	,	PUNCT
dpc-1515	86	36	no	no	INTJ
dpc-1515	86	37	.	.	PUNCT
dpc-1515	87	1	(	(	PUNCT
dpc-1515	87	2	%	%	INTJ
dpc-1515	87	3	)	)	PUNCT
dpc-1515	87	4	male	male	ADJ
dpc-1515	87	5	female	female	NOUN
dpc-1515	87	6	66	66	NUM
dpc-1515	87	7	(	(	PUNCT
dpc-1515	87	8	73.3	73.3	NUM
dpc-1515	87	9	)	)	PUNCT
dpc-1515	87	10	24	24	NUM
dpc-1515	87	11	(	(	PUNCT
dpc-1515	87	12	26.7	26.7	NUM
dpc-1515	87	13	)	)	PUNCT
dpc-1515	87	14	35	35	NUM
dpc-1515	87	15	(	(	PUNCT
dpc-1515	87	16	38.9	38.9	NUM
dpc-1515	87	17	)	)	PUNCT
dpc-1515	87	18	55(61.1	55(61.1	NOUN
dpc-1515	87	19	)	)	PUNCT
dpc-1515	87	20	<	<	X
dpc-1515	87	21	.001	.001	NUM
dpc-1515	87	22	education	education	NOUN
dpc-1515	87	23	,	,	PUNCT
dpc-1515	87	24	no	no	INTJ
dpc-1515	87	25	.	.	PUNCT
dpc-1515	88	1	(	(	PUNCT
dpc-1515	88	2	%	%	INTJ
dpc-1515	88	3	)	)	PUNCT
dpc-1515	88	4	primary	primary	ADJ
dpc-1515	88	5	school	school	NOUN
dpc-1515	88	6	middle	middle	PROPN
dpc-1515	88	7	school	school	PROPN
dpc-1515	88	8	high	high	ADJ
dpc-1515	88	9	school	school	NOUN
dpc-1515	88	10	university	university	NOUN
dpc-1515	88	11	degree	degree	NOUN
dpc-1515	88	12	37	37	NUM
dpc-1515	88	13	(	(	PUNCT
dpc-1515	88	14	41.1	41.1	NUM
dpc-1515	88	15	)	)	SYM
dpc-1515	88	16	19	19	NUM
dpc-1515	88	17	(	(	PUNCT
dpc-1515	88	18	21.1	21.1	NUM
dpc-1515	88	19	)	)	SYM
dpc-1515	88	20	23	23	NUM
dpc-1515	88	21	(	(	PUNCT
dpc-1515	88	22	25.6	25.6	NUM
dpc-1515	88	23	)	)	PUNCT
dpc-1515	88	24	11	11	NUM
dpc-1515	88	25	(	(	PUNCT
dpc-1515	88	26	12.2	12.2	NUM
dpc-1515	88	27	)	)	PUNCT
dpc-1515	88	28	26	26	NUM
dpc-1515	88	29	(	(	PUNCT
dpc-1515	88	30	28.9	28.9	NUM
dpc-1515	88	31	)	)	PUNCT
dpc-1515	88	32	18	18	NUM
dpc-1515	88	33	(	(	PUNCT
dpc-1515	88	34	20.0	20.0	NUM
dpc-1515	88	35	)	)	PUNCT
dpc-1515	88	36	23	23	NUM
dpc-1515	88	37	(	(	PUNCT
dpc-1515	88	38	25.6	25.6	NUM
dpc-1515	88	39	)	)	PUNCT
dpc-1515	88	40	23	23	NUM
dpc-1515	88	41	(	(	PUNCT
dpc-1515	88	42	25.6	25.6	NUM
dpc-1515	88	43	)	)	PUNCT
dpc-1515	88	44	.103	.103	NUM
dpc-1515	88	45	skin	skin	NOUN
dpc-1515	88	46	phototype	phototype	NOUN
dpc-1515	88	47	,	,	PUNCT
dpc-1515	88	48	no	no	INTJ
dpc-1515	88	49	.	.	PUNCT
dpc-1515	89	1	(	(	PUNCT
dpc-1515	89	2	%	%	INTJ
dpc-1515	89	3	)	)	PUNCT
dpc-1515	89	4	i	i	PROPN
dpc-1515	89	5	-	-	PUNCT
dpc-1515	89	6	ii	ii	PROPN
dpc-1515	89	7	iii	iii	PROPN
dpc-1515	89	8	-	-	PUNCT
dpc-1515	89	9	iv	iv	NUM
dpc-1515	89	10	47	47	NUM
dpc-1515	89	11	(	(	PUNCT
dpc-1515	89	12	52.2	52.2	NUM
dpc-1515	89	13	)	)	PUNCT
dpc-1515	89	14	43	43	NUM
dpc-1515	89	15	(	(	PUNCT
dpc-1515	89	16	47.8	47.8	NUM
dpc-1515	89	17	)	)	PUNCT
dpc-1515	89	18	13	13	NUM
dpc-1515	89	19	(	(	PUNCT
dpc-1515	89	20	14.4	14.4	NUM
dpc-1515	89	21	)	)	PUNCT
dpc-1515	89	22	77	77	NUM
dpc-1515	89	23	(	(	PUNCT
dpc-1515	89	24	85.6	85.6	NUM
dpc-1515	89	25	)	)	PUNCT
dpc-1515	89	26	<	<	X
dpc-1515	89	27	.001	.001	NUM
dpc-1515	89	28	sun	sun	NOUN
dpc-1515	89	29	exposure	exposure	NOUN
dpc-1515	89	30	at	at	ADP
dpc-1515	89	31	work	work	NOUN
dpc-1515	89	32	,	,	PUNCT
dpc-1515	89	33	no	no	INTJ
dpc-1515	89	34	.	.	PUNCT
dpc-1515	90	1	(	(	PUNCT
dpc-1515	90	2	%	%	INTJ
dpc-1515	90	3	)	)	PUNCT
dpc-1515	90	4	12	12	NUM
dpc-1515	90	5	(	(	PUNCT
dpc-1515	90	6	13.3	13.3	NUM
dpc-1515	90	7	)	)	PUNCT
dpc-1515	90	8	5	5	NUM
dpc-1515	90	9	(	(	PUNCT
dpc-1515	90	10	5.6	5.6	NUM
dpc-1515	90	11	)	)	PUNCT
dpc-1515	90	12	.07	.07	NUM
dpc-1515	90	13	recreational	recreational	ADJ
dpc-1515	90	14	sun	sun	NOUN
dpc-1515	90	15	exposure	exposure	NOUN
dpc-1515	90	16	,	,	PUNCT
dpc-1515	90	17	no	no	INTJ
dpc-1515	90	18	.	.	PUNCT
dpc-1515	91	1	(	(	PUNCT
dpc-1515	91	2	%	%	INTJ
dpc-1515	91	3	)	)	PUNCT
dpc-1515	91	4	absent	absent	ADJ
dpc-1515	91	5	mild	mild	ADJ
dpc-1515	91	6	-	-	PUNCT
dpc-1515	91	7	moderate	moderate	ADJ
dpc-1515	91	8	high	high	ADJ
dpc-1515	91	9	16	16	NUM
dpc-1515	91	10	(	(	PUNCT
dpc-1515	91	11	17.8	17.8	NUM
dpc-1515	91	12	)	)	PUNCT
dpc-1515	91	13	4	4	NUM
dpc-1515	91	14	(	(	PUNCT
dpc-1515	91	15	4.4	4.4	NUM
dpc-1515	91	16	)	)	PUNCT
dpc-1515	91	17	70	70	NUM
dpc-1515	91	18	(	(	PUNCT
dpc-1515	91	19	77.8	77.8	NUM
dpc-1515	91	20	)	)	PUNCT
dpc-1515	91	21	45	45	NUM
dpc-1515	91	22	(	(	PUNCT
dpc-1515	91	23	50.0	50.0	NUM
dpc-1515	91	24	)	)	PUNCT
dpc-1515	91	25	17	17	NUM
dpc-1515	91	26	(	(	PUNCT
dpc-1515	91	27	18.9	18.9	NUM
dpc-1515	91	28	)	)	PUNCT
dpc-1515	91	29	28	28	NUM
dpc-1515	91	30	(	(	PUNCT
dpc-1515	91	31	31.1	31.1	NUM
dpc-1515	91	32	)	)	PUNCT
dpc-1515	91	33	<	<	X
dpc-1515	91	34	.001	.001	NUM
dpc-1515	91	35	combined	combine	VERB
dpc-1515	91	36	sun	sun	NOUN
dpc-1515	91	37	exposure	exposure	NOUN
dpc-1515	91	38	,	,	PUNCT
dpc-1515	91	39	no	no	INTJ
dpc-1515	91	40	.	.	PUNCT
dpc-1515	92	1	(	(	PUNCT
dpc-1515	92	2	%	%	INTJ
dpc-1515	92	3	)	)	PUNCT
dpc-1515	92	4	absent	absent	ADJ
dpc-1515	92	5	mild	mild	ADJ
dpc-1515	92	6	-	-	PUNCT
dpc-1515	92	7	moderate	moderate	ADJ
dpc-1515	92	8	high	high	ADJ
dpc-1515	92	9	10	10	NUM
dpc-1515	92	10	(	(	PUNCT
dpc-1515	92	11	11.1	11.1	NUM
dpc-1515	92	12	)	)	PUNCT
dpc-1515	92	13	4	4	NUM
dpc-1515	92	14	(	(	PUNCT
dpc-1515	92	15	4.4	4.4	NUM
dpc-1515	92	16	)	)	PUNCT
dpc-1515	92	17	76	76	NUM
dpc-1515	92	18	(	(	PUNCT
dpc-1515	92	19	84.4	84.4	NUM
dpc-1515	92	20	)	)	PUNCT
dpc-1515	92	21	42	42	NUM
dpc-1515	92	22	(	(	PUNCT
dpc-1515	92	23	46.7	46.7	NUM
dpc-1515	92	24	)	)	PUNCT
dpc-1515	92	25	17	17	NUM
dpc-1515	92	26	(	(	PUNCT
dpc-1515	92	27	18.9	18.9	NUM
dpc-1515	92	28	)	)	PUNCT
dpc-1515	92	29	31	31	NUM
dpc-1515	92	30	(	(	PUNCT
dpc-1515	92	31	34.4	34.4	NUM
dpc-1515	92	32	)	)	PUNCT
dpc-1515	92	33	<	<	X
dpc-1515	92	34	0.001	0.001	NUM
dpc-1515	92	35	4	4	NUM
dpc-1515	92	36	research	research	NOUN
dpc-1515	92	37	|	|	ADV
dpc-1515	92	38	dermatol	dermatol	ADJ
dpc-1515	92	39	pract	pract	NOUN
dpc-1515	92	40	concept	concept	NOUN
dpc-1515	92	41	.	.	PUNCT
dpc-1515	93	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	93	2	table	table	NOUN
dpc-1515	93	3	2	2	NUM
dpc-1515	93	4	.	.	NOUN
dpc-1515	93	5	frequency	frequency	NOUN
dpc-1515	93	6	and	and	CCONJ
dpc-1515	93	7	duration	duration	NOUN
dpc-1515	93	8	of	of	ADP
dpc-1515	93	9	exposurea	exposurea	NOUN
dpc-1515	93	10	to	to	ADP
dpc-1515	93	11	the	the	DET
dpc-1515	93	12	examined	examine	VERB
dpc-1515	93	13	drugs	drug	NOUN
dpc-1515	93	14	drug	drug	NOUN
dpc-1515	93	15	class	class	NOUN
dpc-1515	93	16	statistical	statistical	ADJ
dpc-1515	93	17	parameter	parameter	NOUN
dpc-1515	93	18	cases	case	NOUN
dpc-1515	93	19	(	(	PUNCT
dpc-1515	93	20	n	n	NOUN
dpc-1515	93	21	=	=	SYM
dpc-1515	93	22	90	90	NUM
dpc-1515	93	23	)	)	PUNCT
dpc-1515	93	24	controls	control	NOUN
dpc-1515	93	25	(	(	PUNCT
dpc-1515	93	26	n	n	NOUN
dpc-1515	93	27	=	=	SYM
dpc-1515	93	28	90	90	NUM
dpc-1515	93	29	)	)	PUNCT
dpc-1515	93	30	p	p	NOUN
dpc-1515	93	31	angiotensin	angiotensin	NOUN
dpc-1515	93	32	receptor	receptor	NOUN
dpc-1515	93	33	blockers	blocker	NOUN
dpc-1515	93	34	n	n	PRON
dpc-1515	93	35	(	(	PUNCT
dpc-1515	93	36	%	%	INTJ
dpc-1515	93	37	)	)	PUNCT
dpc-1515	93	38	20	20	NUM
dpc-1515	93	39	(	(	PUNCT
dpc-1515	93	40	22.2	22.2	NUM
dpc-1515	93	41	)	)	PUNCT
dpc-1515	93	42	17	17	NUM
dpc-1515	93	43	(	(	PUNCT
dpc-1515	93	44	18.9	18.9	NUM
dpc-1515	93	45	)	)	PUNCT
dpc-1515	93	46	.580	.580	NUM
dpc-1515	93	47	exposure	exposure	NOUN
dpc-1515	93	48	960	960	NUM
dpc-1515	94	1	[	[	X
dpc-1515	94	2	469	469	NUM
dpc-1515	94	3	-	-	NUM
dpc-1515	94	4	2360	2360	NUM
dpc-1515	94	5	]	]	PUNCT
dpc-1515	94	6	300	300	NUM
dpc-1515	94	7	[	[	SYM
dpc-1515	94	8	90	90	NUM
dpc-1515	94	9	-	-	SYM
dpc-1515	94	10	750	750	NUM
dpc-1515	94	11	]	]	PUNCT
dpc-1515	94	12	.015	.015	NUM
dpc-1515	94	13	antiplatelet	antiplatelet	NOUN
dpc-1515	94	14	drugs	drug	NOUN
dpc-1515	94	15	n	n	CCONJ
dpc-1515	94	16	(	(	PUNCT
dpc-1515	94	17	%	%	INTJ
dpc-1515	94	18	)	)	PUNCT
dpc-1515	94	19	44	44	NUM
dpc-1515	94	20	(	(	PUNCT
dpc-1515	94	21	48.9	48.9	NUM
dpc-1515	94	22	)	)	PUNCT
dpc-1515	94	23	20	20	NUM
dpc-1515	94	24	(	(	PUNCT
dpc-1515	94	25	22.2	22.2	NUM
dpc-1515	94	26	)	)	PUNCT
dpc-1515	94	27	<	<	X
dpc-1515	94	28	.001	.001	NUM
dpc-1515	94	29	exposure	exposure	NOUN
dpc-1515	94	30	1100	1100	NUM
dpc-1515	95	1	[	[	X
dpc-1515	95	2	750	750	NUM
dpc-1515	95	3	-	-	SYM
dpc-1515	95	4	1780	1780	NUM
dpc-1515	95	5	]	]	PUNCT
dpc-1515	95	6	750[300	750[300	NUM
dpc-1515	95	7	-	-	SYM
dpc-1515	95	8	1215	1215	NUM
dpc-1515	95	9	]	]	PUNCT
dpc-1515	95	10	.037	.037	NUM
dpc-1515	95	11	statins	statin	NOUN
dpc-1515	95	12	n	n	CCONJ
dpc-1515	95	13	(	(	PUNCT
dpc-1515	95	14	%	%	INTJ
dpc-1515	95	15	)	)	PUNCT
dpc-1515	95	16	29	29	NUM
dpc-1515	95	17	(	(	PUNCT
dpc-1515	95	18	32.2	32.2	NUM
dpc-1515	95	19	)	)	PUNCT
dpc-1515	95	20	30	30	NUM
dpc-1515	95	21	(	(	PUNCT
dpc-1515	95	22	33.3	33.3	NUM
dpc-1515	95	23	)	)	PUNCT
dpc-1515	95	24	.874	.874	NUM
dpc-1515	96	1	exposure	exposure	NOUN
dpc-1515	96	2	110	110	NUM
dpc-1515	97	1	[	[	X
dpc-1515	97	2	80–180	80–180	NUM
dpc-1515	97	3	]	]	PUNCT
dpc-1515	97	4	100	100	NUM
dpc-1515	97	5	[	[	SYM
dpc-1515	97	6	60	60	NUM
dpc-1515	97	7	–	–	PUNCT
dpc-1515	97	8	190	190	NUM
dpc-1515	97	9	]	]	PUNCT
dpc-1515	97	10	.382	.382	NUM
dpc-1515	97	11	calcium	calcium	NOUN
dpc-1515	97	12	channel	channel	NOUN
dpc-1515	97	13	blockers	blocker	NOUN
dpc-1515	97	14	n	n	PRON
dpc-1515	97	15	(	(	PUNCT
dpc-1515	97	16	%	%	INTJ
dpc-1515	97	17	)	)	PUNCT
dpc-1515	97	18	15	15	NUM
dpc-1515	97	19	(	(	PUNCT
dpc-1515	97	20	16.7	16.7	NUM
dpc-1515	97	21	)	)	SYM
dpc-1515	97	22	18	18	NUM
dpc-1515	97	23	(	(	PUNCT
dpc-1515	97	24	20.0	20.0	NUM
dpc-1515	97	25	)	)	PUNCT
dpc-1515	97	26	.563	.563	NUM
dpc-1515	98	1	exposure	exposure	NOUN
dpc-1515	98	2	60	60	NUM
dpc-1515	99	1	[	[	SYM
dpc-1515	99	2	35	35	NUM
dpc-1515	99	3	-	-	SYM
dpc-1515	99	4	100	100	NUM
dpc-1515	99	5	]	]	PUNCT
dpc-1515	99	6	80	80	NUM
dpc-1515	100	1	[	[	SYM
dpc-1515	100	2	40	40	NUM
dpc-1515	100	3	-	-	SYM
dpc-1515	100	4	240	240	NUM
dpc-1515	100	5	]	]	PUNCT
dpc-1515	100	6	.638	.638	NUM
dpc-1515	100	7	beta	beta	NOUN
dpc-1515	100	8	-	-	PUNCT
dpc-1515	100	9	blockers	blocker	NOUN
dpc-1515	100	10	n	n	CCONJ
dpc-1515	100	11	(	(	PUNCT
dpc-1515	100	12	%	%	INTJ
dpc-1515	100	13	)	)	PUNCT
dpc-1515	100	14	29	29	NUM
dpc-1515	100	15	(	(	PUNCT
dpc-1515	100	16	32.2	32.2	NUM
dpc-1515	100	17	)	)	PUNCT
dpc-1515	100	18	24	24	NUM
dpc-1515	100	19	(	(	PUNCT
dpc-1515	100	20	26.7	26.7	NUM
dpc-1515	100	21	)	)	PUNCT
dpc-1515	100	22	.414	.414	NUM
dpc-1515	100	23	exposure	exposure	NOUN
dpc-1515	100	24	400	400	NUM
dpc-1515	101	1	[	[	SYM
dpc-1515	101	2	60	60	NUM
dpc-1515	101	3	-	-	SYM
dpc-1515	101	4	1100	1100	NUM
dpc-1515	101	5	]	]	PUNCT
dpc-1515	102	1	97.5	97.5	NUM
dpc-1515	102	2	[	[	SYM
dpc-1515	102	3	20	20	NUM
dpc-1515	102	4	-	-	SYM
dpc-1515	102	5	860	860	NUM
dpc-1515	102	6	]	]	PUNCT
dpc-1515	102	7	.133	.133	NUM
dpc-1515	102	8	ace	ace	NOUN
dpc-1515	102	9	inhibitors	inhibitor	NOUN
dpc-1515	102	10	n	n	PRON
dpc-1515	102	11	(	(	PUNCT
dpc-1515	102	12	%	%	INTJ
dpc-1515	102	13	)	)	PUNCT
dpc-1515	102	14	29	29	NUM
dpc-1515	102	15	(	(	PUNCT
dpc-1515	102	16	32.2	32.2	NUM
dpc-1515	102	17	)	)	PUNCT
dpc-1515	102	18	29	29	NUM
dpc-1515	102	19	(	(	PUNCT
dpc-1515	102	20	32.2	32.2	NUM
dpc-1515	102	21	)	)	PUNCT
dpc-1515	102	22	1.0	1.0	NUM
dpc-1515	102	23	exposure	exposure	NOUN
dpc-1515	102	24	52.5	52.5	NUM
dpc-1515	102	25	[	[	PUNCT
dpc-1515	102	26	45	45	NUM
dpc-1515	102	27	-	-	SYM
dpc-1515	102	28	120	120	NUM
dpc-1515	102	29	]	]	PUNCT
dpc-1515	102	30	55	55	NUM
dpc-1515	102	31	[	[	X
dpc-1515	102	32	27.5	27.5	NUM
dpc-1515	102	33	-	-	SYM
dpc-1515	102	34	180	180	NUM
dpc-1515	102	35	]	]	PUNCT
dpc-1515	102	36	.870	.870	NUM
dpc-1515	102	37	warfarin	warfarin	NOUN
dpc-1515	102	38	n	n	CCONJ
dpc-1515	102	39	(	(	PUNCT
dpc-1515	102	40	%	%	INTJ
dpc-1515	102	41	)	)	PUNCT
dpc-1515	102	42	7	7	NUM
dpc-1515	102	43	(	(	PUNCT
dpc-1515	102	44	7.8	7.8	NUM
dpc-1515	102	45	)	)	PUNCT
dpc-1515	102	46	8	8	NUM
dpc-1515	102	47	(	(	PUNCT
dpc-1515	102	48	8.9	8.9	NUM
dpc-1515	102	49	)	)	PUNCT
dpc-1515	102	50	.787	.787	NUM
dpc-1515	102	51	exposure	exposure	NOUN
dpc-1515	102	52	45	45	NUM
dpc-1515	103	1	[	[	SYM
dpc-1515	103	2	20	20	NUM
dpc-1515	103	3	-	-	SYM
dpc-1515	103	4	115	115	NUM
dpc-1515	103	5	]	]	SYM
dpc-1515	103	6	50	50	NUM
dpc-1515	104	1	[	[	SYM
dpc-1515	104	2	22.5	22.5	NUM
dpc-1515	104	3	-	-	SYM
dpc-1515	104	4	97.5	97.5	NUM
dpc-1515	104	5	]	]	PUNCT
dpc-1515	104	6	1.0	1.0	NUM
dpc-1515	104	7	novel	novel	ADJ
dpc-1515	104	8	oral	oral	ADJ
dpc-1515	104	9	anticoagulants	anticoagulant	NOUN
dpc-1515	104	10	n	n	X
dpc-1515	104	11	(	(	PUNCT
dpc-1515	104	12	%	%	INTJ
dpc-1515	104	13	)	)	PUNCT
dpc-1515	104	14	2	2	NUM
dpc-1515	104	15	(	(	PUNCT
dpc-1515	104	16	2.2	2.2	NUM
dpc-1515	104	17	)	)	SYM
dpc-1515	104	18	5	5	NUM
dpc-1515	104	19	(	(	PUNCT
dpc-1515	104	20	5.6	5.6	NUM
dpc-1515	104	21	)	)	PUNCT
dpc-1515	104	22	.444	.444	NUM
dpc-1515	104	23	exposure	exposure	NOUN
dpc-1515	104	24	10	10	NUM
dpc-1515	105	1	[	[	SYM
dpc-1515	105	2	5	5	NUM
dpc-1515	105	3	-	-	SYM
dpc-1515	105	4	15	15	NUM
dpc-1515	105	5	]	]	PUNCT
dpc-1515	105	6	75	75	NUM
dpc-1515	105	7	[	[	SYM
dpc-1515	105	8	40	40	NUM
dpc-1515	105	9	-	-	SYM
dpc-1515	105	10	110	110	NUM
dpc-1515	105	11	]	]	PUNCT
dpc-1515	105	12	.171	.171	NUM
dpc-1515	106	1	thiazides	thiazide	NOUN
dpc-1515	106	2	n	n	CCONJ
dpc-1515	106	3	(	(	PUNCT
dpc-1515	106	4	%	%	INTJ
dpc-1515	106	5	)	)	PUNCT
dpc-1515	106	6	20	20	NUM
dpc-1515	106	7	(	(	PUNCT
dpc-1515	106	8	22.2	22.2	NUM
dpc-1515	106	9	)	)	PUNCT
dpc-1515	106	10	12	12	NUM
dpc-1515	106	11	(	(	PUNCT
dpc-1515	106	12	13.3	13.3	NUM
dpc-1515	106	13	)	)	PUNCT
dpc-1515	106	14	.119	.119	NUM
dpc-1515	106	15	exposure	exposure	NOUN
dpc-1515	106	16	225	225	NUM
dpc-1515	107	1	[	[	X
dpc-1515	107	2	87.5	87.5	NUM
dpc-1515	107	3	-	-	SYM
dpc-1515	107	4	412.5	412.5	NUM
dpc-1515	107	5	]	]	PUNCT
dpc-1515	107	6	137.5	137.5	NUM
dpc-1515	107	7	[	[	X
dpc-1515	107	8	56.25	56.25	NUM
dpc-1515	107	9	-	-	SYM
dpc-1515	107	10	387.5	387.5	NUM
dpc-1515	107	11	]	]	PUNCT
dpc-1515	107	12	.402	.402	NUM
dpc-1515	107	13	loop	loop	NOUN
dpc-1515	107	14	diuretics	diuretic	NOUN
dpc-1515	107	15	n	n	CCONJ
dpc-1515	107	16	(	(	PUNCT
dpc-1515	107	17	%	%	INTJ
dpc-1515	107	18	)	)	PUNCT
dpc-1515	107	19	17	17	NUM
dpc-1515	107	20	(	(	PUNCT
dpc-1515	107	21	18.9	18.9	NUM
dpc-1515	107	22	)	)	PUNCT
dpc-1515	107	23	15	15	NUM
dpc-1515	107	24	(	(	PUNCT
dpc-1515	107	25	16.7	16.7	NUM
dpc-1515	107	26	)	)	PUNCT
dpc-1515	107	27	.697	.697	NUM
dpc-1515	107	28	exposure	exposure	NOUN
dpc-1515	107	29	165	165	NUM
dpc-1515	108	1	[	[	SYM
dpc-1515	108	2	50	50	NUM
dpc-1515	108	3	-	-	SYM
dpc-1515	108	4	250	250	NUM
dpc-1515	108	5	]	]	PUNCT
dpc-1515	108	6	150	150	NUM
dpc-1515	108	7	[	[	SYM
dpc-1515	108	8	50	50	NUM
dpc-1515	108	9	-	-	SYM
dpc-1515	108	10	400	400	NUM
dpc-1515	108	11	]	]	PUNCT
dpc-1515	108	12	.406	.406	NUM
dpc-1515	108	13	drug	drug	NOUN
dpc-1515	108	14	exposure	exposure	NOUN
dpc-1515	108	15	was	be	AUX
dpc-1515	108	16	calculated	calculate	VERB
dpc-1515	108	17	as	as	ADP
dpc-1515	108	18	the	the	DET
dpc-1515	108	19	daily	daily	ADJ
dpc-1515	108	20	dose	dose	NOUN
dpc-1515	108	21	multiplied	multiply	VERB
dpc-1515	108	22	by	by	ADP
dpc-1515	108	23	the	the	DET
dpc-1515	108	24	years	year	NOUN
dpc-1515	108	25	of	of	ADP
dpc-1515	108	26	therapy	therapy	NOUN
dpc-1515	108	27	(	(	PUNCT
dpc-1515	108	28	dosage	dosage	NOUN
dpc-1515	108	29	unit	unit	NOUN
dpc-1515	108	30	-	-	PUNCT
dpc-1515	108	31	years	year	NOUN
dpc-1515	108	32	)	)	PUNCT
dpc-1515	108	33	and	and	CCONJ
dpc-1515	108	34	is	be	AUX
dpc-1515	108	35	reported	report	VERB
dpc-1515	108	36	as	as	ADP
dpc-1515	108	37	the	the	DET
dpc-1515	108	38	median	median	NOUN
dpc-1515	108	39	(	(	PUNCT
dpc-1515	108	40	interquartile	interquartile	NOUN
dpc-1515	108	41	range	range	NOUN
dpc-1515	108	42	)	)	PUNCT
dpc-1515	108	43	.	.	PUNCT
dpc-1515	109	1	ace	ace	NOUN
dpc-1515	109	2	=	=	SYM
dpc-1515	109	3	angiotensin	angiotensin	NOUN
dpc-1515	109	4	-	-	PUNCT
dpc-1515	109	5	converting	convert	VERB
dpc-1515	109	6	enzyme	enzyme	NOUN
dpc-1515	109	7	.	.	PUNCT
dpc-1515	109	8	table	table	NOUN
dpc-1515	109	9	3	3	NUM
dpc-1515	109	10	.	.	PUNCT
dpc-1515	109	11	multiple	multiple	ADJ
dpc-1515	109	12	logistic	logistic	ADJ
dpc-1515	109	13	regression	regression	NOUN
dpc-1515	109	14	model	model	NOUN
dpc-1515	109	15	predicting	predict	VERB
dpc-1515	109	16	actinic	actinic	ADJ
dpc-1515	109	17	keratosis	keratosis	NOUN
dpc-1515	109	18	variables	variable	NOUN
dpc-1515	109	19	no	no	INTJ
dpc-1515	109	20	.	.	PUNCT
dpc-1515	110	1	or	or	CCONJ
dpc-1515	110	2	(	(	PUNCT
dpc-1515	110	3	95	95	NUM
dpc-1515	110	4	%	%	NOUN
dpc-1515	110	5	ci	ci	NOUN
dpc-1515	110	6	)	)	PUNCT
dpc-1515	110	7	arbs	arb	NOUN
dpc-1515	110	8	•	•	ADP
dpc-1515	111	1	no	no	DET
dpc-1515	111	2	exposure	exposure	NOUN
dpc-1515	111	3	•	•	ADP
dpc-1515	111	4	low	low	ADJ
dpc-1515	111	5	exposure	exposure	NOUN
dpc-1515	111	6	•	•	ADP
dpc-1515	111	7	high	high	ADJ
dpc-1515	111	8	exposure	exposure	NOUN
dpc-1515	111	9	(	(	PUNCT
dpc-1515	111	10	>	>	SYM
dpc-1515	111	11	750	750	NUM
dpc-1515	111	12	dose	dose	NOUN
dpc-1515	111	13	unit	unit	NOUN
dpc-1515	111	14	-	-	PUNCT
dpc-1515	111	15	years	year	NOUN
dpc-1515	111	16	)	)	PUNCT
dpc-1515	111	17	143	143	NUM
dpc-1515	111	18	18	18	NUM
dpc-1515	111	19	19	19	NUM
dpc-1515	111	20	1.00	1.00	NUM
dpc-1515	111	21	0.25	0.25	NUM
dpc-1515	111	22	(	(	PUNCT
dpc-1515	111	23	0.05	0.05	NUM
dpc-1515	111	24	1.32	1.32	NUM
dpc-1515	111	25	)	)	PUNCT
dpc-1515	111	26	13.6	13.6	NUM
dpc-1515	111	27	(	(	PUNCT
dpc-1515	111	28	2.0	2.0	NUM
dpc-1515	111	29	–	–	SYM
dpc-1515	111	30	93.8	93.8	NUM
dpc-1515	111	31	)	)	PUNCT
dpc-1515	111	32	antiplatelet	antiplatelet	NOUN
dpc-1515	111	33	agents	agent	NOUN
dpc-1515	111	34	•	•	VERB
dpc-1515	111	35	no	no	DET
dpc-1515	111	36	exposure	exposure	NOUN
dpc-1515	111	37	•	•	ADP
dpc-1515	111	38	low	low	ADJ
dpc-1515	111	39	exposure	exposure	NOUN
dpc-1515	111	40	•	•	ADP
dpc-1515	111	41	high	high	ADJ
dpc-1515	111	42	exposure	exposure	NOUN
dpc-1515	111	43	(	(	PUNCT
dpc-1515	111	44	>	>	SYM
dpc-1515	111	45	1100	1100	NUM
dpc-1515	111	46	dose	dose	PROPN
dpc-1515	111	47	unit	unit	NOUN
dpc-1515	111	48	-	-	PUNCT
dpc-1515	111	49	years	year	NOUN
dpc-1515	111	50	)	)	PUNCT
dpc-1515	111	51	116	116	NUM
dpc-1515	111	52	31	31	NUM
dpc-1515	111	53	33	33	NUM
dpc-1515	111	54	1.00	1.00	NUM
dpc-1515	111	55	3.31	3.31	NUM
dpc-1515	111	56	(	(	PUNCT
dpc-1515	111	57	0.86	0.86	NUM
dpc-1515	111	58	–	–	PUNCT
dpc-1515	111	59	12.69	12.69	NUM
dpc-1515	111	60	)	)	PUNCT
dpc-1515	111	61	4.38	4.38	NUM
dpc-1515	111	62	(	(	PUNCT
dpc-1515	111	63	1.16	1.16	NUM
dpc-1515	111	64	–	–	PUNCT
dpc-1515	111	65	16.60	16.60	NUM
dpc-1515	111	66	)	)	PUNCT
dpc-1515	111	67	note	note	NOUN
dpc-1515	111	68	:	:	PUNCT
dpc-1515	111	69	the	the	DET
dpc-1515	111	70	model	model	NOUN
dpc-1515	111	71	is	be	AUX
dpc-1515	111	72	adjusted	adjust	VERB
dpc-1515	111	73	for	for	ADP
dpc-1515	111	74	age	age	NOUN
dpc-1515	111	75	,	,	PUNCT
dpc-1515	111	76	sex	sex	NOUN
dpc-1515	111	77	,	,	PUNCT
dpc-1515	111	78	skin	skin	NOUN
dpc-1515	111	79	type	type	NOUN
dpc-1515	111	80	,	,	PUNCT
dpc-1515	111	81	and	and	CCONJ
dpc-1515	111	82	sun	sun	NOUN
dpc-1515	111	83	exposure	exposure	NOUN
dpc-1515	111	84	.	.	PUNCT
dpc-1515	112	1	arbs	arb	NOUN
dpc-1515	113	1	=	=	SYM
dpc-1515	113	2	angiotensin	angiotensin	NOUN
dpc-1515	113	3	receptor	receptor	NOUN
dpc-1515	113	4	blockers	blocker	NOUN
dpc-1515	113	5	;	;	PUNCT
dpc-1515	113	6	ci	ci	NOUN
dpc-1515	113	7	=	=	NOUN
dpc-1515	113	8	confidence	confidence	NOUN
dpc-1515	113	9	interval	interval	NOUN
dpc-1515	113	10	;	;	PUNCT
dpc-1515	113	11	or	or	CCONJ
dpc-1515	113	12	=	=	NOUN
dpc-1515	113	13	odds	odd	NOUN
dpc-1515	113	14	ratio	ratio	NOUN
dpc-1515	113	15	.	.	PUNCT
dpc-1515	114	1	table	table	NOUN
dpc-1515	114	2	4	4	NUM
dpc-1515	114	3	.	.	PUNCT
dpc-1515	115	1	concomitant	concomitant	ADJ
dpc-1515	115	2	exposure	exposure	NOUN
dpc-1515	115	3	to	to	ADP
dpc-1515	115	4	arbs	arbs	VERB
dpc-1515	115	5	and	and	CCONJ
dpc-1515	115	6	antiplatelet	antiplatelet	VERB
dpc-1515	115	7	drugs	drug	NOUN
dpc-1515	115	8	cases	case	NOUN
dpc-1515	115	9	controls	control	VERB
dpc-1515	115	10	exposure	exposure	NOUN
dpc-1515	115	11	to	to	ADP
dpc-1515	115	12	antiplatelet	antiplatelet	VERB
dpc-1515	115	13	drugs	drug	NOUN
dpc-1515	115	14	,	,	PUNCT
dpc-1515	115	15	n	n	PROPN
dpc-1515	115	16	(	(	PUNCT
dpc-1515	115	17	%	%	INTJ
dpc-1515	115	18	)	)	PUNCT
dpc-1515	115	19	exposure	exposure	NOUN
dpc-1515	115	20	to	to	PART
dpc-1515	115	21	antiplatelet	antiplatelet	VERB
dpc-1515	115	22	drugs	drug	NOUN
dpc-1515	115	23	,	,	PUNCT
dpc-1515	115	24	n	n	PROPN
dpc-1515	115	25	(	(	PUNCT
dpc-1515	115	26	%	%	INTJ
dpc-1515	115	27	)	)	PUNCT
dpc-1515	115	28	low	low	ADJ
dpc-1515	115	29	moderate	moderate	ADJ
dpc-1515	115	30	high	high	ADJ
dpc-1515	115	31	absent	absent	ADJ
dpc-1515	115	32	low	low	ADJ
dpc-1515	115	33	high	high	ADJ
dpc-1515	115	34	exposure	exposure	NOUN
dpc-1515	115	35	to	to	ADP
dpc-1515	115	36	arbs	arbs	X
dpc-1515	115	37	low	low	ADJ
dpc-1515	115	38	38	38	NUM
dpc-1515	115	39	(	(	PUNCT
dpc-1515	115	40	42.2	42.2	NUM
dpc-1515	115	41	)	)	PUNCT
dpc-1515	115	42	16	16	NUM
dpc-1515	115	43	(	(	PUNCT
dpc-1515	115	44	17.8	17.8	NUM
dpc-1515	115	45	)	)	PUNCT
dpc-1515	115	46	16	16	NUM
dpc-1515	115	47	(	(	PUNCT
dpc-1515	115	48	17.8	17.8	NUM
dpc-1515	115	49	)	)	PUNCT
dpc-1515	115	50	absent	absent	ADJ
dpc-1515	115	51	58	58	NUM
dpc-1515	115	52	(	(	PUNCT
dpc-1515	115	53	64.4	64.4	NUM
dpc-1515	115	54	)	)	PUNCT
dpc-1515	115	55	8	8	NUM
dpc-1515	115	56	(	(	PUNCT
dpc-1515	115	57	8.9	8.9	NUM
dpc-1515	115	58	)	)	PUNCT
dpc-1515	115	59	7	7	NUM
dpc-1515	115	60	(	(	PUNCT
dpc-1515	115	61	7.8	7.8	NUM
dpc-1515	115	62	)	)	PUNCT
dpc-1515	115	63	moderate	moderate	ADJ
dpc-1515	115	64	3	3	NUM
dpc-1515	115	65	(	(	PUNCT
dpc-1515	115	66	3.3	3.3	NUM
dpc-1515	115	67	)	)	PUNCT
dpc-1515	115	68	1	1	NUM
dpc-1515	115	69	(	(	PUNCT
dpc-1515	115	70	1.1	1.1	NUM
dpc-1515	115	71	)	)	SYM
dpc-1515	115	72	2	2	NUM
dpc-1515	115	73	(	(	PUNCT
dpc-1515	115	74	2.2	2.2	NUM
dpc-1515	115	75	)	)	PUNCT
dpc-1515	115	76	low	low	ADJ
dpc-1515	115	77	8	8	NUM
dpc-1515	115	78	(	(	PUNCT
dpc-1515	115	79	8.9	8.9	NUM
dpc-1515	115	80	)	)	PUNCT
dpc-1515	115	81	4	4	NUM
dpc-1515	115	82	(	(	PUNCT
dpc-1515	115	83	4.4	4.4	NUM
dpc-1515	115	84	)	)	PUNCT
dpc-1515	115	85	0	0	NUM
dpc-1515	116	1	(	(	PUNCT
dpc-1515	116	2	0	0	NUM
dpc-1515	116	3	)	)	PUNCT
dpc-1515	116	4	high	high	ADJ
dpc-1515	116	5	5	5	NUM
dpc-1515	116	6	(	(	PUNCT
dpc-1515	116	7	5.6	5.6	NUM
dpc-1515	116	8	)	)	SYM
dpc-1515	116	9	1	1	NUM
dpc-1515	116	10	(	(	PUNCT
dpc-1515	116	11	1.1	1.1	NUM
dpc-1515	116	12	)	)	PUNCT
dpc-1515	116	13	8	8	NUM
dpc-1515	116	14	(	(	PUNCT
dpc-1515	116	15	8.9	8.9	NUM
dpc-1515	116	16	)	)	PUNCT
dpc-1515	116	17	high	high	ADJ
dpc-1515	116	18	4	4	NUM
dpc-1515	116	19	(	(	PUNCT
dpc-1515	116	20	4.4	4.4	NUM
dpc-1515	116	21	)	)	PUNCT
dpc-1515	116	22	1	1	NUM
dpc-1515	116	23	(	(	PUNCT
dpc-1515	116	24	1.1	1.1	NUM
dpc-1515	116	25	)	)	PUNCT
dpc-1515	116	26	0	0	NUM
dpc-1515	117	1	(	(	PUNCT
dpc-1515	117	2	0	0	NUM
dpc-1515	117	3	)	)	PUNCT
dpc-1515	117	4	arbs	arb	NOUN
dpc-1515	117	5	=	=	SYM
dpc-1515	117	6	angiotensin	angiotensin	NOUN
dpc-1515	117	7	receptor	receptor	NOUN
dpc-1515	117	8	blockers	blocker	NOUN
dpc-1515	117	9	.	.	PUNCT
dpc-1515	118	1	research	research	NOUN
dpc-1515	118	2	|	|	ADV
dpc-1515	118	3	dermatol	dermatol	ADJ
dpc-1515	118	4	pract	pract	NOUN
dpc-1515	118	5	concept	concept	NOUN
dpc-1515	118	6	.	.	PUNCT
dpc-1515	119	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	119	2	5	5	NUM
dpc-1515	119	3	eight	eight	NUM
dpc-1515	119	4	cases	case	NOUN
dpc-1515	119	5	were	be	AUX
dpc-1515	119	6	concomitantly	concomitantly	ADV
dpc-1515	119	7	exposed	expose	VERB
dpc-1515	119	8	to	to	ADP
dpc-1515	119	9	arbs	arbs	VERB
dpc-1515	119	10	and	and	CCONJ
dpc-1515	119	11	antiplatelet	antiplatelet	NOUN
dpc-1515	119	12	drugs	drug	NOUN
dpc-1515	119	13	,	,	PUNCT
dpc-1515	119	14	whereas	whereas	SCONJ
dpc-1515	119	15	no	no	DET
dpc-1515	119	16	double	double	ADJ
dpc-1515	119	17	exposure	exposure	NOUN
dpc-1515	119	18	was	be	AUX
dpc-1515	119	19	found	find	VERB
dpc-1515	119	20	in	in	ADP
dpc-1515	119	21	controls	control	NOUN
dpc-1515	119	22	(	(	PUNCT
dpc-1515	119	23	table	table	NOUN
dpc-1515	119	24	4	4	NUM
dpc-1515	119	25	)	)	PUNCT
dpc-1515	119	26	.	.	PUNCT
dpc-1515	120	1	discussion	discussion	NOUN
dpc-1515	120	2	two	two	NUM
dpc-1515	120	3	studies	study	NOUN
dpc-1515	120	4	based	base	VERB
dpc-1515	120	5	on	on	ADP
dpc-1515	120	6	danish	danish	PROPN
dpc-1515	120	7	national	national	PROPN
dpc-1515	120	8	data	data	PROPN
dpc-1515	120	9	showed	show	VERB
dpc-1515	120	10	a	a	DET
dpc-1515	120	11	dose	dose	NOUN
dpc-1515	120	12	-	-	PUNCT
dpc-1515	120	13	dependent	dependent	ADJ
dpc-1515	120	14	,	,	PUNCT
dpc-1515	120	15	cumulative	cumulative	ADJ
dpc-1515	120	16	association	association	NOUN
dpc-1515	120	17	between	between	ADP
dpc-1515	120	18	the	the	DET
dpc-1515	120	19	photosensitizing	photosensitize	VERB
dpc-1515	120	20	activity	activity	NOUN
dpc-1515	120	21	of	of	ADP
dpc-1515	120	22	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	120	23	and	and	CCONJ
dpc-1515	120	24	nmsc	nmsc	NOUN
dpc-1515	120	25	,	,	PUNCT
dpc-1515	120	26	including	include	VERB
dpc-1515	120	27	basal	basal	NOUN
dpc-1515	120	28	cell	cell	NOUN
dpc-1515	120	29	carcinoma	carcinoma	NOUN
dpc-1515	120	30	and	and	CCONJ
dpc-1515	120	31	scc	scc	NOUN
dpc-1515	120	32	[	[	X
dpc-1515	120	33	9,10	9,10	NUM
dpc-1515	120	34	]	]	X
dpc-1515	120	35	.	.	PUNCT
dpc-1515	121	1	one	one	NUM
dpc-1515	121	2	of	of	ADP
dpc-1515	121	3	these	these	DET
dpc-1515	121	4	studies	study	NOUN
dpc-1515	121	5	highlighted	highlight	VERB
dpc-1515	121	6	a	a	DET
dpc-1515	121	7	7	7	NUM
dpc-1515	121	8	-	-	ADJ
dpc-1515	121	9	fold	fold	ADJ
dpc-1515	121	10	increased	increased	ADJ
dpc-1515	121	11	risk	risk	NOUN
dpc-1515	121	12	of	of	ADP
dpc-1515	121	13	scc	scc	PROPN
dpc-1515	121	14	lip	lip	NOUN
dpc-1515	121	15	cancer	cancer	NOUN
dpc-1515	121	16	in	in	ADP
dpc-1515	121	17	exposed	expose	VERB
dpc-1515	121	18	subjects	subject	NOUN
dpc-1515	121	19	[	[	X
dpc-1515	121	20	10	10	NUM
dpc-1515	121	21	]	]	PUNCT
dpc-1515	121	22	.	.	PUNCT
dpc-1515	122	1	the	the	DET
dpc-1515	122	2	other	other	ADJ
dpc-1515	122	3	study	study	NOUN
dpc-1515	122	4	found	find	VERB
dpc-1515	122	5	the	the	DET
dpc-1515	122	6	strongest	strong	ADJ
dpc-1515	122	7	associations	association	NOUN
dpc-1515	122	8	with	with	ADP
dpc-1515	122	9	:	:	PUNCT
dpc-1515	122	10	a	a	DET
dpc-1515	122	11	cumulative	cumulative	ADJ
dpc-1515	122	12	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	122	13	dose	dose	VERB
dpc-1515	122	14	>	>	NUM
dpc-1515	122	15	200	200	NUM
dpc-1515	122	16	mg	mg	ADJ
dpc-1515	122	17	,	,	PUNCT
dpc-1515	122	18	female	female	ADJ
dpc-1515	122	19	sex	sex	NOUN
dpc-1515	122	20	,	,	PUNCT
dpc-1515	122	21	upper	upper	ADJ
dpc-1515	122	22	or	or	CCONJ
dpc-1515	122	23	lower	low	ADJ
dpc-1515	122	24	limbs	limb	NOUN
dpc-1515	122	25	,	,	PUNCT
dpc-1515	122	26	and	and	CCONJ
dpc-1515	122	27	age	age	NOUN
dpc-1515	122	28	<	<	X
dpc-1515	122	29	50	50	NUM
dpc-1515	122	30	years	year	NOUN
dpc-1515	123	1	[	[	X
dpc-1515	123	2	9	9	NUM
dpc-1515	123	3	]	]	PUNCT
dpc-1515	123	4	.	.	PUNCT
dpc-1515	124	1	the	the	DET
dpc-1515	124	2	postulated	postulate	VERB
dpc-1515	124	3	pathogenetic	pathogenetic	ADJ
dpc-1515	124	4	mechanism	mechanism	NOUN
dpc-1515	124	5	is	be	AUX
dpc-1515	124	6	photosensitivity	photosensitivity	NOUN
dpc-1515	124	7	due	due	ADJ
dpc-1515	124	8	to	to	ADP
dpc-1515	124	9	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	124	10	,	,	PUNCT
dpc-1515	124	11	which	which	PRON
dpc-1515	124	12	is	be	AUX
dpc-1515	124	13	well	well	ADV
dpc-1515	124	14	documented	document	VERB
dpc-1515	124	15	and	and	CCONJ
dpc-1515	124	16	could	could	AUX
dpc-1515	124	17	enhance	enhance	VERB
dpc-1515	124	18	photocarcinogenesis	photocarcinogenesis	NOUN
dpc-1515	124	19	[	[	X
dpc-1515	124	20	1	1	NUM
dpc-1515	124	21	-	-	SYM
dpc-1515	124	22	14	14	NUM
dpc-1515	124	23	]	]	PUNCT
dpc-1515	124	24	.	.	PUNCT
dpc-1515	125	1	subsequently	subsequently	ADV
dpc-1515	125	2	,	,	PUNCT
dpc-1515	125	3	further	further	ADJ
dpc-1515	125	4	papers	paper	NOUN
dpc-1515	125	5	on	on	ADP
dpc-1515	125	6	the	the	DET
dpc-1515	125	7	association	association	NOUN
dpc-1515	125	8	between	between	ADP
dpc-1515	125	9	photosensitizing	photosensitize	VERB
dpc-1515	125	10	agents	agent	NOUN
dpc-1515	125	11	and	and	CCONJ
dpc-1515	125	12	nmsc	nmsc	NOUN
dpc-1515	125	13	were	be	AUX
dpc-1515	125	14	published	publish	VERB
dpc-1515	125	15	and	and	CCONJ
dpc-1515	125	16	yielded	yield	VERB
dpc-1515	125	17	conflicting	conflicting	ADJ
dpc-1515	125	18	results	result	NOUN
dpc-1515	125	19	.	.	PUNCT
dpc-1515	126	1	indeed	indeed	ADV
dpc-1515	126	2	,	,	PUNCT
dpc-1515	126	3	some	some	DET
dpc-1515	126	4	studies	study	NOUN
dpc-1515	126	5	showed	show	VERB
dpc-1515	126	6	no	no	DET
dpc-1515	126	7	association	association	NOUN
dpc-1515	126	8	between	between	ADP
dpc-1515	126	9	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	126	10	and	and	CCONJ
dpc-1515	126	11	nmsc	nmsc	NOUN
dpc-1515	126	12	,	,	PUNCT
dpc-1515	126	13	and	and	CCONJ
dpc-1515	126	14	some	some	DET
dpc-1515	126	15	authors	author	NOUN
dpc-1515	126	16	raised	raise	VERB
dpc-1515	126	17	concerns	concern	NOUN
dpc-1515	126	18	about	about	ADP
dpc-1515	126	19	the	the	DET
dpc-1515	126	20	methodological	methodological	ADJ
dpc-1515	126	21	limitations	limitation	NOUN
dpc-1515	126	22	of	of	ADP
dpc-1515	126	23	the	the	DET
dpc-1515	126	24	2	2	NUM
dpc-1515	126	25	danish	danish	ADJ
dpc-1515	126	26	studies	study	NOUN
dpc-1515	126	27	[	[	X
dpc-1515	126	28	15	15	NUM
dpc-1515	126	29	-	-	SYM
dpc-1515	126	30	24	24	NUM
dpc-1515	126	31	]	]	PUNCT
dpc-1515	126	32	.	.	PUNCT
dpc-1515	127	1	in	in	ADP
dpc-1515	127	2	contrast	contrast	NOUN
dpc-1515	127	3	to	to	ADP
dpc-1515	127	4	the	the	DET
dpc-1515	127	5	danish	danish	ADJ
dpc-1515	127	6	studies	study	NOUN
dpc-1515	127	7	,	,	PUNCT
dpc-1515	127	8	our	our	PRON
dpc-1515	127	9	study	study	NOUN
dpc-1515	127	10	did	do	AUX
dpc-1515	127	11	not	not	PART
dpc-1515	127	12	find	find	VERB
dpc-1515	127	13	any	any	DET
dpc-1515	127	14	evidence	evidence	NOUN
dpc-1515	127	15	of	of	ADP
dpc-1515	127	16	an	an	DET
dpc-1515	127	17	association	association	NOUN
dpc-1515	127	18	between	between	ADP
dpc-1515	127	19	thiazide	thiazide	ADJ
dpc-1515	127	20	diuretics	diuretic	NOUN
dpc-1515	127	21	and	and	CCONJ
dpc-1515	127	22	actinic	actinic	ADJ
dpc-1515	127	23	keratosis	keratosis	NOUN
dpc-1515	127	24	,	,	PUNCT
dpc-1515	127	25	probably	probably	ADV
dpc-1515	127	26	due	due	ADP
dpc-1515	127	27	to	to	ADP
dpc-1515	127	28	the	the	DET
dpc-1515	127	29	limited	limited	ADJ
dpc-1515	127	30	use	use	NOUN
dpc-1515	127	31	of	of	ADP
dpc-1515	127	32	thiazides	thiazide	NOUN
dpc-1515	127	33	in	in	ADP
dpc-1515	127	34	our	our	PRON
dpc-1515	127	35	sample	sample	NOUN
dpc-1515	127	36	.	.	PUNCT
dpc-1515	128	1	instead	instead	ADV
dpc-1515	128	2	,	,	PUNCT
dpc-1515	128	3	our	our	PRON
dpc-1515	128	4	study	study	NOUN
dpc-1515	128	5	showed	show	VERB
dpc-1515	128	6	that	that	SCONJ
dpc-1515	128	7	high	high	ADJ
dpc-1515	128	8	exposure	exposure	NOUN
dpc-1515	128	9	to	to	ADP
dpc-1515	128	10	arbs	arb	NOUN
dpc-1515	128	11	and	and	CCONJ
dpc-1515	128	12	even	even	ADV
dpc-1515	128	13	low	low	ADJ
dpc-1515	128	14	exposure	exposure	NOUN
dpc-1515	128	15	to	to	PART
dpc-1515	128	16	antiplatelet	antiplatelet	VERB
dpc-1515	128	17	drugs	drug	NOUN
dpc-1515	128	18	,	,	PUNCT
dpc-1515	128	19	in	in	ADP
dpc-1515	128	20	a	a	DET
dpc-1515	128	21	dose	dose	NOUN
dpc-1515	128	22	-	-	PUNCT
dpc-1515	128	23	dependent	dependent	ADJ
dpc-1515	128	24	pattern	pattern	NOUN
dpc-1515	128	25	,	,	PUNCT
dpc-1515	128	26	represent	represent	VERB
dpc-1515	128	27	significant	significant	ADJ
dpc-1515	128	28	risk	risk	NOUN
dpc-1515	128	29	factors	factor	NOUN
dpc-1515	128	30	for	for	ADP
dpc-1515	128	31	the	the	DET
dpc-1515	128	32	development	development	NOUN
dpc-1515	128	33	of	of	ADP
dpc-1515	128	34	ak	ak	PROPN
dpc-1515	128	35	.	.	PROPN
dpc-1515	128	36	in	in	ADP
dpc-1515	128	37	the	the	DET
dpc-1515	128	38	literature	literature	NOUN
dpc-1515	128	39	,	,	PUNCT
dpc-1515	128	40	a	a	DET
dpc-1515	128	41	similar	similar	ADJ
dpc-1515	128	42	study	study	NOUN
dpc-1515	128	43	conducted	conduct	VERB
dpc-1515	128	44	in	in	ADP
dpc-1515	128	45	1999	1999	NUM
dpc-1515	128	46	assessed	assess	VERB
dpc-1515	128	47	the	the	DET
dpc-1515	128	48	impact	impact	NOUN
dpc-1515	128	49	of	of	ADP
dpc-1515	128	50	photosensitizing	photosensitize	VERB
dpc-1515	128	51	drugs	drug	NOUN
dpc-1515	128	52	on	on	ADP
dpc-1515	128	53	the	the	DET
dpc-1515	128	54	development	development	NOUN
dpc-1515	128	55	of	of	ADP
dpc-1515	128	56	ak	ak	PROPN
dpc-1515	128	57	.	.	PROPN
dpc-1515	128	58	however	however	ADV
dpc-1515	128	59	,	,	PUNCT
dpc-1515	128	60	the	the	DET
dpc-1515	128	61	number	number	NOUN
dpc-1515	128	62	of	of	ADP
dpc-1515	128	63	patients	patient	NOUN
dpc-1515	128	64	was	be	AUX
dpc-1515	128	65	small	small	ADJ
dpc-1515	128	66	(	(	PUNCT
dpc-1515	128	67	34	34	NUM
dpc-1515	128	68	cases	case	NOUN
dpc-1515	128	69	and	and	CCONJ
dpc-1515	128	70	34	34	NUM
dpc-1515	128	71	controls	control	NOUN
dpc-1515	128	72	)	)	PUNCT
dpc-1515	128	73	,	,	PUNCT
dpc-1515	128	74	and	and	CCONJ
dpc-1515	128	75	the	the	DET
dpc-1515	128	76	use	use	NOUN
dpc-1515	128	77	of	of	ADP
dpc-1515	128	78	cardiovascular	cardiovascular	ADJ
dpc-1515	128	79	drugs	drug	NOUN
dpc-1515	128	80	was	be	AUX
dpc-1515	128	81	also	also	ADV
dpc-1515	128	82	considerably	considerably	ADV
dpc-1515	128	83	low	low	ADJ
dpc-1515	129	1	[	[	X
dpc-1515	129	2	7	7	NUM
dpc-1515	129	3	]	]	PUNCT
dpc-1515	129	4	.	.	PUNCT
dpc-1515	130	1	other	other	ADJ
dpc-1515	130	2	recent	recent	ADJ
dpc-1515	130	3	studies	study	NOUN
dpc-1515	130	4	demonstrated	demonstrate	VERB
dpc-1515	130	5	the	the	DET
dpc-1515	130	6	induction	induction	NOUN
dpc-1515	130	7	of	of	ADP
dpc-1515	130	8	photosensitivity	photosensitivity	NOUN
dpc-1515	130	9	in	in	ADP
dpc-1515	130	10	patients	patient	NOUN
dpc-1515	130	11	taking	take	VERB
dpc-1515	130	12	arbs	arb	NOUN
dpc-1515	130	13	,	,	PUNCT
dpc-1515	130	14	and	and	CCONJ
dpc-1515	130	15	hypothesized	hypothesized	ADJ
dpc-1515	130	16	drug	drug	NOUN
dpc-1515	130	17	-	-	PUNCT
dpc-1515	130	18	driven	drive	VERB
dpc-1515	130	19	carcinogenesis	carcinogenesis	NOUN
dpc-1515	130	20	favored	favor	VERB
dpc-1515	130	21	by	by	ADP
dpc-1515	130	22	sun	sun	NOUN
dpc-1515	130	23	exposure	exposure	NOUN
dpc-1515	130	24	[	[	X
dpc-1515	130	25	25	25	NUM
dpc-1515	130	26	-	-	SYM
dpc-1515	130	27	29	29	NUM
dpc-1515	130	28	]	]	PUNCT
dpc-1515	130	29	.	.	PUNCT
dpc-1515	131	1	however	however	ADV
dpc-1515	131	2	,	,	PUNCT
dpc-1515	131	3	as	as	ADP
dpc-1515	131	4	for	for	ADP
dpc-1515	131	5	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	131	6	,	,	PUNCT
dpc-1515	131	7	the	the	DET
dpc-1515	131	8	results	result	NOUN
dpc-1515	131	9	of	of	ADP
dpc-1515	131	10	different	different	ADJ
dpc-1515	131	11	studies	study	NOUN
dpc-1515	131	12	are	be	AUX
dpc-1515	131	13	contradictory	contradictory	ADJ
dpc-1515	131	14	.	.	PUNCT
dpc-1515	132	1	conflicting	conflict	VERB
dpc-1515	132	2	evidence	evidence	NOUN
dpc-1515	132	3	regarding	regard	VERB
dpc-1515	132	4	the	the	DET
dpc-1515	132	5	use	use	NOUN
dpc-1515	132	6	of	of	ADP
dpc-1515	132	7	antiplatelet	antiplatelet	NOUN
dpc-1515	132	8	agents	agent	NOUN
dpc-1515	132	9	comes	come	VERB
dpc-1515	132	10	from	from	ADP
dpc-1515	132	11	a	a	DET
dpc-1515	132	12	brazilian	brazilian	ADJ
dpc-1515	132	13	case	case	NOUN
dpc-1515	132	14	-	-	PUNCT
dpc-1515	132	15	control	control	NOUN
dpc-1515	132	16	study	study	NOUN
dpc-1515	132	17	,	,	PUNCT
dpc-1515	132	18	which	which	PRON
dpc-1515	132	19	demonstrated	demonstrate	VERB
dpc-1515	132	20	a	a	DET
dpc-1515	132	21	protective	protective	ADJ
dpc-1515	132	22	effect	effect	NOUN
dpc-1515	132	23	of	of	ADP
dpc-1515	132	24	acetylsalicylic	acetylsalicylic	ADJ
dpc-1515	132	25	acid	acid	NOUN
dpc-1515	132	26	on	on	ADP
dpc-1515	132	27	the	the	DET
dpc-1515	132	28	development	development	NOUN
dpc-1515	132	29	of	of	ADP
dpc-1515	132	30	ak	ak	PROPN
dpc-1515	132	31	[	[	X
dpc-1515	132	32	30	30	NUM
dpc-1515	132	33	]	]	PUNCT
dpc-1515	132	34	.	.	PUNCT
dpc-1515	133	1	this	this	DET
dpc-1515	133	2	study	study	NOUN
dpc-1515	133	3	enrolled	enrol	VERB
dpc-1515	133	4	74	74	NUM
dpc-1515	133	5	cases	case	NOUN
dpc-1515	133	6	and	and	CCONJ
dpc-1515	133	7	216	216	NUM
dpc-1515	133	8	controls	control	NOUN
dpc-1515	133	9	,	,	PUNCT
dpc-1515	133	10	and	and	CCONJ
dpc-1515	133	11	the	the	DET
dpc-1515	133	12	median	median	ADJ
dpc-1515	133	13	duration	duration	NOUN
dpc-1515	133	14	of	of	ADP
dpc-1515	133	15	therapy	therapy	NOUN
dpc-1515	133	16	was	be	AUX
dpc-1515	133	17	36	36	NUM
dpc-1515	133	18	months	month	NOUN
dpc-1515	133	19	.	.	PUNCT
dpc-1515	134	1	the	the	DET
dpc-1515	134	2	use	use	NOUN
dpc-1515	134	3	of	of	ADP
dpc-1515	134	4	acetylsalicylic	acetylsalicylic	PROPN
dpc-1515	134	5	acid	acid	PROPN
dpc-1515	134	6	was	be	AUX
dpc-1515	134	7	an	an	DET
dpc-1515	134	8	independent	independent	ADJ
dpc-1515	134	9	protective	protective	ADJ
dpc-1515	134	10	factor	factor	NOUN
dpc-1515	134	11	for	for	ADP
dpc-1515	134	12	ak	ak	PROPN
dpc-1515	134	13	onset	onset	NOUN
dpc-1515	134	14	since	since	SCONJ
dpc-1515	134	15	it	it	PRON
dpc-1515	134	16	was	be	AUX
dpc-1515	134	17	associated	associate	VERB
dpc-1515	134	18	with	with	ADP
dpc-1515	134	19	a	a	DET
dpc-1515	134	20	lower	low	ADJ
dpc-1515	134	21	ak	ak	NOUN
dpc-1515	134	22	count	count	NOUN
dpc-1515	134	23	on	on	ADP
dpc-1515	134	24	the	the	DET
dpc-1515	134	25	face	face	NOUN
dpc-1515	134	26	and	and	CCONJ
dpc-1515	134	27	upper	upper	ADJ
dpc-1515	134	28	extremities	extremity	NOUN
dpc-1515	134	29	,	,	PUNCT
dpc-1515	134	30	regardless	regardless	ADV
dpc-1515	134	31	of	of	ADP
dpc-1515	134	32	concomitant	concomitant	ADJ
dpc-1515	134	33	risk	risk	NOUN
dpc-1515	134	34	factors	factor	NOUN
dpc-1515	134	35	.	.	PUNCT
dpc-1515	135	1	in	in	ADP
dpc-1515	135	2	our	our	PRON
dpc-1515	135	3	study	study	NOUN
dpc-1515	135	4	,	,	PUNCT
dpc-1515	135	5	ticlopidine	ticlopidine	NOUN
dpc-1515	135	6	and	and	CCONJ
dpc-1515	135	7	clopidogrel	clopidogrel	NOUN
dpc-1515	135	8	were	be	AUX
dpc-1515	135	9	used	use	VERB
dpc-1515	135	10	by	by	ADP
dpc-1515	135	11	only	only	ADV
dpc-1515	135	12	3	3	NUM
dpc-1515	135	13	cases	case	NOUN
dpc-1515	135	14	and	and	CCONJ
dpc-1515	135	15	1	1	NUM
dpc-1515	135	16	control	control	NOUN
dpc-1515	135	17	:	:	PUNCT
dpc-1515	135	18	for	for	ADP
dpc-1515	135	19	this	this	DET
dpc-1515	135	20	reason	reason	NOUN
dpc-1515	135	21	,	,	PUNCT
dpc-1515	135	22	we	we	PRON
dpc-1515	135	23	included	include	VERB
dpc-1515	135	24	all	all	DET
dpc-1515	135	25	antiplatelet	antiplatelet	ADJ
dpc-1515	135	26	agents	agent	NOUN
dpc-1515	135	27	within	within	ADP
dpc-1515	135	28	a	a	DET
dpc-1515	135	29	single	single	ADJ
dpc-1515	135	30	group	group	NOUN
dpc-1515	135	31	.	.	PUNCT
dpc-1515	136	1	the	the	DET
dpc-1515	136	2	main	main	ADJ
dpc-1515	136	3	limitation	limitation	NOUN
dpc-1515	136	4	of	of	ADP
dpc-1515	136	5	our	our	PRON
dpc-1515	136	6	study	study	NOUN
dpc-1515	136	7	is	be	AUX
dpc-1515	136	8	that	that	SCONJ
dpc-1515	136	9	it	it	PRON
dpc-1515	136	10	is	be	AUX
dpc-1515	136	11	inadequately	inadequately	ADV
dpc-1515	136	12	powered	power	VERB
dpc-1515	136	13	to	to	PART
dpc-1515	136	14	detected	detect	VERB
dpc-1515	136	15	mild	mild	ADJ
dpc-1515	136	16	differences	difference	NOUN
dpc-1515	136	17	in	in	ADP
dpc-1515	136	18	drug	drug	NOUN
dpc-1515	136	19	exposures	exposure	NOUN
dpc-1515	136	20	between	between	ADP
dpc-1515	136	21	cases	case	NOUN
dpc-1515	136	22	and	and	CCONJ
dpc-1515	136	23	controls	control	NOUN
dpc-1515	136	24	.	.	PUNCT
dpc-1515	137	1	for	for	ADP
dpc-1515	137	2	instance	instance	NOUN
dpc-1515	137	3	,	,	PUNCT
dpc-1515	137	4	the	the	DET
dpc-1515	137	5	differential	differential	ADJ
dpc-1515	137	6	percentage	percentage	NOUN
dpc-1515	137	7	in	in	ADP
dpc-1515	137	8	the	the	DET
dpc-1515	137	9	use	use	NOUN
dpc-1515	137	10	of	of	ADP
dpc-1515	137	11	oral	oral	ADJ
dpc-1515	137	12	diuretic	diuretic	ADJ
dpc-1515	137	13	thiazides	thiazide	NOUN
dpc-1515	137	14	(	(	PUNCT
dpc-1515	137	15	22.2	22.2	NUM
dpc-1515	137	16	%	%	NOUN
dpc-1515	137	17	vs.	vs.	ADP
dpc-1515	137	18	13.3	13.3	NUM
dpc-1515	137	19	%	%	NOUN
dpc-1515	137	20	)	)	PUNCT
dpc-1515	137	21	would	would	AUX
dpc-1515	137	22	require	require	VERB
dpc-1515	137	23	a	a	DET
dpc-1515	137	24	sample	sample	NOUN
dpc-1515	137	25	size	size	NOUN
dpc-1515	137	26	of	of	ADP
dpc-1515	137	27	288	288	NUM
dpc-1515	137	28	cases	case	NOUN
dpc-1515	137	29	and	and	CCONJ
dpc-1515	137	30	288	288	NUM
dpc-1515	137	31	controls	control	NOUN
dpc-1515	137	32	to	to	PART
dpc-1515	137	33	be	be	AUX
dpc-1515	137	34	significant	significant	ADJ
dpc-1515	137	35	at	at	ADP
dpc-1515	137	36	p	p	X
dpc-1515	137	37	<	<	X
dpc-1515	137	38	.05	.05	NUM
dpc-1515	137	39	,	,	PUNCT
dpc-1515	137	40	with	with	ADP
dpc-1515	137	41	80	80	NUM
dpc-1515	137	42	%	%	NOUN
dpc-1515	137	43	power	power	NOUN
dpc-1515	137	44	.	.	PUNCT
dpc-1515	138	1	furthermore	furthermore	ADV
dpc-1515	138	2	,	,	PUNCT
dpc-1515	138	3	cases	case	NOUN
dpc-1515	138	4	were	be	AUX
dpc-1515	138	5	not	not	PART
dpc-1515	138	6	closely	closely	ADV
dpc-1515	138	7	matched	match	VERB
dpc-1515	138	8	to	to	ADP
dpc-1515	138	9	controls	control	NOUN
dpc-1515	138	10	in	in	ADP
dpc-1515	138	11	terms	term	NOUN
dpc-1515	138	12	of	of	ADP
dpc-1515	138	13	age	age	NOUN
dpc-1515	138	14	,	,	PUNCT
dpc-1515	138	15	sex	sex	NOUN
dpc-1515	138	16	,	,	PUNCT
dpc-1515	138	17	or	or	CCONJ
dpc-1515	138	18	skin	skin	NOUN
dpc-1515	138	19	phototype	phototype	NOUN
dpc-1515	138	20	.	.	PUNCT
dpc-1515	139	1	consecutive	consecutive	ADJ
dpc-1515	139	2	recruitment	recruitment	NOUN
dpc-1515	139	3	of	of	ADP
dpc-1515	139	4	patients	patient	NOUN
dpc-1515	139	5	was	be	AUX
dpc-1515	139	6	pursued	pursue	VERB
dpc-1515	139	7	to	to	PART
dpc-1515	139	8	avoid	avoid	VERB
dpc-1515	139	9	selection	selection	NOUN
dpc-1515	139	10	bias	bias	NOUN
dpc-1515	139	11	but	but	CCONJ
dpc-1515	139	12	implied	imply	VERB
dpc-1515	139	13	a	a	DET
dpc-1515	139	14	significant	significant	ADJ
dpc-1515	139	15	inhomogeneity	inhomogeneity	NOUN
dpc-1515	139	16	in	in	ADP
dpc-1515	139	17	the	the	DET
dpc-1515	139	18	2	2	NUM
dpc-1515	139	19	groups	group	NOUN
dpc-1515	139	20	.	.	PUNCT
dpc-1515	140	1	the	the	DET
dpc-1515	140	2	study	study	NOUN
dpc-1515	140	3	design	design	NOUN
dpc-1515	140	4	foresaw	foresee	VERB
dpc-1515	140	5	these	these	DET
dpc-1515	140	6	results	result	NOUN
dpc-1515	140	7	,	,	PUNCT
dpc-1515	140	8	and	and	CCONJ
dpc-1515	140	9	aimed	aim	VERB
dpc-1515	140	10	to	to	PART
dpc-1515	140	11	adjust	adjust	VERB
dpc-1515	140	12	all	all	DET
dpc-1515	140	13	possible	possible	ADJ
dpc-1515	140	14	confounding	confound	VERB
dpc-1515	140	15	factors	factor	NOUN
dpc-1515	140	16	by	by	ADP
dpc-1515	140	17	multivariate	multivariate	NOUN
dpc-1515	140	18	analysis	analysis	NOUN
dpc-1515	140	19	.	.	PUNCT
dpc-1515	141	1	in	in	ADP
dpc-1515	141	2	southern	southern	PROPN
dpc-1515	141	3	europe	europe	PROPN
dpc-1515	141	4	,	,	PUNCT
dpc-1515	141	5	the	the	DET
dpc-1515	141	6	high	high	ADJ
dpc-1515	141	7	prevalence	prevalence	NOUN
dpc-1515	141	8	of	of	ADP
dpc-1515	141	9	ak	ak	PROPN
dpc-1515	141	10	made	make	VERB
dpc-1515	141	11	the	the	DET
dpc-1515	141	12	recruitment	recruitment	NOUN
dpc-1515	141	13	of	of	ADP
dpc-1515	141	14	controls	control	NOUN
dpc-1515	141	15	extremely	extremely	ADV
dpc-1515	141	16	difficult	difficult	ADJ
dpc-1515	141	17	in	in	ADP
dpc-1515	141	18	older	old	ADJ
dpc-1515	141	19	age	age	NOUN
dpc-1515	141	20	groups	group	NOUN
dpc-1515	141	21	.	.	PUNCT
dpc-1515	142	1	besides	besides	SCONJ
dpc-1515	142	2	,	,	PUNCT
dpc-1515	142	3	the	the	DET
dpc-1515	142	4	case	case	NOUN
dpc-1515	142	5	group	group	NOUN
dpc-1515	142	6	had	have	VERB
dpc-1515	142	7	significantly	significantly	ADV
dpc-1515	142	8	more	more	ADJ
dpc-1515	142	9	men	man	NOUN
dpc-1515	142	10	and	and	CCONJ
dpc-1515	142	11	fairskin	fairskin	ADJ
dpc-1515	142	12	individuals	individual	NOUN
dpc-1515	142	13	.	.	PUNCT
dpc-1515	143	1	the	the	DET
dpc-1515	143	2	sex	sex	NOUN
dpc-1515	143	3	difference	difference	NOUN
dpc-1515	143	4	between	between	ADP
dpc-1515	143	5	the	the	DET
dpc-1515	143	6	groups	group	NOUN
dpc-1515	143	7	may	may	AUX
dpc-1515	143	8	have	have	AUX
dpc-1515	143	9	affected	affect	VERB
dpc-1515	143	10	their	their	PRON
dpc-1515	143	11	use	use	NOUN
dpc-1515	143	12	of	of	ADP
dpc-1515	143	13	sun	sun	NOUN
dpc-1515	143	14	-	-	PUNCT
dpc-1515	143	15	protective	protective	ADJ
dpc-1515	143	16	measures	measure	NOUN
dpc-1515	143	17	,	,	PUNCT
dpc-1515	143	18	as	as	SCONJ
dpc-1515	143	19	women	woman	NOUN
dpc-1515	143	20	are	be	AUX
dpc-1515	143	21	more	more	ADV
dpc-1515	143	22	inclined	inclined	ADJ
dpc-1515	143	23	to	to	PART
dpc-1515	143	24	apply	apply	VERB
dpc-1515	143	25	sunscreen	sunscreen	NOUN
dpc-1515	143	26	.	.	PUNCT
dpc-1515	144	1	however	however	ADV
dpc-1515	144	2	,	,	PUNCT
dpc-1515	144	3	sun	sun	NOUN
dpc-1515	144	4	-	-	PUNCT
dpc-1515	144	5	protective	protective	ADJ
dpc-1515	144	6	behaviors	behavior	NOUN
dpc-1515	144	7	were	be	AUX
dpc-1515	144	8	not	not	PART
dpc-1515	144	9	recorded	record	VERB
dpc-1515	144	10	in	in	ADP
dpc-1515	144	11	our	our	PRON
dpc-1515	144	12	survey	survey	NOUN
dpc-1515	144	13	.	.	PUNCT
dpc-1515	145	1	they	they	PRON
dpc-1515	145	2	could	could	AUX
dpc-1515	145	3	have	have	AUX
dpc-1515	145	4	affected	affect	VERB
dpc-1515	145	5	the	the	DET
dpc-1515	145	6	quality	quality	NOUN
dpc-1515	145	7	of	of	ADP
dpc-1515	145	8	our	our	PRON
dpc-1515	145	9	data	datum	NOUN
dpc-1515	145	10	due	due	ADP
dpc-1515	145	11	to	to	ADP
dpc-1515	145	12	the	the	DET
dpc-1515	145	13	dose	dose	NOUN
dpc-1515	145	14	-	-	PUNCT
dpc-1515	145	15	dependent	dependent	ADJ
dpc-1515	145	16	ability	ability	NOUN
dpc-1515	145	17	of	of	ADP
dpc-1515	145	18	sun	sun	NOUN
dpc-1515	145	19	-	-	PUNCT
dpc-1515	145	20	blockers	blocker	NOUN
dpc-1515	145	21	to	to	PART
dpc-1515	145	22	increase	increase	VERB
dpc-1515	145	23	the	the	DET
dpc-1515	145	24	ak	ak	PROPN
dpc-1515	145	25	remission	remission	NOUN
dpc-1515	145	26	rate	rate	NOUN
dpc-1515	145	27	and	and	CCONJ
dpc-1515	145	28	prevent	prevent	VERB
dpc-1515	145	29	the	the	DET
dpc-1515	145	30	development	development	NOUN
dpc-1515	145	31	of	of	ADP
dpc-1515	145	32	new	new	ADJ
dpc-1515	145	33	lesions	lesion	NOUN
dpc-1515	145	34	[	[	X
dpc-1515	145	35	2	2	NUM
dpc-1515	145	36	]	]	PUNCT
dpc-1515	145	37	.	.	PUNCT
dpc-1515	146	1	another	another	DET
dpc-1515	146	2	limitation	limitation	NOUN
dpc-1515	146	3	of	of	ADP
dpc-1515	146	4	our	our	PRON
dpc-1515	146	5	study	study	NOUN
dpc-1515	146	6	is	be	AUX
dpc-1515	146	7	the	the	DET
dpc-1515	146	8	inclusion	inclusion	NOUN
dpc-1515	146	9	of	of	ADP
dpc-1515	146	10	patients	patient	NOUN
dpc-1515	146	11	using	use	VERB
dpc-1515	146	12	multidrug	multidrug	NOUN
dpc-1515	146	13	therapies	therapy	NOUN
dpc-1515	146	14	,	,	PUNCT
dpc-1515	146	15	which	which	PRON
dpc-1515	146	16	,	,	PUNCT
dpc-1515	146	17	however	however	ADV
dpc-1515	146	18	,	,	PUNCT
dpc-1515	146	19	reflects	reflect	VERB
dpc-1515	146	20	real	real	ADJ
dpc-1515	146	21	practices	practice	NOUN
dpc-1515	146	22	and	and	CCONJ
dpc-1515	146	23	the	the	DET
dpc-1515	146	24	disease	disease	NOUN
dpc-1515	146	25	burden	burden	NOUN
dpc-1515	146	26	of	of	ADP
dpc-1515	146	27	elderly	elderly	ADJ
dpc-1515	146	28	patients	patient	NOUN
dpc-1515	146	29	.	.	PUNCT
dpc-1515	147	1	the	the	DET
dpc-1515	147	2	current	current	ADJ
dpc-1515	147	3	study	study	NOUN
dpc-1515	147	4	was	be	AUX
dpc-1515	147	5	underpowered	underpowered	ADJ
dpc-1515	147	6	to	to	PART
dpc-1515	147	7	identify	identify	VERB
dpc-1515	147	8	potential	potential	ADJ
dpc-1515	147	9	synergic	synergic	ADJ
dpc-1515	147	10	or	or	CCONJ
dpc-1515	147	11	antagonistic	antagonistic	ADJ
dpc-1515	147	12	effects	effect	NOUN
dpc-1515	147	13	of	of	ADP
dpc-1515	147	14	the	the	DET
dpc-1515	147	15	simultaneous	simultaneous	ADJ
dpc-1515	147	16	use	use	NOUN
dpc-1515	147	17	of	of	ADP
dpc-1515	147	18	multiple	multiple	ADJ
dpc-1515	147	19	drugs	drug	NOUN
dpc-1515	147	20	.	.	PUNCT
dpc-1515	148	1	supplementary	supplementary	ADJ
dpc-1515	148	2	analyses	analysis	NOUN
dpc-1515	148	3	adjusted	adjust	VERB
dpc-1515	148	4	for	for	ADP
dpc-1515	148	5	the	the	DET
dpc-1515	148	6	concomitant	concomitant	ADJ
dpc-1515	148	7	use	use	NOUN
dpc-1515	148	8	of	of	ADP
dpc-1515	148	9	antihypertensive	antihypertensive	ADJ
dpc-1515	148	10	/	/	SYM
dpc-1515	148	11	diuretic	diuretic	ADJ
dpc-1515	148	12	drugs	drug	NOUN
dpc-1515	148	13	should	should	AUX
dpc-1515	148	14	be	be	AUX
dpc-1515	148	15	performed	perform	VERB
dpc-1515	148	16	in	in	ADP
dpc-1515	148	17	a	a	DET
dpc-1515	148	18	larger	large	ADJ
dpc-1515	148	19	series	series	NOUN
dpc-1515	148	20	.	.	PUNCT
dpc-1515	149	1	a	a	DET
dpc-1515	149	2	possible	possible	ADJ
dpc-1515	149	3	synergistic	synergistic	ADJ
dpc-1515	149	4	effect	effect	NOUN
dpc-1515	149	5	of	of	ADP
dpc-1515	149	6	taking	take	VERB
dpc-1515	149	7	two	two	NUM
dpc-1515	149	8	photosensitizing	photosensitize	VERB
dpc-1515	149	9	drugs	drug	NOUN
dpc-1515	149	10	favoring	favor	VERB
dpc-1515	149	11	ak	ak	PROPN
dpc-1515	149	12	genesis	genesis	NOUN
dpc-1515	149	13	could	could	AUX
dpc-1515	149	14	not	not	PART
dpc-1515	149	15	be	be	AUX
dpc-1515	149	16	excluded	exclude	VERB
dpc-1515	149	17	.	.	PUNCT
dpc-1515	150	1	in	in	ADP
dpc-1515	150	2	our	our	PRON
dpc-1515	150	3	study	study	NOUN
dpc-1515	150	4	,	,	PUNCT
dpc-1515	150	5	the	the	DET
dpc-1515	150	6	number	number	NOUN
dpc-1515	150	7	of	of	ADP
dpc-1515	150	8	patients	patient	NOUN
dpc-1515	150	9	on	on	ADP
dpc-1515	150	10	both	both	CCONJ
dpc-1515	150	11	antiplatelet	antiplatelet	NOUN
dpc-1515	150	12	and	and	CCONJ
dpc-1515	150	13	arb	arb	NOUN
dpc-1515	150	14	therapy	therapy	NOUN
dpc-1515	150	15	was	be	AUX
dpc-1515	150	16	very	very	ADV
dpc-1515	150	17	low	low	ADJ
dpc-1515	150	18	.	.	PUNCT
dpc-1515	151	1	table	table	NOUN
dpc-1515	151	2	4	4	NUM
dpc-1515	151	3	shows	show	VERB
dpc-1515	151	4	that	that	SCONJ
dpc-1515	151	5	none	none	NOUN
dpc-1515	151	6	of	of	ADP
dpc-1515	151	7	the	the	DET
dpc-1515	151	8	controls	control	NOUN
dpc-1515	151	9	with	with	ADP
dpc-1515	151	10	high	high	ADJ
dpc-1515	151	11	exposure	exposure	NOUN
dpc-1515	151	12	to	to	ADP
dpc-1515	151	13	antiplatelet	antiplatelet	NOUN
dpc-1515	151	14	agents	agent	NOUN
dpc-1515	151	15	was	be	AUX
dpc-1515	151	16	exposed	expose	VERB
dpc-1515	151	17	to	to	ADP
dpc-1515	151	18	arbs	arb	NOUN
dpc-1515	151	19	at	at	ADP
dpc-1515	151	20	the	the	DET
dpc-1515	151	21	same	same	ADJ
dpc-1515	151	22	time	time	NOUN
dpc-1515	151	23	.	.	PUNCT
dpc-1515	152	1	in	in	ADP
dpc-1515	152	2	contrast	contrast	NOUN
dpc-1515	152	3	,	,	PUNCT
dpc-1515	152	4	the	the	DET
dpc-1515	152	5	8	8	NUM
dpc-1515	152	6	patients	patient	NOUN
dpc-1515	152	7	on	on	ADP
dpc-1515	152	8	dual	dual	ADJ
dpc-1515	152	9	therapy	therapy	NOUN
dpc-1515	152	10	with	with	ADP
dpc-1515	152	11	high	high	ADJ
dpc-1515	152	12	exposure	exposure	NOUN
dpc-1515	152	13	to	to	PART
dpc-1515	152	14	antiplatelet	antiplatelet	VERB
dpc-1515	152	15	drugs	drug	NOUN
dpc-1515	152	16	and	and	CCONJ
dpc-1515	152	17	arbs	arb	NOUN
dpc-1515	152	18	were	be	AUX
dpc-1515	152	19	in	in	ADP
dpc-1515	152	20	the	the	DET
dpc-1515	152	21	case	case	NOUN
dpc-1515	152	22	group	group	NOUN
dpc-1515	152	23	.	.	PUNCT
dpc-1515	153	1	therefore	therefore	ADV
dpc-1515	153	2	,	,	PUNCT
dpc-1515	153	3	a	a	DET
dpc-1515	153	4	more	more	ADV
dpc-1515	153	5	extensive	extensive	ADJ
dpc-1515	153	6	study	study	NOUN
dpc-1515	153	7	with	with	ADP
dpc-1515	153	8	a	a	DET
dpc-1515	153	9	larger	large	ADJ
dpc-1515	153	10	population	population	NOUN
dpc-1515	153	11	size	size	NOUN
dpc-1515	153	12	is	be	AUX
dpc-1515	153	13	warranted	warrant	VERB
dpc-1515	153	14	to	to	PART
dpc-1515	153	15	characterize	characterize	VERB
dpc-1515	153	16	patients	patient	NOUN
dpc-1515	153	17	taking	take	VERB
dpc-1515	153	18	both	both	DET
dpc-1515	153	19	drugs	drug	NOUN
dpc-1515	153	20	,	,	PUNCT
dpc-1515	153	21	and	and	CCONJ
dpc-1515	153	22	to	to	PART
dpc-1515	153	23	define	define	VERB
dpc-1515	153	24	the	the	DET
dpc-1515	153	25	attributable	attributable	ADJ
dpc-1515	153	26	risk	risk	NOUN
dpc-1515	153	27	of	of	ADP
dpc-1515	153	28	developing	develop	VERB
dpc-1515	153	29	ak	ak	PROPN
dpc-1515	153	30	for	for	ADP
dpc-1515	153	31	each	each	DET
dpc-1515	153	32	medication	medication	NOUN
dpc-1515	153	33	.	.	PUNCT
dpc-1515	154	1	conclusions	conclusion	NOUN
dpc-1515	154	2	our	our	PRON
dpc-1515	154	3	study	study	NOUN
dpc-1515	154	4	was	be	AUX
dpc-1515	154	5	designed	design	VERB
dpc-1515	154	6	to	to	PART
dpc-1515	154	7	investigate	investigate	VERB
dpc-1515	154	8	a	a	DET
dpc-1515	154	9	possible	possible	ADJ
dpc-1515	154	10	association	association	NOUN
dpc-1515	154	11	of	of	ADP
dpc-1515	154	12	photosensitizing	photosensitize	VERB
dpc-1515	154	13	drugs	drug	NOUN
dpc-1515	154	14	and	and	CCONJ
dpc-1515	154	15	ak	ak	PROPN
dpc-1515	154	16	.	.	PUNCT
dpc-1515	155	1	our	our	PRON
dpc-1515	155	2	results	result	NOUN
dpc-1515	155	3	suggest	suggest	VERB
dpc-1515	155	4	a	a	DET
dpc-1515	155	5	correlation	correlation	NOUN
dpc-1515	155	6	between	between	ADP
dpc-1515	155	7	the	the	DET
dpc-1515	155	8	use	use	NOUN
dpc-1515	155	9	of	of	ADP
dpc-1515	155	10	arbs	arb	NOUN
dpc-1515	155	11	or	or	CCONJ
dpc-1515	155	12	antiplatelet	antiplatelet	NOUN
dpc-1515	155	13	agents	agent	NOUN
dpc-1515	155	14	and	and	CCONJ
dpc-1515	155	15	the	the	DET
dpc-1515	155	16	onset	onset	NOUN
dpc-1515	155	17	of	of	ADP
dpc-1515	155	18	ak	ak	PROPN
dpc-1515	155	19	.	.	PROPN
dpc-1515	155	20	arbs	arbs	PROPN
dpc-1515	155	21	possess	possess	VERB
dpc-1515	155	22	a	a	DET
dpc-1515	155	23	known	know	VERB
dpc-1515	155	24	photosensitizing	photosensitize	VERB
dpc-1515	155	25	effect	effect	NOUN
dpc-1515	155	26	,	,	PUNCT
dpc-1515	155	27	which	which	PRON
dpc-1515	155	28	could	could	AUX
dpc-1515	155	29	be	be	AUX
dpc-1515	155	30	the	the	DET
dpc-1515	155	31	missing	miss	VERB
dpc-1515	155	32	link	link	NOUN
dpc-1515	155	33	between	between	ADP
dpc-1515	155	34	their	their	PRON
dpc-1515	155	35	use	use	NOUN
dpc-1515	155	36	and	and	CCONJ
dpc-1515	155	37	the	the	DET
dpc-1515	155	38	development	development	NOUN
dpc-1515	155	39	of	of	ADP
dpc-1515	155	40	ak	ak	PROPN
dpc-1515	155	41	.	.	PROPN
dpc-1515	155	42	antiplatelet	antiplatelet	NOUN
dpc-1515	155	43	agents	agent	NOUN
dpc-1515	155	44	do	do	AUX
dpc-1515	155	45	not	not	PART
dpc-1515	155	46	induce	induce	VERB
dpc-1515	155	47	photosensitivity	photosensitivity	NOUN
dpc-1515	155	48	,	,	PUNCT
dpc-1515	155	49	and	and	CCONJ
dpc-1515	155	50	their	their	PRON
dpc-1515	155	51	association	association	NOUN
dpc-1515	155	52	with	with	ADP
dpc-1515	155	53	ak	ak	PROPN
dpc-1515	155	54	remains	remain	VERB
dpc-1515	155	55	unknown	unknown	ADJ
dpc-1515	155	56	.	.	PUNCT
dpc-1515	156	1	further	further	ADJ
dpc-1515	156	2	studies	study	NOUN
dpc-1515	156	3	are	be	AUX
dpc-1515	156	4	needed	need	VERB
dpc-1515	156	5	to	to	PART
dpc-1515	156	6	assess	assess	VERB
dpc-1515	156	7	the	the	DET
dpc-1515	156	8	pro	pro	ADJ
dpc-1515	156	9	-	-	ADJ
dpc-1515	156	10	car6	car6	ADJ
dpc-1515	156	11	research	research	NOUN
dpc-1515	156	12	|	|	ADV
dpc-1515	156	13	dermatol	dermatol	ADJ
dpc-1515	156	14	pract	pract	NOUN
dpc-1515	156	15	concept	concept	NOUN
dpc-1515	156	16	.	.	PUNCT
dpc-1515	157	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	157	2	cinogenic	cinogenic	ADJ
dpc-1515	157	3	potentials	potential	VERB
dpc-1515	157	4	of	of	ADP
dpc-1515	157	5	these	these	DET
dpc-1515	157	6	2	2	NUM
dpc-1515	157	7	classes	class	NOUN
dpc-1515	157	8	of	of	ADP
dpc-1515	157	9	drugs	drug	NOUN
dpc-1515	157	10	,	,	PUNCT
dpc-1515	157	11	in	in	ADP
dpc-1515	157	12	order	order	NOUN
dpc-1515	157	13	to	to	PART
dpc-1515	157	14	prompt	prompt	VERB
dpc-1515	157	15	adequate	adequate	ADJ
dpc-1515	157	16	dermatological	dermatological	ADJ
dpc-1515	157	17	screening	screening	NOUN
dpc-1515	157	18	and	and	CCONJ
dpc-1515	157	19	sun	sun	NOUN
dpc-1515	157	20	protection	protection	NOUN
dpc-1515	157	21	,	,	PUNCT
dpc-1515	157	22	mainly	mainly	ADV
dpc-1515	157	23	in	in	ADP
dpc-1515	157	24	patients	patient	NOUN
dpc-1515	157	25	with	with	ADP
dpc-1515	157	26	a	a	DET
dpc-1515	157	27	medical	medical	ADJ
dpc-1515	157	28	history	history	NOUN
dpc-1515	157	29	of	of	ADP
dpc-1515	157	30	nmsc	nmsc	NOUN
dpc-1515	157	31	.	.	PUNCT
dpc-1515	158	1	references	reference	NOUN
dpc-1515	158	2	1	1	NUM
dpc-1515	158	3	.	.	PUNCT
dpc-1515	158	4	criscione	criscione	NOUN
dpc-1515	158	5	vd	vd	PROPN
dpc-1515	158	6	,	,	PUNCT
dpc-1515	158	7	weinstock	weinstock	PROPN
dpc-1515	158	8	ma	ma	PROPN
dpc-1515	158	9	,	,	PUNCT
dpc-1515	158	10	naylor	naylor	PROPN
dpc-1515	158	11	mf	mf	PROPN
dpc-1515	158	12	,	,	PUNCT
dpc-1515	158	13	et	et	PROPN
dpc-1515	158	14	al	al	PROPN
dpc-1515	158	15	;	;	PUNCT
dpc-1515	158	16	department	department	PROPN
dpc-1515	158	17	of	of	ADP
dpc-1515	158	18	veteran	veteran	PROPN
dpc-1515	158	19	affairs	affairs	PROPN
dpc-1515	158	20	topical	topical	ADJ
dpc-1515	158	21	tretinoin	tretinoin	PROPN
dpc-1515	158	22	chemoprevention	chemoprevention	PROPN
dpc-1515	158	23	trial	trial	NOUN
dpc-1515	158	24	group	group	NOUN
dpc-1515	158	25	.	.	PUNCT
dpc-1515	159	1	actinic	actinic	ADJ
dpc-1515	159	2	keratoses	keratose	NOUN
dpc-1515	159	3	:	:	PUNCT
dpc-1515	159	4	natural	natural	ADJ
dpc-1515	159	5	history	history	NOUN
dpc-1515	159	6	and	and	CCONJ
dpc-1515	159	7	risk	risk	NOUN
dpc-1515	159	8	of	of	ADP
dpc-1515	159	9	malignant	malignant	ADJ
dpc-1515	159	10	transformation	transformation	NOUN
dpc-1515	159	11	in	in	ADP
dpc-1515	159	12	the	the	DET
dpc-1515	159	13	veterans	veteran	NOUN
dpc-1515	159	14	affairs	affairs	PROPN
dpc-1515	159	15	topical	topical	ADJ
dpc-1515	159	16	tretinoin	tretinoin	PROPN
dpc-1515	159	17	chemoprevention	chemoprevention	NOUN
dpc-1515	159	18	trial	trial	NOUN
dpc-1515	159	19	.	.	PUNCT
dpc-1515	160	1	cancer	cancer	NOUN
dpc-1515	160	2	.	.	PUNCT
dpc-1515	161	1	2009;115(11):2523	2009;115(11):2523	NOUN
dpc-1515	161	2	.	.	PUNCT
dpc-1515	162	1	doi	doi	NOUN
dpc-1515	162	2	:	:	PUNCT
dpc-1515	162	3	10.1002	10.1002	NUM
dpc-1515	162	4	/	/	SYM
dpc-1515	162	5	cncr.24284	cncr.24284	PROPN
dpc-1515	162	6	.	.	PUNCT
dpc-1515	163	1	pmid	pmid	PROPN
dpc-1515	163	2	:	:	PUNCT
dpc-1515	163	3	19382202	19382202	NUM
dpc-1515	163	4	.	.	PUNCT
dpc-1515	164	1	2	2	X
dpc-1515	164	2	.	.	X
dpc-1515	164	3	siegel	siegel	PROPN
dpc-1515	164	4	ja	ja	PROPN
dpc-1515	164	5	,	,	PUNCT
dpc-1515	164	6	korgavkar	korgavkar	PROPN
dpc-1515	164	7	k	k	PROPN
dpc-1515	164	8	,	,	PUNCT
dpc-1515	164	9	weinstock	weinstock	PROPN
dpc-1515	164	10	ma	ma	PROPN
dpc-1515	164	11	.	.	PROPN
dpc-1515	165	1	current	current	ADJ
dpc-1515	165	2	perspective	perspective	NOUN
dpc-1515	165	3	on	on	ADP
dpc-1515	165	4	actinic	actinic	ADJ
dpc-1515	165	5	keratosis	keratosis	NOUN
dpc-1515	165	6	:	:	PUNCT
dpc-1515	165	7	a	a	DET
dpc-1515	165	8	review	review	NOUN
dpc-1515	165	9	.	.	PUNCT
dpc-1515	166	1	br	br	PROPN
dpc-1515	166	2	j	j	PROPN
dpc-1515	166	3	dermatol	dermatol	NOUN
dpc-1515	166	4	.	.	PUNCT
dpc-1515	167	1	2017;177(2):350	2017;177(2):350	NUM
dpc-1515	167	2	-	-	SYM
dpc-1515	167	3	358	358	NUM
dpc-1515	167	4	.	.	PUNCT
dpc-1515	168	1	doi	doi	NOUN
dpc-1515	168	2	:	:	PUNCT
dpc-1515	168	3	10.1111	10.1111	NUM
dpc-1515	168	4	/	/	SYM
dpc-1515	168	5	bjd.14852	bjd.14852	NOUN
dpc-1515	168	6	.	.	PUNCT
dpc-1515	169	1	pmid	pmid	NOUN
dpc-1515	169	2	:	:	PUNCT
dpc-1515	169	3	27500794	27500794	NUM
dpc-1515	169	4	.	.	PUNCT
dpc-1515	170	1	3	3	X
dpc-1515	170	2	.	.	X
dpc-1515	170	3	quaedvlieg	quaedvlieg	PROPN
dpc-1515	170	4	pj	pj	PROPN
dpc-1515	170	5	,	,	PUNCT
dpc-1515	170	6	tirsi	tirsi	NOUN
dpc-1515	170	7	e	e	NOUN
dpc-1515	170	8	,	,	PUNCT
dpc-1515	170	9	thissen	thissen	VERB
dpc-1515	170	10	mr	mr	PROPN
dpc-1515	170	11	,	,	PUNCT
dpc-1515	170	12	et	et	PROPN
dpc-1515	170	13	al	al	PROPN
dpc-1515	170	14	.	.	PROPN
dpc-1515	170	15	actinic	actinic	ADJ
dpc-1515	170	16	keratosis	keratosis	NOUN
dpc-1515	170	17	:	:	PUNCT
dpc-1515	170	18	how	how	SCONJ
dpc-1515	170	19	to	to	PART
dpc-1515	170	20	differentiate	differentiate	VERB
dpc-1515	170	21	the	the	DET
dpc-1515	170	22	good	good	NOUN
dpc-1515	170	23	from	from	ADP
dpc-1515	170	24	the	the	DET
dpc-1515	170	25	bad	bad	ADJ
dpc-1515	170	26	ones	one	NOUN
dpc-1515	170	27	?	?	PUNCT
dpc-1515	171	1	eur	eur	PROPN
dpc-1515	171	2	j	j	PROPN
dpc-1515	171	3	dermatol	dermatol	NOUN
dpc-1515	171	4	.	.	PUNCT
dpc-1515	172	1	2006;16(4):335–339	2006;16(4):335–339	NUM
dpc-1515	172	2	.	.	PUNCT
dpc-1515	172	3	pmid	pmid	NOUN
dpc-1515	172	4	:	:	PUNCT
dpc-1515	172	5	16935787	16935787	NUM
dpc-1515	172	6	.	.	PUNCT
dpc-1515	173	1	4	4	X
dpc-1515	173	2	.	.	X
dpc-1515	173	3	hensen	hensen	PROPN
dpc-1515	173	4	p	p	PROPN
dpc-1515	173	5	,	,	PUNCT
dpc-1515	173	6	müller	müller	PROPN
dpc-1515	173	7	ml	ml	PROPN
dpc-1515	173	8	,	,	PUNCT
dpc-1515	173	9	haschemi	haschemi	ADV
dpc-1515	173	10	r	r	NOUN
dpc-1515	173	11	,	,	PUNCT
dpc-1515	173	12	et	et	PROPN
dpc-1515	173	13	al	al	PROPN
dpc-1515	173	14	.	.	PUNCT
dpc-1515	174	1	predisposing	predispose	VERB
dpc-1515	174	2	factors	factor	NOUN
dpc-1515	174	3	of	of	ADP
dpc-1515	174	4	actinic	actinic	ADJ
dpc-1515	174	5	keratosis	keratosis	NOUN
dpc-1515	174	6	in	in	ADP
dpc-1515	174	7	a	a	DET
dpc-1515	174	8	north	north	NOUN
dpc-1515	174	9	-	-	PUNCT
dpc-1515	174	10	west	west	ADJ
dpc-1515	174	11	german	german	ADJ
dpc-1515	174	12	population	population	NOUN
dpc-1515	174	13	.	.	PUNCT
dpc-1515	175	1	eur	eur	PROPN
dpc-1515	175	2	j	j	PROPN
dpc-1515	175	3	dermatol	dermatol	NOUN
dpc-1515	175	4	.	.	PUNCT
dpc-1515	176	1	2009;19(4):345	2009;19(4):345	NUM
dpc-1515	176	2	.	.	PUNCT
dpc-1515	177	1	doi	doi	NOUN
dpc-1515	177	2	:	:	PUNCT
dpc-1515	177	3	10.1684	10.1684	NUM
dpc-1515	177	4	/	/	SYM
dpc-1515	177	5	ejd.2009.0706	ejd.2009.0706	PROPN
dpc-1515	177	6	.	.	PUNCT
dpc-1515	178	1	pmid	pmid	NOUN
dpc-1515	178	2	:	:	PUNCT
dpc-1515	178	3	19470418	19470418	NUM
dpc-1515	178	4	.	.	PUNCT
dpc-1515	179	1	5	5	X
dpc-1515	179	2	.	.	X
dpc-1515	179	3	frost	frost	NOUN
dpc-1515	179	4	ca	ca	NOUN
dpc-1515	179	5	,	,	PUNCT
dpc-1515	179	6	green	green	PROPN
dpc-1515	179	7	ac	ac	PROPN
dpc-1515	179	8	,	,	PUNCT
dpc-1515	179	9	williams	williams	PROPN
dpc-1515	179	10	gm	gm	PROPN
dpc-1515	179	11	.	.	PUNCT
dpc-1515	180	1	the	the	DET
dpc-1515	180	2	prevalence	prevalence	NOUN
dpc-1515	180	3	and	and	CCONJ
dpc-1515	180	4	determinants	determinant	NOUN
dpc-1515	180	5	of	of	ADP
dpc-1515	180	6	solar	solar	ADJ
dpc-1515	180	7	keratoses	keratose	NOUN
dpc-1515	180	8	at	at	ADP
dpc-1515	180	9	a	a	DET
dpc-1515	180	10	subtropical	subtropical	ADJ
dpc-1515	180	11	latitude	latitude	NOUN
dpc-1515	180	12	(	(	PUNCT
dpc-1515	180	13	queensland	queensland	PROPN
dpc-1515	180	14	,	,	PUNCT
dpc-1515	180	15	australia	australia	PROPN
dpc-1515	180	16	)	)	PUNCT
dpc-1515	180	17	.	.	PUNCT
dpc-1515	181	1	br	br	PROPN
dpc-1515	181	2	j	j	PROPN
dpc-1515	181	3	dermatol	dermatol	NOUN
dpc-1515	181	4	.	.	PUNCT
dpc-1515	182	1	1998;139(6):1033	1998;139(6):1033	NUM
dpc-1515	182	2	-	-	SYM
dpc-1515	182	3	1039	1039	NUM
dpc-1515	182	4	.	.	PUNCT
dpc-1515	182	5	 	 	SPACE
dpc-1515	183	1	doi	doi	NOUN
dpc-1515	183	2	:	:	PUNCT
dpc-1515	183	3	10.1046	10.1046	NUM
dpc-1515	183	4	/	/	SYM
dpc-1515	183	5	j.1365	j.1365	NOUN
dpc-1515	183	6	-	-	PUNCT
dpc-1515	183	7	2133.1998.02560.x	2133.1998.02560.x	NUM
dpc-1515	183	8	.	.	PUNCT
dpc-1515	184	1	pmid	pmid	NOUN
dpc-1515	184	2	:	:	PUNCT
dpc-1515	184	3	9990367	9990367	NUM
dpc-1515	184	4	.	.	PUNCT
dpc-1515	185	1	6	6	NUM
dpc-1515	185	2	.	.	X
dpc-1515	185	3	de	de	X
dpc-1515	185	4	berker	berker	PROPN
dpc-1515	186	1	d	d	PROPN
dpc-1515	186	2	,	,	PUNCT
dpc-1515	186	3	mcgregor	mcgregor	PROPN
dpc-1515	186	4	jm	jm	PROPN
dpc-1515	186	5	,	,	PUNCT
dpc-1515	186	6	mohd	mohd	PROPN
dpc-1515	186	7	mustapa	mustapa	PROPN
dpc-1515	186	8	mf	mf	PROPN
dpc-1515	186	9	,	,	PUNCT
dpc-1515	186	10	exton	exton	PROPN
dpc-1515	186	11	ls	ls	PROPN
dpc-1515	186	12	,	,	PUNCT
dpc-1515	186	13	hughes	hughes	PROPN
dpc-1515	186	14	br	br	PROPN
dpc-1515	186	15	.	.	PUNCT
dpc-1515	187	1	british	british	PROPN
dpc-1515	187	2	association	association	PROPN
dpc-1515	187	3	of	of	ADP
dpc-1515	187	4	dermatologists	dermatologist	NOUN
dpc-1515	187	5	’	'	PUNCT
dpc-1515	187	6	guidelines	guideline	NOUN
dpc-1515	187	7	for	for	ADP
dpc-1515	187	8	the	the	DET
dpc-1515	187	9	care	care	NOUN
dpc-1515	187	10	of	of	ADP
dpc-1515	187	11	patients	patient	NOUN
dpc-1515	187	12	with	with	ADP
dpc-1515	187	13	actinic	actinic	ADJ
dpc-1515	187	14	keratosis	keratosis	NOUN
dpc-1515	187	15	2017	2017	NUM
dpc-1515	187	16	.	.	PUNCT
dpc-1515	187	17	 	 	SPACE
dpc-1515	188	1	br	br	PROPN
dpc-1515	188	2	j	j	PROPN
dpc-1515	188	3	dermatol	dermatol	NOUN
dpc-1515	188	4	2017;176(1):20	2017;176(1):20	NUM
dpc-1515	188	5	-	-	SYM
dpc-1515	188	6	43	43	NUM
dpc-1515	188	7	.	.	PUNCT
dpc-1515	189	1	doi	doi	NOUN
dpc-1515	189	2	:	:	PUNCT
dpc-1515	189	3	10.1111	10.1111	NUM
dpc-1515	189	4	/	/	SYM
dpc-1515	189	5	bjd.15107	bjd.15107	PROPN
dpc-1515	189	6	.	.	PUNCT
dpc-1515	190	1	pmid	pmid	NOUN
dpc-1515	190	2	:	:	PUNCT
dpc-1515	190	3	28098380	28098380	NUM
dpc-1515	190	4	.	.	PUNCT
dpc-1515	191	1	7	7	X
dpc-1515	191	2	.	.	X
dpc-1515	191	3	placzek	placzek	NUM
dpc-1515	191	4	m	m	PROPN
dpc-1515	191	5	,	,	PUNCT
dpc-1515	191	6	eberlein	eberlein	NOUN
dpc-1515	191	7	-	-	PUNCT
dpc-1515	191	8	könig	könig	PROPN
dpc-1515	191	9	b	b	PROPN
dpc-1515	191	10	,	,	PUNCT
dpc-1515	191	11	przybilla	przybilla	PROPN
dpc-1515	191	12	b.	b.	PROPN
dpc-1515	191	13	association	association	PROPN
dpc-1515	191	14	between	between	ADP
dpc-1515	191	15	actinic	actinic	ADJ
dpc-1515	191	16	keratoses	keratose	NOUN
dpc-1515	191	17	and	and	CCONJ
dpc-1515	191	18	potentially	potentially	ADV
dpc-1515	191	19	photosensitizing	photosensitize	VERB
dpc-1515	191	20	drugs	drug	NOUN
dpc-1515	191	21	.	.	PUNCT
dpc-1515	192	1	n	n	PRON
dpc-1515	192	2	engl	engl	PROPN
dpc-1515	192	3	j	j	PROPN
dpc-1515	192	4	med	me	VERB
dpc-1515	192	5	1999;341(19):1474	1999;341(19):1474	PROPN
dpc-1515	192	6	-	-	SYM
dpc-1515	192	7	1475	1475	NUM
dpc-1515	192	8	.	.	PUNCT
dpc-1515	193	1	doi	doi	NOUN
dpc-1515	193	2	:	:	PUNCT
dpc-1515	193	3	10.1056/	10.1056/	NUM
dpc-1515	193	4	nejm199911043411915	nejm199911043411915	PROPN
dpc-1515	193	5	.	.	PUNCT
dpc-1515	194	1	pmid	pmid	NOUN
dpc-1515	194	2	:	:	PUNCT
dpc-1515	194	3	10577103	10577103	NUM
dpc-1515	194	4	.	.	PUNCT
dpc-1515	195	1	8	8	X
dpc-1515	195	2	.	.	PUNCT
dpc-1515	195	3	european	european	PROPN
dpc-1515	195	4	medicines	medicine	NOUN
dpc-1515	195	5	agency	agency	NOUN
dpc-1515	195	6	—	—	PUNCT
dpc-1515	195	7	pharmacovigilance	pharmacovigilance	NOUN
dpc-1515	195	8	risk	risk	NOUN
dpc-1515	195	9	assessment	assessment	NOUN
dpc-1515	195	10	committee	committee	NOUN
dpc-1515	195	11	(	(	PUNCT
dpc-1515	195	12	prac	prac	NOUN
dpc-1515	195	13	)	)	PUNCT
dpc-1515	195	14	.	.	PUNCT
dpc-1515	196	1	prac	prac	NOUN
dpc-1515	196	2	recommendations	recommendation	NOUN
dpc-1515	196	3	on	on	ADP
dpc-1515	196	4	signals	signal	NOUN
dpc-1515	196	5	.	.	PUNCT
dpc-1515	197	1	1	1	NUM
dpc-1515	197	2	october	october	PROPN
dpc-1515	197	3	2018	2018	NUM
dpc-1515	197	4	.	.	PUNCT
dpc-1515	198	1	accessed	access	VERB
dpc-1515	198	2	:	:	PUNCT
dpc-1515	198	3	february	february	PROPN
dpc-1515	198	4	14	14	NUM
dpc-1515	198	5	,	,	PUNCT
dpc-1515	198	6	2021	2021	NUM
dpc-1515	198	7	.	.	PUNCT
dpc-1515	199	1	available	available	ADJ
dpc-1515	199	2	at	at	ADP
dpc-1515	199	3	:	:	PUNCT
dpc-1515	199	4	https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf	https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf	ADJ
dpc-1515	199	5	.	.	NOUN
dpc-1515	200	1	9	9	X
dpc-1515	200	2	.	.	X
dpc-1515	200	3	pedersen	pedersen	PROPN
dpc-1515	200	4	sa	sa	PROPN
dpc-1515	200	5	,	,	PUNCT
dpc-1515	200	6	gaist	gaist	NOUN
dpc-1515	200	7	d	d	PROPN
dpc-1515	200	8	,	,	PUNCT
dpc-1515	200	9	schmidt	schmidt	PROPN
dpc-1515	200	10	saj	saj	PROPN
dpc-1515	200	11	,	,	PUNCT
dpc-1515	200	12	hölmich	hölmich	PROPN
dpc-1515	200	13	lr	lr	PROPN
dpc-1515	200	14	,	,	PUNCT
dpc-1515	200	15	friis	friis	PROPN
dpc-1515	200	16	s	s	PART
dpc-1515	200	17	,	,	PUNCT
dpc-1515	200	18	pottegård	pottegård	ADJ
dpc-1515	200	19	a.	a.	PROPN
dpc-1515	200	20	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	200	21	use	use	NOUN
dpc-1515	200	22	and	and	CCONJ
dpc-1515	200	23	risk	risk	NOUN
dpc-1515	200	24	of	of	ADP
dpc-1515	200	25	nonmelanoma	nonmelanoma	ADJ
dpc-1515	200	26	skin	skin	NOUN
dpc-1515	200	27	cancer	cancer	NOUN
dpc-1515	200	28	:	:	PUNCT
dpc-1515	200	29	a	a	DET
dpc-1515	200	30	 	 	SPACE
dpc-1515	200	31	nationwide	nationwide	ADJ
dpc-1515	200	32	case	case	NOUN
dpc-1515	200	33	-	-	PUNCT
dpc-1515	200	34	control	control	NOUN
dpc-1515	200	35	study	study	NOUN
dpc-1515	200	36	from	from	ADP
dpc-1515	200	37	denmark	denmark	PROPN
dpc-1515	200	38	.	.	PUNCT
dpc-1515	200	39	 	 	SPACE
dpc-1515	201	1	j	j	PROPN
dpc-1515	201	2	am	be	AUX
dpc-1515	201	3	acad	acad	ADJ
dpc-1515	201	4	dermatol	dermatol	NOUN
dpc-1515	201	5	2018;78(4):673	2018;78(4):673	PROPN
dpc-1515	201	6	-	-	PUNCT
dpc-1515	201	7	681.e9	681.e9	PROPN
dpc-1515	201	8	.	.	PUNCT
dpc-1515	202	1	doi	doi	NOUN
dpc-1515	202	2	:	:	PUNCT
dpc-1515	202	3	10.1016	10.1016	NUM
dpc-1515	202	4	/	/	SYM
dpc-1515	202	5	j.	j.	PROPN
dpc-1515	202	6	jaad.2017.11.042	jaad.2017.11.042	PROPN
dpc-1515	202	7	.	.	PUNCT
dpc-1515	203	1	pmid	pmid	NOUN
dpc-1515	203	2	:	:	PUNCT
dpc-1515	203	3	29217346	29217346	NUM
dpc-1515	203	4	.	.	PUNCT
dpc-1515	204	1	10	10	NUM
dpc-1515	204	2	.	.	PUNCT
dpc-1515	205	1	pottegård	pottegård	PROPN
dpc-1515	205	2	a	a	PRON
dpc-1515	205	3	,	,	PUNCT
dpc-1515	205	4	hallas	hallas	PROPN
dpc-1515	205	5	j	j	PROPN
dpc-1515	205	6	,	,	PUNCT
dpc-1515	205	7	olesen	olesen	VERB
dpc-1515	205	8	m	m	PROPN
dpc-1515	205	9	,	,	PUNCT
dpc-1515	205	10	et	et	PROPN
dpc-1515	205	11	al	al	PROPN
dpc-1515	205	12	.	.	PROPN
dpc-1515	206	1	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	206	2	use	use	NOUN
dpc-1515	206	3	is	be	AUX
dpc-1515	206	4	strongly	strongly	ADV
dpc-1515	206	5	associated	associate	VERB
dpc-1515	206	6	with	with	ADP
dpc-1515	206	7	risk	risk	NOUN
dpc-1515	206	8	of	of	ADP
dpc-1515	206	9	lip	lip	NOUN
dpc-1515	206	10	cancer	cancer	NOUN
dpc-1515	206	11	.	.	PUNCT
dpc-1515	206	12	 	 	SPACE
dpc-1515	207	1	j	j	PROPN
dpc-1515	207	2	intern	intern	NOUN
dpc-1515	207	3	med	me	VERB
dpc-1515	207	4	2017;282(4):322–331	2017;282(4):322–331	PROPN
dpc-1515	208	1	.	.	PUNCT
dpc-1515	208	2	 	 	SPACE
dpc-1515	208	3	doi	doi	NOUN
dpc-1515	208	4	:	:	PUNCT
dpc-1515	208	5	10.1111	10.1111	NUM
dpc-1515	208	6	/	/	SYM
dpc-1515	208	7	joim.12629	joim.12629	PROPN
dpc-1515	208	8	.	.	PUNCT
dpc-1515	209	1	pmid	pmid	NOUN
dpc-1515	209	2	:	:	PUNCT
dpc-1515	209	3	28480532	28480532	NUM
dpc-1515	209	4	.	.	PUNCT
dpc-1515	210	1	11	11	NUM
dpc-1515	210	2	.	.	PUNCT
dpc-1515	211	1	friedman	friedman	PROPN
dpc-1515	211	2	gd	gd	PROPN
dpc-1515	211	3	,	,	PUNCT
dpc-1515	211	4	asgari	asgari	PROPN
dpc-1515	211	5	mm	mm	PROPN
dpc-1515	211	6	,	,	PUNCT
dpc-1515	211	7	warton	warton	VERB
dpc-1515	211	8	em	em	PRON
dpc-1515	211	9	,	,	PUNCT
dpc-1515	211	10	chan	chan	PROPN
dpc-1515	211	11	j	j	PROPN
dpc-1515	211	12	,	,	PUNCT
dpc-1515	211	13	habel	habel	PROPN
dpc-1515	211	14	la	la	PROPN
dpc-1515	211	15	.	.	PROPN
dpc-1515	212	1	antihypertensive	antihypertensive	ADJ
dpc-1515	212	2	drugs	drug	NOUN
dpc-1515	212	3	and	and	CCONJ
dpc-1515	212	4	lip	lip	NOUN
dpc-1515	212	5	cancer	cancer	NOUN
dpc-1515	212	6	in	in	ADP
dpc-1515	212	7	non	non	ADJ
dpc-1515	212	8	-	-	ADJ
dpc-1515	212	9	hispanic	hispanic	ADJ
dpc-1515	212	10	whites	white	NOUN
dpc-1515	212	11	.	.	PUNCT
dpc-1515	213	1	arch	arch	ADJ
dpc-1515	213	2	intern	intern	PROPN
dpc-1515	213	3	med	med	PROPN
dpc-1515	213	4	.	.	PUNCT
dpc-1515	214	1	2012;172(16):1246	2012;172(16):1246	NUM
dpc-1515	214	2	-	-	SYM
dpc-1515	214	3	1251	1251	NUM
dpc-1515	214	4	.	.	PUNCT
dpc-1515	215	1	doi	doi	NOUN
dpc-1515	215	2	:	:	PUNCT
dpc-1515	215	3	10.1001/	10.1001/	NUM
dpc-1515	215	4	archinternmed.2012.2754	archinternmed.2012.2754	PROPN
dpc-1515	215	5	.	.	PUNCT
dpc-1515	216	1	pmid	pmid	NOUN
dpc-1515	216	2	:	:	PUNCT
dpc-1515	216	3	22869299	22869299	NUM
dpc-1515	216	4	.	.	PUNCT
dpc-1515	217	1	12	12	NUM
dpc-1515	217	2	.	.	PUNCT
dpc-1515	218	1	o’gorman	o’gorman	NOUN
dpc-1515	218	2	sm	sm	PROPN
dpc-1515	218	3	,	,	PUNCT
dpc-1515	218	4	murphy	murphy	PROPN
dpc-1515	218	5	gm	gm	PROPN
dpc-1515	218	6	.	.	PUNCT
dpc-1515	219	1	photosensitizing	photosensitize	VERB
dpc-1515	219	2	medications	medication	NOUN
dpc-1515	219	3	and	and	CCONJ
dpc-1515	219	4	photocarcinogenesis	photocarcinogenesis	NOUN
dpc-1515	219	5	.	.	PUNCT
dpc-1515	220	1	photodermatol	photodermatol	PROPN
dpc-1515	220	2	photoimmunol	photoimmunol	PROPN
dpc-1515	220	3	photomed	photome	VERB
dpc-1515	220	4	.	.	PUNCT
dpc-1515	221	1	2014;30(1):8	2014;30(1):8	NUM
dpc-1515	221	2	-	-	SYM
dpc-1515	221	3	14	14	NUM
dpc-1515	221	4	.	.	PUNCT
dpc-1515	222	1	doi	doi	NOUN
dpc-1515	222	2	:	:	PUNCT
dpc-1515	222	3	10.1111	10.1111	NUM
dpc-1515	222	4	/	/	SYM
dpc-1515	223	1	phpp.12085	phpp.12085	PROPN
dpc-1515	223	2	.	.	PUNCT
dpc-1515	224	1	pmid	pmid	NOUN
dpc-1515	224	2	:	:	PUNCT
dpc-1515	224	3	24393207	24393207	NUM
dpc-1515	224	4	.	.	PUNCT
dpc-1515	225	1	13	13	NUM
dpc-1515	225	2	.	.	PUNCT
dpc-1515	226	1	jensen	jensen	PROPN
dpc-1515	226	2	aø	aø	PROPN
dpc-1515	226	3	,	,	PUNCT
dpc-1515	226	4	thomsen	thomsen	PROPN
dpc-1515	226	5	hf	hf	PROPN
dpc-1515	226	6	,	,	PUNCT
dpc-1515	226	7	engebjerg	engebjerg	PROPN
dpc-1515	226	8	mc	mc	PROPN
dpc-1515	226	9	,	,	PUNCT
dpc-1515	226	10	olesen	olesen	PROPN
dpc-1515	226	11	ab	ab	PROPN
dpc-1515	226	12	,	,	PUNCT
dpc-1515	226	13	sørensen	sørensen	PROPN
dpc-1515	226	14	ht	ht	PROPN
dpc-1515	226	15	,	,	PUNCT
dpc-1515	226	16	karagas	karagas	PROPN
dpc-1515	226	17	mr	mr	PROPN
dpc-1515	226	18	.	.	PROPN
dpc-1515	226	19	use	use	NOUN
dpc-1515	226	20	of	of	ADP
dpc-1515	226	21	photosensitising	photosensitise	VERB
dpc-1515	226	22	diuretics	diuretic	NOUN
dpc-1515	226	23	and	and	CCONJ
dpc-1515	226	24	risk	risk	NOUN
dpc-1515	226	25	of	of	ADP
dpc-1515	226	26	skin	skin	NOUN
dpc-1515	226	27	cancer	cancer	NOUN
dpc-1515	226	28	:	:	PUNCT
dpc-1515	226	29	a	a	DET
dpc-1515	226	30	population	population	NOUN
dpc-1515	226	31	-	-	PUNCT
dpc-1515	226	32	based	base	VERB
dpc-1515	226	33	case	case	NOUN
dpc-1515	226	34	-	-	PUNCT
dpc-1515	226	35	control	control	NOUN
dpc-1515	226	36	study	study	NOUN
dpc-1515	226	37	.	.	PUNCT
dpc-1515	227	1	br	br	PROPN
dpc-1515	227	2	j	j	PROPN
dpc-1515	227	3	cancer	cancer	NOUN
dpc-1515	227	4	.	.	PUNCT
dpc-1515	228	1	2008;99(9):1522	2008;99(9):1522	NUM
dpc-1515	228	2	-	-	SYM
dpc-1515	228	3	1528	1528	NUM
dpc-1515	228	4	.	.	PUNCT
dpc-1515	229	1	doi	doi	NOUN
dpc-1515	229	2	:	:	PUNCT
dpc-1515	229	3	10.1038	10.1038	NUM
dpc-1515	229	4	/	/	SYM
dpc-1515	229	5	sj.bjc.6604686	sj.bjc.6604686	NOUN
dpc-1515	229	6	.	.	PUNCT
dpc-1515	230	1	pmid	pmid	NOUN
dpc-1515	230	2	:	:	PUNCT
dpc-1515	230	3	18813314	18813314	NUM
dpc-1515	230	4	.	.	PUNCT
dpc-1515	231	1	14	14	NUM
dpc-1515	231	2	.	.	PUNCT
dpc-1515	232	1	schmidt	schmidt	PROPN
dpc-1515	232	2	saj	saj	PROPN
dpc-1515	232	3	,	,	PUNCT
dpc-1515	232	4	schmidt	schmidt	PROPN
dpc-1515	232	5	m	m	PROPN
dpc-1515	232	6	,	,	PUNCT
dpc-1515	232	7	mehnert	mehnert	PROPN
dpc-1515	232	8	f	f	PROPN
dpc-1515	232	9	,	,	PUNCT
dpc-1515	232	10	et	et	PROPN
dpc-1515	232	11	al	al	PROPN
dpc-1515	232	12	.	.	PUNCT
dpc-1515	232	13	use	use	NOUN
dpc-1515	232	14	of	of	ADP
dpc-1515	232	15	antihypertensive	antihypertensive	ADJ
dpc-1515	232	16	drugs	drug	NOUN
dpc-1515	232	17	and	and	CCONJ
dpc-1515	232	18	risk	risk	NOUN
dpc-1515	232	19	of	of	ADP
dpc-1515	232	20	skin	skin	NOUN
dpc-1515	232	21	cancer	cancer	NOUN
dpc-1515	232	22	.	.	PUNCT
dpc-1515	233	1	j	j	PROPN
dpc-1515	233	2	eur	eur	PROPN
dpc-1515	233	3	acad	acad	PROPN
dpc-1515	233	4	dermatol	dermatol	NOUN
dpc-1515	233	5	venereol	venereol	NOUN
dpc-1515	233	6	.	.	PUNCT
dpc-1515	234	1	2015;29(8):1545–1554	2015;29(8):1545–1554	NUM
dpc-1515	234	2	.	.	PUNCT
dpc-1515	235	1	doi	doi	NOUN
dpc-1515	235	2	:	:	PUNCT
dpc-1515	235	3	10.1111	10.1111	NUM
dpc-1515	235	4	/	/	SYM
dpc-1515	235	5	jdv.12921	jdv.12921	X
dpc-1515	235	6	.	.	PUNCT
dpc-1515	236	1	pmid	pmid	NOUN
dpc-1515	236	2	:	:	PUNCT
dpc-1515	236	3	25640031	25640031	NUM
dpc-1515	236	4	.	.	PUNCT
dpc-1515	237	1	15	15	NUM
dpc-1515	237	2	.	.	PUNCT
dpc-1515	238	1	pottegård	pottegård	PROPN
dpc-1515	238	2	a	a	PRON
dpc-1515	238	3	,	,	PUNCT
dpc-1515	238	4	pedersen	pedersen	PROPN
dpc-1515	238	5	sa	sa	PROPN
dpc-1515	238	6	,	,	PUNCT
dpc-1515	238	7	schmidt	schmidt	PROPN
dpc-1515	238	8	saj	saj	PROPN
dpc-1515	238	9	,	,	PUNCT
dpc-1515	238	10	et	et	PROPN
dpc-1515	238	11	al	al	PROPN
dpc-1515	238	12	.	.	PUNCT
dpc-1515	238	13	use	use	NOUN
dpc-1515	238	14	of	of	ADP
dpc-1515	238	15	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	238	16	and	and	CCONJ
dpc-1515	238	17	risk	risk	NOUN
dpc-1515	238	18	of	of	ADP
dpc-1515	238	19	skin	skin	NOUN
dpc-1515	238	20	cancer	cancer	NOUN
dpc-1515	238	21	:	:	PUNCT
dpc-1515	238	22	a	a	DET
dpc-1515	238	23	nationwide	nationwide	ADJ
dpc-1515	238	24	taiwanese	taiwanese	ADJ
dpc-1515	238	25	case	case	NOUN
dpc-1515	238	26	-	-	PUNCT
dpc-1515	238	27	control	control	NOUN
dpc-1515	238	28	study	study	NOUN
dpc-1515	238	29	.	.	PUNCT
dpc-1515	238	30	 	 	SPACE
dpc-1515	239	1	br	br	PROPN
dpc-1515	239	2	j	j	PROPN
dpc-1515	239	3	cancer	cancer	NOUN
dpc-1515	239	4	.	.	PUNCT
dpc-1515	240	1	2019;121(11):973	2019;121(11):973	NUM
dpc-1515	240	2	-	-	SYM
dpc-1515	240	3	978	978	NUM
dpc-1515	240	4	.	.	PUNCT
dpc-1515	241	1	doi	doi	NOUN
dpc-1515	241	2	:	:	PUNCT
dpc-1515	241	3	10.1038	10.1038	NUM
dpc-1515	241	4	/	/	SYM
dpc-1515	241	5	s41416	s41416	NOUN
dpc-1515	241	6	-	-	PUNCT
dpc-1515	241	7	019	019	NUM
dpc-1515	241	8	-	-	PUNCT
dpc-1515	241	9	0613	0613	NUM
dpc-1515	241	10	-	-	PUNCT
dpc-1515	241	11	4	4	NUM
dpc-1515	241	12	.	.	PUNCT
dpc-1515	242	1	pmid	pmid	NOUN
dpc-1515	242	2	:	:	PUNCT
dpc-1515	242	3	31673105	31673105	NUM
dpc-1515	242	4	.	.	PUNCT
dpc-1515	243	1	16	16	NUM
dpc-1515	243	2	.	.	PUNCT
dpc-1515	244	1	han	han	PROPN
dpc-1515	244	2	s	s	PROPN
dpc-1515	244	3	,	,	PUNCT
dpc-1515	244	4	wolfe	wolfe	PROPN
dpc-1515	244	5	cm	cm	PROPN
dpc-1515	244	6	,	,	PUNCT
dpc-1515	244	7	angnardo	angnardo	PROPN
dpc-1515	244	8	l	l	PROPN
dpc-1515	244	9	,	,	PUNCT
dpc-1515	244	10	et	et	PROPN
dpc-1515	244	11	al	al	PROPN
dpc-1515	244	12	.	.	PROPN
dpc-1515	245	1	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	245	2	use	use	NOUN
dpc-1515	245	3	and	and	CCONJ
dpc-1515	245	4	increased	increase	VERB
dpc-1515	245	5	squamous	squamous	ADJ
dpc-1515	245	6	cell	cell	NOUN
dpc-1515	245	7	carcinoma	carcinoma	NOUN
dpc-1515	245	8	burden	burden	NOUN
dpc-1515	245	9	in	in	ADP
dpc-1515	245	10	a	a	DET
dpc-1515	245	11	highrisk	highrisk	NOUN
dpc-1515	245	12	mohs	mohs	NOUN
dpc-1515	245	13	population	population	NOUN
dpc-1515	245	14	:	:	PUNCT
dpc-1515	245	15	a	a	DET
dpc-1515	245	16	cross	cross	ADJ
dpc-1515	245	17	-	-	ADJ
dpc-1515	245	18	sectional	sectional	ADJ
dpc-1515	245	19	study	study	NOUN
dpc-1515	245	20	.	.	PUNCT
dpc-1515	246	1	dermatol	dermatol	NOUN
dpc-1515	246	2	surg	surg	NOUN
dpc-1515	246	3	.	.	PUNCT
dpc-1515	247	1	2020;46(5):704	2020;46(5):704	NUM
dpc-1515	247	2	-	-	SYM
dpc-1515	247	3	708	708	NUM
dpc-1515	247	4	.	.	PUNCT
dpc-1515	248	1	doi	doi	NOUN
dpc-1515	248	2	:	:	PUNCT
dpc-1515	248	3	10.1097	10.1097	NUM
dpc-1515	248	4	/	/	SYM
dpc-1515	248	5	dss.0000000000001875	dss.0000000000001875	PROPN
dpc-1515	248	6	.	.	PUNCT
dpc-1515	248	7	  	  	SPACE
dpc-1515	248	8	17	17	NUM
dpc-1515	248	9	.	.	PUNCT
dpc-1515	249	1	park	park	PROPN
dpc-1515	249	2	e	e	PROPN
dpc-1515	249	3	,	,	PUNCT
dpc-1515	249	4	lee	lee	PROPN
dpc-1515	249	5	y	y	PROPN
dpc-1515	249	6	,	,	PUNCT
dpc-1515	249	7	jue	jue	PROPN
dpc-1515	249	8	ms	ms	PROPN
dpc-1515	249	9	.	.	PROPN
dpc-1515	249	10	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	249	11	use	use	NOUN
dpc-1515	249	12	and	and	CCONJ
dpc-1515	249	13	the	the	DET
dpc-1515	249	14	risk	risk	NOUN
dpc-1515	249	15	of	of	ADP
dpc-1515	249	16	skin	skin	NOUN
dpc-1515	249	17	cancer	cancer	NOUN
dpc-1515	249	18	in	in	ADP
dpc-1515	249	19	patients	patient	NOUN
dpc-1515	249	20	with	with	ADP
dpc-1515	249	21	hypertensive	hypertensive	ADJ
dpc-1515	249	22	disorder	disorder	NOUN
dpc-1515	249	23	:	:	PUNCT
dpc-1515	249	24	a	a	DET
dpc-1515	249	25	nationwide	nationwide	ADJ
dpc-1515	249	26	retrospective	retrospective	ADJ
dpc-1515	249	27	cohort	cohort	NOUN
dpc-1515	249	28	study	study	NOUN
dpc-1515	249	29	from	from	ADP
dpc-1515	249	30	korea	korea	PROPN
dpc-1515	249	31	.	.	PUNCT
dpc-1515	249	32	 	 	SPACE
dpc-1515	250	1	korean	korean	PROPN
dpc-1515	250	2	j	j	PROPN
dpc-1515	250	3	intern	intern	PROPN
dpc-1515	250	4	med	me	VERB
dpc-1515	250	5	.	.	PUNCT
dpc-1515	251	1	2019;35(4):917	2019;35(4):917	NUM
dpc-1515	251	2	-	-	SYM
dpc-1515	251	3	928	928	NUM
dpc-1515	251	4	.	.	PUNCT
dpc-1515	252	1	doi	doi	NOUN
dpc-1515	252	2	:	:	PUNCT
dpc-1515	252	3	10.3904	10.3904	NUM
dpc-1515	252	4	/	/	SYM
dpc-1515	252	5	kjim.2019.218	kjim.2019.218	PROPN
dpc-1515	252	6	.	.	PUNCT
dpc-1515	252	7	  	  	SPACE
dpc-1515	252	8	18	18	NUM
dpc-1515	252	9	.	.	PUNCT
dpc-1515	253	1	olde	olde	PROPN
dpc-1515	253	2	engberink	engberink	PROPN
dpc-1515	253	3	rhg	rhg	PROPN
dpc-1515	253	4	,	,	PUNCT
dpc-1515	253	5	van	van	PROPN
dpc-1515	253	6	der	der	PROPN
dpc-1515	253	7	hoeven	hoeven	PROPN
dpc-1515	253	8	nv	nv	PROPN
dpc-1515	253	9	,	,	PUNCT
dpc-1515	253	10	zwinderman	zwinderman	NOUN
dpc-1515	253	11	ah	ah	INTJ
dpc-1515	253	12	,	,	PUNCT
dpc-1515	253	13	van	van	PROPN
dpc-1515	253	14	den	den	PROPN
dpc-1515	253	15	born	bear	VERB
dpc-1515	253	16	bh	bh	NOUN
dpc-1515	253	17	.	.	PROPN
dpc-1515	253	18	hydrochloorthiazide	hydrochloorthiazide	PROPN
dpc-1515	254	1	en	en	PROPN
dpc-1515	254	2	huidkanker	huidkanker	NOUN
dpc-1515	255	1	[	[	X
dpc-1515	255	2	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	255	3	and	and	CCONJ
dpc-1515	255	4	skin	skin	NOUN
dpc-1515	255	5	cancer	cancer	NOUN
dpc-1515	255	6	]	]	PUNCT
dpc-1515	255	7	.	.	PUNCT
dpc-1515	255	8	 	 	SPACE
dpc-1515	255	9	ned	ned	ADJ
dpc-1515	255	10	tijdschr	tijdschr	ADJ
dpc-1515	255	11	geneeskd	geneeskd	NOUN
dpc-1515	255	12	.	.	PUNCT
dpc-1515	256	1	2019;163	2019;163	NUM
dpc-1515	256	2	:	:	PUNCT
dpc-1515	256	3	d3755	d3755	NOUN
dpc-1515	256	4	.	.	NOUN
dpc-1515	256	5	19	19	NUM
dpc-1515	256	6	.	.	PUNCT
dpc-1515	256	7	mhra	mhra	NOUN
dpc-1515	256	8	drug	drug	PROPN
dpc-1515	256	9	safety	safety	NOUN
dpc-1515	256	10	update	update	NOUN
dpc-1515	256	11	:	:	PUNCT
dpc-1515	256	12	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	256	13	and	and	CCONJ
dpc-1515	256	14	non	non	ADJ
dpc-1515	256	15	-	-	ADJ
dpc-1515	256	16	melanoma	melanoma	ADJ
dpc-1515	256	17	skin	skin	NOUN
dpc-1515	256	18	cancer	cancer	NOUN
dpc-1515	256	19	.	.	PUNCT
dpc-1515	256	20	 	 	SPACE
dpc-1515	257	1	drug	drug	NOUN
dpc-1515	257	2	ther	ther	PROPN
dpc-1515	257	3	bull	bull	PROPN
dpc-1515	257	4	.	.	PUNCT
dpc-1515	258	1	2019;57(5):70	2019;57(5):70	NUM
dpc-1515	258	2	.	.	PUNCT
dpc-1515	258	3	 	 	SPACE
dpc-1515	258	4	doi	doi	NOUN
dpc-1515	258	5	:	:	PUNCT
dpc-1515	258	6	10.1136/	10.1136/	NUM
dpc-1515	258	7	dtb.2019.000023	dtb.2019.000023	NUM
dpc-1515	258	8	.	.	PUNCT
dpc-1515	259	1	pmid	pmid	NOUN
dpc-1515	259	2	:	:	PUNCT
dpc-1515	259	3	31018928	31018928	NUM
dpc-1515	259	4	.	.	PUNCT
dpc-1515	260	1	20	20	NUM
dpc-1515	260	2	.	.	PUNCT
dpc-1515	261	1	morales	morales	PROPN
dpc-1515	261	2	dr	dr	PROPN
dpc-1515	261	3	,	,	PUNCT
dpc-1515	261	4	pacurariu	pacurariu	VERB
dpc-1515	261	5	a	a	PRON
dpc-1515	261	6	,	,	PUNCT
dpc-1515	261	7	slattery	slattery	PROPN
dpc-1515	261	8	j	j	PROPN
dpc-1515	261	9	,	,	PUNCT
dpc-1515	261	10	kurz	kurz	PROPN
dpc-1515	261	11	x.	x.	PROPN
dpc-1515	261	12	association	association	PROPN
dpc-1515	261	13	between	between	ADP
dpc-1515	261	14	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	261	15	exposure	exposure	NOUN
dpc-1515	261	16	and	and	CCONJ
dpc-1515	261	17	different	different	ADJ
dpc-1515	261	18	incident	incident	NOUN
dpc-1515	261	19	skin	skin	NOUN
dpc-1515	261	20	,	,	PUNCT
dpc-1515	261	21	lip	lip	NOUN
dpc-1515	261	22	and	and	CCONJ
dpc-1515	261	23	oral	oral	ADJ
dpc-1515	261	24	cavity	cavity	NOUN
dpc-1515	261	25	cancers	cancer	NOUN
dpc-1515	261	26	:	:	PUNCT
dpc-1515	261	27	a	a	DET
dpc-1515	261	28	series	series	NOUN
dpc-1515	261	29	of	of	ADP
dpc-1515	261	30	population	population	NOUN
dpc-1515	261	31	-	-	PUNCT
dpc-1515	261	32	based	base	VERB
dpc-1515	261	33	nested	nested	ADJ
dpc-1515	261	34	case	case	NOUN
dpc-1515	261	35	-	-	PUNCT
dpc-1515	261	36	control	control	NOUN
dpc-1515	261	37	studies	study	NOUN
dpc-1515	261	38	.	.	PUNCT
dpc-1515	262	1	br	br	PROPN
dpc-1515	263	1	j	j	PROPN
dpc-1515	263	2	clin	clin	PROPN
dpc-1515	263	3	pharmacol	pharmacol	PROPN
dpc-1515	263	4	.	.	PUNCT
dpc-1515	264	1	2020	2020	NUM
dpc-1515	264	2	;	;	PUNCT
dpc-1515	264	3	86(7):1336	86(7):1336	NUM
dpc-1515	264	4	-	-	PUNCT
dpc-1515	264	5	1345	1345	NUM
dpc-1515	264	6	.	.	PUNCT
dpc-1515	265	1	doi	doi	NOUN
dpc-1515	265	2	:	:	PUNCT
dpc-1515	265	3	10.1111	10.1111	NUM
dpc-1515	265	4	/	/	SYM
dpc-1515	265	5	bcp.14245	bcp.14245	PROPN
dpc-1515	265	6	.	.	PUNCT
dpc-1515	266	1	pmid	pmid	NOUN
dpc-1515	266	2	:	:	PUNCT
dpc-1515	266	3	32068906	32068906	NUM
dpc-1515	266	4	.	.	PUNCT
dpc-1515	267	1	21	21	NUM
dpc-1515	267	2	.	.	PUNCT
dpc-1515	268	1	kreutz	kreutz	PROPN
dpc-1515	268	2	r	r	NOUN
dpc-1515	268	3	,	,	PUNCT
dpc-1515	268	4	algharably	algharably	ADV
dpc-1515	268	5	eah	eah	PROPN
dpc-1515	268	6	,	,	PUNCT
dpc-1515	268	7	douros	douros	PROPN
dpc-1515	268	8	a.	a.	NOUN
dpc-1515	268	9	reviewing	review	VERB
dpc-1515	268	10	the	the	DET
dpc-1515	268	11	effects	effect	NOUN
dpc-1515	268	12	of	of	ADP
dpc-1515	268	13	thiazide	thiazide	ADP
dpc-1515	268	14	and	and	CCONJ
dpc-1515	268	15	thiazide	thiazide	ADV
dpc-1515	268	16	-	-	PUNCT
dpc-1515	268	17	like	like	ADJ
dpc-1515	268	18	diuretics	diuretic	NOUN
dpc-1515	268	19	as	as	ADP
dpc-1515	268	20	photosensitizing	photosensitize	VERB
dpc-1515	268	21	drugs	drug	NOUN
dpc-1515	268	22	on	on	ADP
dpc-1515	268	23	the	the	DET
dpc-1515	268	24	risk	risk	NOUN
dpc-1515	268	25	of	of	ADP
dpc-1515	268	26	skin	skin	NOUN
dpc-1515	268	27	cancer	cancer	NOUN
dpc-1515	268	28	.	.	PUNCT
dpc-1515	268	29	 	 	SPACE
dpc-1515	269	1	j	j	PROPN
dpc-1515	269	2	hypertens	hypertens	PROPN
dpc-1515	269	3	.	.	PUNCT
dpc-1515	270	1	2019;37(10):1950	2019;37(10):1950	X
dpc-1515	270	2	-	-	SYM
dpc-1515	270	3	1958	1958	NUM
dpc-1515	270	4	.	.	PUNCT
dpc-1515	271	1	doi	doi	NOUN
dpc-1515	271	2	:	:	PUNCT
dpc-1515	271	3	10.1097	10.1097	NUM
dpc-1515	271	4	/	/	SYM
dpc-1515	271	5	hjh.0000000000002136	hjh.0000000000002136	NOUN
dpc-1515	271	6	.	.	PUNCT
dpc-1515	272	1	pmid	pmid	NOUN
dpc-1515	272	2	:	:	PUNCT
dpc-1515	272	3	31145177	31145177	NUM
dpc-1515	272	4	.	.	PUNCT
dpc-1515	273	1	22	22	NUM
dpc-1515	273	2	.	.	PUNCT
dpc-1515	274	1	becquart	becquart	PROPN
dpc-1515	274	2	o	o	NOUN
dpc-1515	274	3	,	,	PUNCT
dpc-1515	274	4	guillot	guillot	ADJ
dpc-1515	274	5	b	b	NOUN
dpc-1515	274	6	,	,	PUNCT
dpc-1515	274	7	bourrain	bourrain	PROPN
dpc-1515	274	8	j	j	PROPN
dpc-1515	274	9	-	-	PROPN
dpc-1515	274	10	l	l	PROPN
dpc-1515	274	11	,	,	PUNCT
dpc-1515	274	12	duflos	duflos	PROPN
dpc-1515	274	13	c	c	X
dpc-1515	274	14	,	,	PUNCT
dpc-1515	274	15	du	du	PROPN
dpc-1515	274	16	-	-	ADJ
dpc-1515	274	17	thanh	thanh	ADJ
dpc-1515	274	18	a.	a.	PROPN
dpc-1515	274	19	risque	risque	PROPN
dpc-1515	274	20	de	de	X
dpc-1515	274	21	cancers	cancer	NOUN
dpc-1515	274	22	cutanés	cutanés	VERB
dpc-1515	274	23	sous	sous	ADJ
dpc-1515	274	24	hydrochlorothiazide	hydrochlorothiazide	NOUN
dpc-1515	274	25	:	:	PUNCT
dpc-1515	274	26	revue	revue	NOUN
dpc-1515	274	27	systématique	systématique	NOUN
dpc-1515	275	1	[	[	X
dpc-1515	275	2	hydrochlorothiazide	hydrochlorothiazide	VERB
dpc-1515	275	3	use	use	NOUN
dpc-1515	275	4	and	and	CCONJ
dpc-1515	275	5	risk	risk	NOUN
dpc-1515	275	6	of	of	ADP
dpc-1515	275	7	skin	skin	NOUN
dpc-1515	275	8	cancers	cancer	NOUN
dpc-1515	275	9	:	:	PUNCT
dpc-1515	275	10	a	a	DET
dpc-1515	275	11	systematic	systematic	ADJ
dpc-1515	275	12	review	review	NOUN
dpc-1515	275	13	]	]	X
dpc-1515	275	14	.	.	PUNCT
dpc-1515	275	15	 	 	SPACE
dpc-1515	275	16	rev	rev	VERB
dpc-1515	275	17	med	med	ADJ
dpc-1515	275	18	interne	interne	NOUN
dpc-1515	275	19	.	.	PUNCT
dpc-1515	276	1	2019;40(9):617	2019;40(9):617	NUM
dpc-1515	276	2	-	-	PUNCT
dpc-1515	276	3	622	622	NUM
dpc-1515	276	4	.	.	PUNCT
dpc-1515	277	1	doi	doi	NOUN
dpc-1515	277	2	:	:	PUNCT
dpc-1515	277	3	10.1016	10.1016	NUM
dpc-1515	277	4	/	/	SYM
dpc-1515	277	5	j.revmed.2019.04.008	j.revmed.2019.04.008	PROPN
dpc-1515	277	6	.	.	PUNCT
dpc-1515	278	1	pmid	pmid	NOUN
dpc-1515	278	2	:	:	PUNCT
dpc-1515	278	3	31101331	31101331	NUM
dpc-1515	278	4	.	.	PUNCT
dpc-1515	279	1	23	23	NUM
dpc-1515	279	2	.	.	PUNCT
dpc-1515	279	3	shin	shin	PROPN
dpc-1515	279	4	d	d	PROPN
dpc-1515	279	5	,	,	PUNCT
dpc-1515	279	6	lee	lee	PROPN
dpc-1515	279	7	es	es	PROPN
dpc-1515	279	8	,	,	PUNCT
dpc-1515	279	9	kim	kim	PROPN
dpc-1515	279	10	j	j	PROPN
dpc-1515	279	11	,	,	PUNCT
dpc-1515	279	12	guerra	guerra	PROPN
dpc-1515	279	13	l	l	PROPN
dpc-1515	279	14	,	,	PUNCT
dpc-1515	279	15	naik	naik	PROPN
dpc-1515	279	16	d	d	PROPN
dpc-1515	279	17	,	,	PUNCT
dpc-1515	279	18	prida	prida	PROPN
dpc-1515	279	19	x.	x.	PROPN
dpc-1515	279	20	association	association	PROPN
dpc-1515	279	21	between	between	ADP
dpc-1515	279	22	the	the	DET
dpc-1515	279	23	use	use	NOUN
dpc-1515	279	24	of	of	ADP
dpc-1515	279	25	thiazide	thiazide	ADJ
dpc-1515	279	26	diuretics	diuretic	NOUN
dpc-1515	279	27	and	and	CCONJ
dpc-1515	279	28	the	the	DET
dpc-1515	279	29	risk	risk	NOUN
dpc-1515	279	30	of	of	ADP
dpc-1515	279	31	skin	skin	NOUN
dpc-1515	279	32	cancers	cancer	NOUN
dpc-1515	279	33	:	:	PUNCT
dpc-1515	279	34	a	a	DET
dpc-1515	279	35	meta	meta	ADJ
dpc-1515	279	36	-	-	PUNCT
dpc-1515	279	37	analysis	analysis	NOUN
dpc-1515	279	38	of	of	ADP
dpc-1515	279	39	observational	observational	ADJ
dpc-1515	279	40	studies	study	NOUN
dpc-1515	279	41	.	.	PUNCT
dpc-1515	279	42	 	 	SPACE
dpc-1515	280	1	j	j	PROPN
dpc-1515	280	2	clin	clin	PROPN
dpc-1515	280	3	med	med	PROPN
dpc-1515	280	4	res	re	NOUN
dpc-1515	280	5	.	.	PUNCT
dpc-1515	281	1	2019;11(4):247	2019;11(4):247	NUM
dpc-1515	281	2	-	-	SYM
dpc-1515	281	3	255	255	NUM
dpc-1515	281	4	.	.	PUNCT
dpc-1515	282	1	doi	doi	NOUN
dpc-1515	282	2	:	:	PUNCT
dpc-1515	282	3	10.14740	10.14740	NUM
dpc-1515	282	4	/	/	SYM
dpc-1515	282	5	jocmr3744	jocmr3744	PROPN
dpc-1515	282	6	.	.	PUNCT
dpc-1515	283	1	pmid	pmid	NOUN
dpc-1515	283	2	:	:	PUNCT
dpc-1515	283	3	30937114	30937114	NUM
dpc-1515	283	4	.	.	PUNCT
dpc-1515	284	1	24	24	NUM
dpc-1515	284	2	.	.	PUNCT
dpc-1515	284	3	faconti	faconti	PROPN
dpc-1515	284	4	l	l	PROPN
dpc-1515	284	5	,	,	PUNCT
dpc-1515	284	6	ferro	ferro	VERB
dpc-1515	284	7	a	a	DET
dpc-1515	284	8	,	,	PUNCT
dpc-1515	284	9	webb	webb	PROPN
dpc-1515	284	10	aj	aj	PROPN
dpc-1515	284	11	,	,	PUNCT
dpc-1515	284	12	cruickshank	cruickshank	PROPN
dpc-1515	284	13	jk	jk	PROPN
dpc-1515	284	14	,	,	PUNCT
dpc-1515	284	15	chowienczyk	chowienczyk	PROPN
dpc-1515	284	16	pj	pj	PROPN
dpc-1515	284	17	;	;	PUNCT
dpc-1515	284	18	british	british	ADJ
dpc-1515	284	19	and	and	CCONJ
dpc-1515	284	20	irish	irish	ADJ
dpc-1515	284	21	hypertension	hypertension	NOUN
dpc-1515	284	22	society	society	NOUN
dpc-1515	284	23	.	.	PUNCT
dpc-1515	285	1	hydrochlorothiazide	hydrochlorothiazide	PROPN
dpc-1515	285	2	and	and	CCONJ
dpc-1515	285	3	the	the	DET
dpc-1515	285	4	risk	risk	NOUN
dpc-1515	285	5	of	of	ADP
dpc-1515	285	6	skin	skin	NOUN
dpc-1515	285	7	cancer	cancer	NOUN
dpc-1515	285	8	.	.	PUNCT
dpc-1515	286	1	a	a	DET
dpc-1515	286	2	scientific	scientific	ADJ
dpc-1515	286	3	statement	statement	NOUN
dpc-1515	286	4	of	of	ADP
dpc-1515	286	5	the	the	DET
dpc-1515	286	6	british	british	ADJ
dpc-1515	286	7	and	and	CCONJ
dpc-1515	286	8	irish	irish	ADJ
dpc-1515	286	9	hypertension	hypertension	NOUN
dpc-1515	286	10	society	society	NOUN
dpc-1515	286	11	.	.	PUNCT
dpc-1515	286	12	 	 	SPACE
dpc-1515	287	1	j	j	PROPN
dpc-1515	287	2	hum	hum	PROPN
dpc-1515	287	3	hypertens	hyperten	NOUN
dpc-1515	287	4	.	.	PUNCT
dpc-1515	288	1	2019;33(4):257258	2019;33(4):257258	NUM
dpc-1515	288	2	.	.	PUNCT
dpc-1515	288	3	doi	doi	NOUN
dpc-1515	288	4	:	:	PUNCT
dpc-1515	288	5	10.1038	10.1038	NUM
dpc-1515	288	6	/	/	SYM
dpc-1515	288	7	s41371	s41371	PROPN
dpc-1515	288	8	-	-	PUNCT
dpc-1515	288	9	019	019	NUM
dpc-1515	288	10	-	-	PUNCT
dpc-1515	288	11	0190	0190	NUM
dpc-1515	288	12	-	-	PUNCT
dpc-1515	288	13	2	2	NUM
dpc-1515	288	14	.	.	PUNCT
dpc-1515	289	1	pmid	pmid	NOUN
dpc-1515	289	2	:	:	PUNCT
dpc-1515	289	3	30842544	30842544	NUM
dpc-1515	289	4	.	.	PUNCT
dpc-1515	290	1	25	25	NUM
dpc-1515	290	2	.	.	PUNCT
dpc-1515	291	1	viola	viola	PROPN
dpc-1515	291	2	e	e	PROPN
dpc-1515	291	3	,	,	PUNCT
dpc-1515	291	4	coggiola	coggiola	PROPN
dpc-1515	291	5	pittoni	pittoni	VERB
dpc-1515	291	6	a	a	PRON
dpc-1515	291	7	,	,	PUNCT
dpc-1515	291	8	drahos	drahos	PROPN
dpc-1515	291	9	a	a	PROPN
dpc-1515	291	10	,	,	PUNCT
dpc-1515	291	11	moretti	moretti	PROPN
dpc-1515	291	12	u	u	PROPN
dpc-1515	291	13	,	,	PUNCT
dpc-1515	291	14	conforti	conforti	PROPN
dpc-1515	291	15	a.	a.	NOUN
dpc-1515	291	16	photosensitivity	photosensitivity	NOUN
dpc-1515	291	17	with	with	ADP
dpc-1515	291	18	angiotensin	angiotensin	PROPN
dpc-1515	291	19	ii	ii	PROPN
dpc-1515	291	20	receptor	receptor	NOUN
dpc-1515	291	21	blockers	blocker	NOUN
dpc-1515	291	22	:	:	PUNCT
dpc-1515	291	23	a	a	DET
dpc-1515	291	24	retrospective	retrospective	ADJ
dpc-1515	291	25	study	study	NOUN
dpc-1515	291	26	using	use	VERB
dpc-1515	291	27	data	datum	NOUN
dpc-1515	291	28	from	from	ADP
dpc-1515	291	29	vigibase	vigibase	PROPN
dpc-1515	291	30	®	®	PROPN
dpc-1515	291	31	.	.	PUNCT
dpc-1515	291	32	drug	drug	PROPN
dpc-1515	291	33	saf	saf	PROPN
dpc-1515	291	34	.	.	PUNCT
dpc-1515	292	1	2015;38	2015;38	NUM
dpc-1515	292	2	(	(	PUNCT
dpc-1515	292	3	10):889	10):889	NUM
dpc-1515	292	4	-	-	SYM
dpc-1515	292	5	894	894	NUM
dpc-1515	292	6	.	.	PUNCT
dpc-1515	293	1	doi	doi	NOUN
dpc-1515	293	2	:	:	PUNCT
dpc-1515	293	3	10.1007	10.1007	NUM
dpc-1515	293	4	/	/	SYM
dpc-1515	293	5	s40264	s40264	ADJ
dpc-1515	293	6	-	-	ADJ
dpc-1515	293	7	015	015	NUM
dpc-1515	293	8	-	-	PUNCT
dpc-1515	293	9	0323	0323	NUM
dpc-1515	293	10	-	-	PUNCT
dpc-1515	293	11	7	7	NUM
dpc-1515	293	12	.	.	PUNCT
dpc-1515	294	1	pmid	pmid	NOUN
dpc-1515	294	2	:	:	PUNCT
dpc-1515	294	3	26187686	26187686	NUM
dpc-1515	294	4	.	.	PUNCT
dpc-1515	295	1	26	26	NUM
dpc-1515	295	2	.	.	PUNCT
dpc-1515	296	1	nardone	nardone	PROPN
dpc-1515	296	2	b	b	PROPN
dpc-1515	296	3	,	,	PUNCT
dpc-1515	296	4	orrell	orrell	ADJ
dpc-1515	296	5	ka	ka	PROPN
dpc-1515	296	6	,	,	PUNCT
dpc-1515	296	7	vakharia	vakharia	PROPN
dpc-1515	296	8	pp	pp	PROPN
dpc-1515	296	9	,	,	PUNCT
dpc-1515	296	10	west	west	PROPN
dpc-1515	296	11	dp	dp	PROPN
dpc-1515	296	12	.	.	PROPN
dpc-1515	296	13	skin	skin	NOUN
dpc-1515	296	14	cancer	cancer	NOUN
dpc-1515	296	15	associated	associate	VERB
dpc-1515	296	16	with	with	ADP
dpc-1515	296	17	commonly	commonly	ADV
dpc-1515	296	18	prescribed	prescribe	VERB
dpc-1515	296	19	drugs	drug	NOUN
dpc-1515	296	20	:	:	PUNCT
dpc-1515	296	21	tumor	tumor	NOUN
dpc-1515	296	22	necrosis	necrosis	NOUN
dpc-1515	296	23	factor	factor	NOUN
dpc-1515	296	24	alpha	alpha	NOUN
dpc-1515	296	25	inhibitors	inhibitor	NOUN
dpc-1515	296	26	(	(	PUNCT
dpc-1515	296	27	tnf	tnf	PROPN
dpc-1515	296	28	-	-	PUNCT
dpc-1515	296	29	αis	αis	PROPN
dpc-1515	296	30	)	)	PUNCT
dpc-1515	296	31	,	,	PUNCT
dpc-1515	296	32	angiotensin	angiotensin	NOUN
dpc-1515	296	33	-	-	PUNCT
dpc-1515	296	34	receptor	receptor	NOUN
dpc-1515	296	35	blockers	blocker	NOUN
dpc-1515	296	36	(	(	PUNCT
dpc-1515	296	37	arbs	arb	NOUN
dpc-1515	296	38	)	)	PUNCT
dpc-1515	296	39	,	,	PUNCT
dpc-1515	296	40	phosphodiesterase	phosphodiesterase	NOUN
dpc-1515	296	41	type	type	NOUN
dpc-1515	296	42	5	5	NUM
dpc-1515	296	43	inhibitors	inhibitor	NOUN
dpc-1515	296	44	(	(	PUNCT
dpc-1515	296	45	pde5is	pde5is	PROPN
dpc-1515	296	46	)	)	PUNCT
dpc-1515	296	47	and	and	CCONJ
dpc-1515	296	48	statins	statin	NOUN
dpc-1515	296	49	—	—	PUNCT
dpc-1515	296	50	weighing	weigh	VERB
dpc-1515	296	51	the	the	DET
dpc-1515	296	52	evidence	evidence	NOUN
dpc-1515	296	53	.	.	PUNCT
dpc-1515	296	54	 	 	SPACE
dpc-1515	297	1	expert	expert	ADJ
dpc-1515	297	2	opin	opin	NOUN
dpc-1515	297	3	drug	drug	NOUN
dpc-1515	297	4	saf	saf	PROPN
dpc-1515	297	5	.	.	PUNCT
dpc-1515	298	1	2018;17(2):139	2018;17(2):139	PROPN
dpc-1515	298	2	-	-	PUNCT
dpc-1515	298	3	147	147	NUM
dpc-1515	298	4	.	.	PUNCT
dpc-1515	299	1	doi	doi	NOUN
dpc-1515	299	2	:	:	PUNCT
dpc-1515	299	3	10.1080/14740338.2018.1400530	10.1080/14740338.2018.1400530	NUM
dpc-1515	299	4	.	.	PUNCT
dpc-1515	300	1	pmid	pmid	NOUN
dpc-1515	300	2	:	:	PUNCT
dpc-1515	300	3	29103328	29103328	NUM
dpc-1515	300	4	.	.	PUNCT
dpc-1515	301	1	research	research	NOUN
dpc-1515	301	2	|	|	ADV
dpc-1515	301	3	dermatol	dermatol	ADJ
dpc-1515	301	4	pract	pract	NOUN
dpc-1515	301	5	concept	concept	NOUN
dpc-1515	301	6	.	.	PUNCT
dpc-1515	302	1	2021;11(2):e2021031	2021;11(2):e2021031	NUM
dpc-1515	302	2	7	7	NUM
dpc-1515	302	3	27	27	NUM
dpc-1515	302	4	.	.	PUNCT
dpc-1515	303	1	nardone	nardone	NOUN
dpc-1515	303	2	b	b	PROPN
dpc-1515	303	3	,	,	PUNCT
dpc-1515	303	4	majewski	majewski	NOUN
dpc-1515	303	5	s	s	PROPN
dpc-1515	303	6	,	,	PUNCT
dpc-1515	303	7	kim	kim	PROPN
dpc-1515	303	8	as	as	ADP
dpc-1515	303	9	,	,	PUNCT
dpc-1515	303	10	et	et	PROPN
dpc-1515	303	11	al	al	PROPN
dpc-1515	303	12	.	.	PROPN
dpc-1515	304	1	melanoma	melanoma	PROPN
dpc-1515	304	2	and	and	CCONJ
dpc-1515	304	3	non	non	ADJ
dpc-1515	304	4	-	-	ADJ
dpc-1515	304	5	melanoma	melanoma	ADJ
dpc-1515	304	6	skin	skin	NOUN
dpc-1515	304	7	cancer	cancer	NOUN
dpc-1515	304	8	associated	associate	VERB
dpc-1515	304	9	with	with	ADP
dpc-1515	304	10	angiotensin	angiotensin	NOUN
dpc-1515	304	11	-	-	PUNCT
dpc-1515	304	12	converting	convert	VERB
dpc-1515	304	13	-	-	PUNCT
dpc-1515	304	14	enzyme	enzyme	NOUN
dpc-1515	304	15	inhibitors	inhibitor	NOUN
dpc-1515	304	16	,	,	PUNCT
dpc-1515	304	17	angiotensin	angiotensin	NOUN
dpc-1515	304	18	-	-	PUNCT
dpc-1515	304	19	receptor	receptor	NOUN
dpc-1515	304	20	blockers	blocker	NOUN
dpc-1515	304	21	and	and	CCONJ
dpc-1515	304	22	thiazides	thiazide	NOUN
dpc-1515	304	23	:	:	PUNCT
dpc-1515	304	24	a	a	DET
dpc-1515	304	25	matched	match	VERB
dpc-1515	304	26	cohort	cohort	NOUN
dpc-1515	304	27	study	study	NOUN
dpc-1515	304	28	.	.	PUNCT
dpc-1515	304	29	 	 	SPACE
dpc-1515	304	30	drug	drug	PROPN
dpc-1515	304	31	saf	saf	PROPN
dpc-1515	304	32	.	.	PROPN
dpc-1515	305	1	2017;40(3):249–255	2017;40(3):249–255	X
dpc-1515	305	2	.	.	PUNCT
dpc-1515	305	3	doi	doi	NOUN
dpc-1515	305	4	:	:	PUNCT
dpc-1515	305	5	10.1007/	10.1007/	NUM
dpc-1515	305	6	s40264	s40264	ADJ
dpc-1515	305	7	-	-	PUNCT
dpc-1515	305	8	016	016	NUM
dpc-1515	305	9	-	-	PUNCT
dpc-1515	305	10	0487	0487	NUM
dpc-1515	305	11	-	-	SYM
dpc-1515	305	12	9	9	NUM
dpc-1515	305	13	.	.	PUNCT
dpc-1515	306	1	pmid	pmid	NOUN
dpc-1515	306	2	:	:	PUNCT
dpc-1515	306	3	27943160	27943160	NUM
dpc-1515	306	4	.	.	PUNCT
dpc-1515	307	1	28	28	NUM
dpc-1515	307	2	.	.	PUNCT
dpc-1515	307	3	moscarelli	moscarelli	PROPN
dpc-1515	307	4	l	l	PROPN
dpc-1515	307	5	,	,	PUNCT
dpc-1515	307	6	zanazzi	zanazzi	NOUN
dpc-1515	307	7	m	m	PROPN
dpc-1515	307	8	,	,	PUNCT
dpc-1515	307	9	mancini	mancini	PROPN
dpc-1515	307	10	g	g	PROPN
dpc-1515	307	11	,	,	PUNCT
dpc-1515	307	12	et	et	PROPN
dpc-1515	307	13	al	al	PROPN
dpc-1515	307	14	.	.	PROPN
dpc-1515	307	15	keratinocyte	keratinocyte	PROPN
dpc-1515	307	16	cancer	cancer	NOUN
dpc-1515	307	17	prevention	prevention	NOUN
dpc-1515	307	18	with	with	ADP
dpc-1515	307	19	ace	ace	NOUN
dpc-1515	307	20	inhibitors	inhibitor	NOUN
dpc-1515	307	21	,	,	PUNCT
dpc-1515	307	22	angiotensin	angiotensin	NOUN
dpc-1515	307	23	receptor	receptor	NOUN
dpc-1515	307	24	blockers	blocker	NOUN
dpc-1515	307	25	or	or	CCONJ
dpc-1515	307	26	their	their	PRON
dpc-1515	307	27	combination	combination	NOUN
dpc-1515	307	28	in	in	ADP
dpc-1515	307	29	renal	renal	ADJ
dpc-1515	307	30	transplant	transplant	NOUN
dpc-1515	307	31	recipients	recipient	NOUN
dpc-1515	307	32	.	.	PUNCT
dpc-1515	307	33	 	 	SPACE
dpc-1515	307	34	clin	clin	PROPN
dpc-1515	307	35	nephrol	nephrol	NOUN
dpc-1515	307	36	.	.	PUNCT
dpc-1515	308	1	2010;73:439	2010;73:439	X
dpc-1515	308	2	-	-	PUNCT
dpc-1515	308	3	445	445	NUM
dpc-1515	308	4	.	.	PUNCT
dpc-1515	309	1	doi	doi	NOUN
dpc-1515	309	2	:	:	PUNCT
dpc-1515	309	3	10.5414	10.5414	NUM
dpc-1515	309	4	/	/	SYM
dpc-1515	309	5	cnp73439	cnp73439	NOUN
dpc-1515	309	6	.	.	PUNCT
dpc-1515	310	1	pmid	pmid	NOUN
dpc-1515	310	2	:	:	PUNCT
dpc-1515	310	3	20497756	20497756	NUM
dpc-1515	310	4	29	29	NUM
dpc-1515	310	5	.	.	PUNCT
dpc-1515	311	1	christian	christian	PROPN
dpc-1515	311	2	jb	jb	PROPN
dpc-1515	311	3	,	,	PUNCT
dpc-1515	311	4	lapane	lapane	PROPN
dpc-1515	311	5	kl	kl	PROPN
dpc-1515	311	6	,	,	PUNCT
dpc-1515	311	7	hume	hume	PROPN
dpc-1515	311	8	al	al	PROPN
dpc-1515	311	9	,	,	PUNCT
dpc-1515	311	10	eaton	eaton	PROPN
dpc-1515	311	11	cb	cb	PROPN
dpc-1515	311	12	,	,	PUNCT
dpc-1515	311	13	weinstock	weinstock	PROPN
dpc-1515	311	14	ma	ma	PROPN
dpc-1515	311	15	;	;	PUNCT
dpc-1515	311	16	vattc	vattc	NOUN
dpc-1515	311	17	trial	trial	NOUN
dpc-1515	311	18	.	.	PUNCT
dpc-1515	312	1	association	association	NOUN
dpc-1515	312	2	of	of	ADP
dpc-1515	312	3	ace	ace	ADJ
dpc-1515	312	4	inhibitors	inhibitor	NOUN
dpc-1515	312	5	and	and	CCONJ
dpc-1515	312	6	angiotensin	angiotensin	NOUN
dpc-1515	312	7	receptor	receptor	NOUN
dpc-1515	312	8	blockers	blocker	NOUN
dpc-1515	312	9	with	with	ADP
dpc-1515	312	10	keratinocyte	keratinocyte	NOUN
dpc-1515	312	11	cancer	cancer	NOUN
dpc-1515	312	12	prevention	prevention	NOUN
dpc-1515	312	13	in	in	ADP
dpc-1515	312	14	the	the	DET
dpc-1515	312	15	randomized	randomized	ADJ
dpc-1515	312	16	vattc	vattc	NOUN
dpc-1515	312	17	trial	trial	NOUN
dpc-1515	312	18	.	.	PUNCT
dpc-1515	312	19	 	 	SPACE
dpc-1515	312	20	j	j	PROPN
dpc-1515	312	21	natl	natl	PROPN
dpc-1515	312	22	cancer	cancer	PROPN
dpc-1515	312	23	inst	inst	PROPN
dpc-1515	312	24	.	.	PUNCT
dpc-1515	313	1	2008;100:1223	2008;100:1223	NUM
dpc-1515	313	2	-	-	SYM
dpc-1515	313	3	1232	1232	NUM
dpc-1515	313	4	.	.	PUNCT
dpc-1515	314	1	doi	doi	NOUN
dpc-1515	314	2	:	:	PUNCT
dpc-1515	314	3	10.1093	10.1093	NUM
dpc-1515	314	4	/	/	SYM
dpc-1515	314	5	jnci	jnci	PROPN
dpc-1515	314	6	/	/	SYM
dpc-1515	314	7	djn262	djn262	PROPN
dpc-1515	314	8	.	.	PUNCT
dpc-1515	315	1	pmid	pmid	NOUN
dpc-1515	315	2	:	:	PUNCT
dpc-1515	315	3	18728281	18728281	NUM
dpc-1515	315	4	30	30	NUM
dpc-1515	315	5	.	.	PUNCT
dpc-1515	316	1	schmitt	schmitt	PROPN
dpc-1515	316	2	j	j	PROPN
dpc-1515	316	3	,	,	PUNCT
dpc-1515	316	4	miot	miot	PROPN
dpc-1515	316	5	h.	h.	PROPN
dpc-1515	316	6	oral	oral	PROPN
dpc-1515	316	7	acetylsalicylic	acetylsalicylic	PROPN
dpc-1515	316	8	acid	acid	PROPN
dpc-1515	316	9	and	and	CCONJ
dpc-1515	316	10	prevalence	prevalence	NOUN
dpc-1515	316	11	of	of	ADP
dpc-1515	316	12	actinic	actinic	ADJ
dpc-1515	316	13	keratosis	keratosis	NOUN
dpc-1515	316	14	.	.	PUNCT
dpc-1515	317	1	rev	rev	PROPN
dpc-1515	317	2	assoc	assoc	PROPN
dpc-1515	317	3	médica	médica	PROPN
dpc-1515	317	4	bras	bras	PROPN
dpc-1515	317	5	.	.	PUNCT
dpc-1515	318	1	2014;60(2):131	2014;60(2):131	NUM
dpc-1515	318	2	-	-	SYM
dpc-1515	318	3	138	138	NUM
dpc-1515	318	4	.	.	PUNCT
dpc-1515	319	1	doi	doi	NOUN
dpc-1515	319	2	:	:	PUNCT
dpc-1515	319	3	10.1590/1806	10.1590/1806	NUM
dpc-1515	319	4	-	-	SYM
dpc-1515	319	5	9282.60.02.010	9282.60.02.010	NUM
dpc-1515	319	6	.	.	PUNCT
dpc-1515	320	1	pmid	pmid	NOUN
dpc-1515	320	2	:	:	PUNCT
dpc-1515	320	3	24919000	24919000	NUM
dpc-1515	320	4	.	.	PUNCT